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The aim of this thesis is to investigate the role of the recently discovered post-
translational modification, O-GlcNAcylation, in the regulation of human placenta 
physiology. The rationale for this research work arises from the increasing evidence 
showing that O-GlcNAc signalling is a key mediator of cellular functions involved in 
a wide range of chronic diseases. However, there is a paucity of studies investigating 
its role in human placenta. Abnormal placenta physiology is considered as an 
underlying cause of poor pregnancy outcomes including miscarriage, preeclampsia 
and intrauterine growth alterations, the latter associated with increased risk for the 
development of chronic disorders later in life. Despite its importance, some of the 
molecular mechanisms controlling placental formation and function are still poorly 
understood. In this thesis, the BeWo cell line, a validated model to study in vitro 
mechanisms occurring in human trophoblast, and term placental biopsies, were 
employed. A transient OGT-depleted BeWo cell line was generated using a small 
interfering RNA (siRNA) methodology, and was used to identify the role of O-
GlcNAc transferase (OGT) and its biochemical mark O-GlcNAcylation during the 
formation of syncytiotrophoblast, a crucial structure controlling the majority of 
placental functions. In addition, an antibody-based enrichment method, followed by 
proteomic analysis, was used to identify O-GlcNAc-modified proteins in BeWo 
extracts. Term placental biopsies were used to investigate correlations between OGT 
and feto-maternal parameters. Overall, the results obtained in this research work 
support a critical role for OGT in the control of syncytiotrophoblast formation via 
mechanisms involving PKA-MAPKs signalling. Importantly, the proteomic analysis 
showed that O-GlcNAc-modified proteins belong to a wide range of functional 
classes, in particular, transcription and chromatin remodelling factors. Finally, 
maternal body mass index (BMI) and depression target OGT signalling in term 
placentas with consequences on the activity of regulators of fetal growth and 
mechanisms of placental response to stress. Taken together, this thesis uncovered 
novel roles for placental OGT in controlling a wide range of placental mechanisms 
that are crucial to human reproduction success and identified O-GlcNAc signalling as 
the molecular link between maternal environment and in utero fetal programming of 
human diseases.  
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1.1 Human placenta 
1.1.1 Formation of human placenta  
Approximately 4–5 days after fertilization of human oocyte, the blastocyst is 
segregated into two lineages: the inner cell mass , which will give origin to the embryo, 
and the trophectoderm, precursor of all placental cells (Hamilton and Boyd, 1960). At 
day 6–7 post-conception, the trophectoderm makes contact and fuses with the 
endometrium, the epithelium of the uterine mucosa (Figure 1.1, A). At this stage, the 
stem cells of the trophectoderm generate the early mononuclear cytotrophoblast and 
the multinuclear primary syncytium, which penetrates in the maternal decidua, a 
specialized tissue formed from the endometrium under the influence of progesterone 
(Figure 1.1, B) (Okada et al., 2018; Schlafke and Enders, 1975). At 14 days after 
fertilization, the blastocyst is completely embedded in the decidua. At this stage, 
cytotrophoblast cells rapidly proliferate and project toward the primary syncytium to 
form finger-like extensions into the maternal decidua thus forming the primary villi 
(Figure 1.1, C) (Hertig et al., 1956; Turco and Moffett, 2019). During the following 
days, the villous tree develops by continuous proliferation and cell fusion of 
cytotrophoblast which gives origin to the multinuclear syncytiotrophoblast layer, the 
mother/fetus interface (Castellucci et al., 2000). By day 18 post-fertilization, fetal 
capillaries appear within the core of the villi to form the tertiary villi (Hamilton and 
Boyd, 1960). The recruitment of pericytes, specialized cells that wrap around the 
endothelial cells of fetal capillaries, stabilizes placental vascular network which 
further expands to finally connect to the vasculature of the fetus (Burton et al., 2009; 
Knöfler et al., 2019). At 4 weeks post-implantation, the formation of the basic 







Figure 1.1 Early stages of human placentation and syncytiotrophoblast 
formation. A) At 6-7 days post-fertilisation, the trophectoderm of the blastocyst 
makes contact and fuses with the endometrial epithelium of the uterus. B) The stem 
cells of the trophectoderm give origin to mononuclear trophoblast cells from which 
the primary syncytium develops by cell fusion. C) 14 days after fertilization, primary 
villi are formed by sustained proliferation of cytotrophoblast which takes contact with 
the decidua and fuses to form syncytiotrophoblast, the feto-maternal interface 




1.1.2 Signalling pathways regulating syncytiotrophoblast formation 
The syncytiotrophoblast originates from asymmetrical cell division and fusion of 
villous cytotrophoblast cells (Kliman et al., 1986). The proliferation of the 
cytotrophoblast layer increases significantly within two weeks post-conception when 
the villous tree is forming and relies on physical contact with syncytiotrophoblast 
(Forbes et al., 2008). Human chorionic gonadotropin (hCG), a key hormone secreted 
by syncytiotrophoblast, is the best characterized factor which promotes 
syncytialization via autocrine mechanisms (Pidoux et al., 2007; Shi, 1993; Yang et al., 
2003). It has been suggested that hCG may constitute the earliest signal which triggers 
the formation of the primary syncytium. In fact, although hCG is almost exclusively 
secreted by the mature syncytiotrophoblast, it is also produced by the human embryo 
as early as 7 days post-fertilization (Bonduelle et al., 1988).  
The best characterized molecular signalling pathway which promotes 
syncytiotrophoblast formation is the cyclic adenosine monophosphate/protein kinase 
A (cAMP/PKA) pathway activated by several factors including hCG and calcitonin-
gene related peptide (CGRP) (Green et al., 2006; Shi et al., 1993). In human 
trophoblast, the hCG binding to the luteinizing hormone/choriogonadotropin receptor 
(LH/CG-R), a rhodopsin-like G protein-coupled receptor (GPCR) of 674 amino acids, 
induces conformational changes in the receptor and mechanical activation and release 
of protein G which activates, in turn, the adenylyl cyclase (AC). AC catalyses the 
conversion of ATP to cyclic AMP (cAMP) increasing the intracellular levels of this 
second messenger (Keryer et al., 1998; Pidoux et al., 2007) (Figure 1.2). Mostly, the 
biological effects of cAMP are mediated via PKA. The latter exists as a tetramer 
consisting of two regulatory and two catalytic subunits. When cAMP levels are low, 
the tetramer remains intact and the enzyme inactive. When the intracellular cAMP 
rises, two cAMP molecules bind to each regulatory subunit inducing a conformational 
change which causes the release of the catalytic subunits (Kim et al., 2007). The 
liberated catalytic subunits promote the transfer of ATP terminal phosphates to protein 
substrates at serine (Ser) and threonine (Thr) residues on the Arg-Arg-X-Ser/Thr 
consensus motif (Shabb, 2001). In trophoblast, activation of PKA results in the 
downstream activation of cAMP response element-binding protein (CREB) via 
phosphorylation at Ser133 and the recruitment of the transcriptional co-activators 
CREB-binding protein (CBP) and P300 which initiate the transcription of specific 
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genes involved in trophoblast differentiation including hCG, glial cells missing 
transcription factor 1 (GCM1) and the fusogenic proteins syncytin-1 and syncytin-2 
(Chen and Cheong, 2011; Gerbaud and Pidoux, 2015; Gupta et al., 2016) (Figure 1.2). 
Syncytin-1 and syncytin-2 are two transmembrane proteins encoded by the envelope 
genes of human endogenous retrovirus (HERVs) (Blaise et al., 2003; Sha et al., 2000). 
Their expression increases during trophoblast differentiation and they are both 
essentials for syncytium formation (Frendo et al., 2003; Vargas et al., 2009). In 
addition, induction of cAMP/PKA signalling regulates the expression of cadherin and 
connexin, two key players in syncytiotrophoblast formation, which mediate cell–cell 
adhesion and assembly of the fusogenic machinery (Gerbaud and Pidoux, 2015). In 
particular, E-cadherin is important for the formation of adherens junctions, 
intercellular adhesive structures, during the aggregation of mononuclear 
cytotrophoblasts while its protein expression diminishes during cell fusion (Coutifaris 
et al., 1991).  
A second key signalling pathway controlling syncytiotrophoblast formation is the 
mitogen-activated protein kinase (MAPK) cascade. During pregnancy, a sophisticated 
cross-talk between cAMP/PKA pathway and ERK1/2 and p38 MAPKs regulates 
different processes including placental leptin expression (Ge et al., 2011; Maymó et 
al., 2010), protection from maternal stress via 11β-HSD2 enzyme (Shu et al., 2014), 
decidualization (Yoshino et al., 2003), extravillous trophoblast migration (McKinnon 
et al., 2001) and syncytiotrophoblast formation (Vaillancourt et al., 2012; Daoud et 
al., 2005; Delidaki et al., 2011; Nadeau and Charron, 2014). The latter has been widely 
explored in vitro. In BeWo cells, ERK1/2 and p38 are both activated downstream of 
cAMP/PKA and contribute to hCG production and syncytin-2 expression via different 
mechanisms. In addition, p38 regulates gene expression of syncytin-1 by controlling 





Figure 1.2 Cyclic AMP signalling pathway regulates syncytiotrophoblast 
formation. hCG binds to the LH-CG receptor, a G protein-coupled receptor (GPCR), 
which activates adenylyl cyclase to generates cAMP. Four molecules of cAMP bind 
to PKA regulatory subunits, which releases and activates PKA catalytic subunits 
which, in turn, enter the nucleus and activate CREB and GCM1 to promote 
transcription of specific markers of trophoblast differentiation (Adapted from Gerbaud 




1.1.2.1 Experimental models to study human trophoblast differentiation  
Primary cultures and cell lines. Considering the complex dynamic of the placenta 
physiology, it is not surprising that the study of its diverse functions, including 
syncytiotrophoblast formation, at different stages of development remains limited. 
Human primary cytotrophoblast constitutes the most valid model to study cell fusion 
and syncytialization in human trophoblast (Cotte et al., 1980). The availability of 
placenta specimens, however, is limited for ethical issues making primary trophoblast 
cells difficult to be obtained. In addition, primary cytotrophoblast cells cannot be 
replicated in culture and spontaneously differentiate within about 12 h of plating (Li 
and Schust, 2015) limiting their application for intensive biochemical and functional 
studies. Moreover, cytotrophoblast isolation procedures are prone to contamination 
with low levels of fibroblasts that multiply more rapidly than the cytotrophoblast cells 
themselves in culture (Frank et al., 2001; James et al., 2016, 2007).  
For that reason, alternative self-renewing cellular model systems are widely employed 
to enable functional studies of placentation. While such systems have their 
disadvantages compared to primary cells, including genetic abnormalities due to their 
cancerogenic origin and genotypic and phenotypic variations caused by serial culture 
passages, they are advantageous in terms of reproducibility, stability and proliferation, 
enabling researchers to evaluate the effect of therapeutic agents on protein expression 
as well as physiological processes including syncytial fusion (Orendi et al., 2011). The 
choriocarcinoma cell lines BeWo, JAR and JEG3, remain the most widely employed 
in vitro model for placental research as they are easy to handle and propagate (Hannan 
et al., 2010). Although these cells represent a cancer cell model, and their behaviour 
may diverge significantly in many aspects from a physiological condition, they display 
various key characteristics and functions of human placental trophoblast cells. In 
particular, BeWo cells display most of the characteristics of villous trophoblast, 
including syncytial fusion and the ability to form a barrier with low permeability as 
well as secretion of hormones including hCG, hPL, progesterone and estradiol (Liu et 
al., 1997; Orendi et al., 2010; Wolfe, 2006). Recently, a comparative study was 
conducted to evaluate the endocrine and transport properties of different human 
trophoblast-derived cell lines including BeWo, JAR and JEG3. The functional 
evaluation focused on characteristics displayed by the placental barrier including tight 
junction formation, sodium fluorescein retardation, trans epithelial resistance, glucose 
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transport and hormone secretion (Rothbauer et al., 2017). Interestingly, BeWo and 
JAR displayed high glucose transport, which was similar to data derived from term 
placenta explants. In addition, among the tested cell lines, the choriocarcinoma cell 
line BeWo resulted the best model for studies on syncytial fusion (Rothbauer et al., 
2017).  
Murine models. Mouse experimental models, and particularly loss-of-function 
mutants with disrupted placental development, have proven to be very useful in 
providing novel insights in the understanding of molecular mechanisms underlying 
human placental function and disorders. Indeed, human and mouse placentas show 
many structural and functional similarities. For instance, the labyrinth layer in mice is 
analogous, in terms of function, to the chorionic villi of the human placenta 
constituting the site of the feto-maternal exchanges. Moreover, both labyrinth and 
human placental villi, are covered by the syncytiotrophoblast which takes direct 
contact with maternal blood (Rossant and Cross, 2001). Interestingly, a recent study 
compared the molecular similarities between the murine labyrinth and the human 
villous tree by assessing the proteome and gene expression profile discovering that 
almost 80% of ortholog genes, evolved in parallel with the diversification of species, 
are co-expressed in human and mouse (Cox et al., 2009). Studies on loss-of-function 
mutants have shown that many of these genes are important for a correct trophoblast 
formation in mice and are also crucial in the analogous cell type in humans. In 
particular, in mice lacking Gcm1 gene the labyrinthine trophoblasts did not 
differentiate and placentas fail to form the labyrinthine layer, necessary for feto-
maternal nutrient and gas exchange, resulting in placenta insufficiency whereas all 
other layers of the murine placenta formed normally indicating a specific role of Gmc1 
in trophoblast differentiation (Schreiber et al., 2000). Similar studies showed a critical 
role for p38 MAPK in controlling murine labyrinthine formation as targeted 
inactivation of p38 or its upstream activator Mekk3, resulted in insufficient oxygen 
and nutrient transfer across the placenta along with severe growth retardation which 
were no longer present when p38 was reintroduced (Adams et al., 2000; Yang et al., 
2000). Interestingly, the existence of two murine endogenous retroviral genes, 
syncytin-A and syncytin-B, homologous to the human syncytin genes, was also 
reported (Dupressoir et al., 2005). More recently, it has been demonstrated that, 
homozygous syncytin-A null mouse embryos die in utero at mid-gestation due to 
specific disruption of the architecture of the syncytiotrophoblast, with the trophoblast 
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cells failing to fuse into a syncytial layer (Dupressoir et al., 2009) suggesting the 
importance of this fusogenic protein for the syncytiotrophoblast formation in both 
humans and mice.  
Although many similarities, the murine and human placentas are very different from 
an endocrine point of view limiting the employment of this model when studying 
endocrine functions of human placenta. One of the unique characteristics of human 
placenta, in fact, is the secretion of steroidogenic hormones throughout pregnancy 
which occurs in much larger amounts in humans than in any other mammal (Malassine 
et al., 2003). For instance, no β-hCG genes have been found in mice (Maston and 
Ruvolo, 2002) suggesting that this major and fundamental hormone for human 
pregnancy is not produced during murine gestation. A major difference is also 
detectable in the regulation and function of a crucial placental enzyme, the 11β-
hydroxysteroid dehydrogenase 2 (11β-HSD2), which will be extensively explored 
later in this thesis. In humans, 11β-HSD2 protects the fetus from the exposure to an 
excess of maternal stress hormones throughout pregnancy and its downregulation is 
associated with intrauterine growth retardation highlighting its fundamental role in the 
regulation of fetal growth (Burton and Waddell, 1999). However, in mice, this enzyme 
is switched off at mid-gestation (Brown, 1996) suggesting a different regulation in 





1.1.3 Functions of human placenta: role of placental barrier 
During pregnancy, the placenta fulfils a variety of vital functions ranging from 
immunological acceptance, nourishment and protection of the embryo to endocrine 
control of pregnancy, maternal metabolism and fetal growth (Gude et al., 2004; 
Murphy et al., 2006; PrabhuDas et al., 2015). The mature placenta appears as a 
discoidal organ constituted by a basal plate and a chorionic plate enclosing the 
intervillous space filled with maternal blood (Figure 1.3). The basal plate is the 
maternal site of the placenta in contact with the uterine wall and is where the uterine 
arteries and veins are directed to and from the intervillous space. The chorionic plate 
is the fetal side of the placenta and gives origin to umbilical cord and branched 
chorionic villi floating in the intervillous space rich in maternal nutrients. The 
umbilical vein transports nutrient and oxygen from the mother to the fetus while the 
arteries transport waste products from the fetus. In a longitudinal section, a chorionic 
villous appears as a multilayer structure called “placental barrier” formed by 1) 
trophoblast cells (syncytiotrophoblasts and cytotrophoblasts) that cover the surface of 
the villous tree; 2) connective tissue forming the villous core which contains 
mesenchymal cells, macrophages and fibroblasts; 3) endothelium of fetal capillaries 
(Figure 1.3) (Benirschke et al., 2012; Chatuphonprasert et al., 2018).  
The predominant functions of the placenta are operated by the syncytiotrophoblast. 
The syncytiotrophoblast, from the Greek syn - "together", cytio - "of cells", tropho - 
"nutrition" and blast - "bud", is a multinucleated layer taking origin from continuous 
proliferation and fusion of the inner cytotrophoblast cells. It is characterized by an 
apical membrane (or maternal-facing microvillous membrane MVM), in direct contact 
with the maternal circulation, and a basal membrane (BM) facing the fetal capillaries. 
The syntytiotrophoblast represents the primary site of nutrient and gas exchange 
between the mother and the fetus thus preventing the direct contact of maternal and 
fetal blood (Lager and Powell, 2012). In addition to its role in sustaining fetal 
metabolism, syncytiotrophoblast produces a multitude of factors and hormones crucial 
for both placental and fetal development and gives protection to the fetus against a 







Figure 1.3 Cartoon depicting structure and functions of placental barrier. The 
mature placenta appears as a discoidal organ with the chorionic villi floating in the 
intervillous space filled with maternal blood. In longitudinal sections, the villi appear 
as three-layered structures. The apical membrane of syncytiotrophoblast takes contact 
with the maternal blood whereas the basal membrane faces fetal circulation. 
Syncytiotrophoblast fulfils the majority of placenta functions including transport of 
macronutrients, production of placental hormones and constitutes both a physical and 
enzymatic barrier against a variety of insults coming from the maternal environment. 




1.1.3.1 Transport of macronutrients glucose, amino acids and lipids  
Flux across the syncytiotrophoblast represents the rate-limiting steps in maternal-fetal 
transfer of most important nutrients as only smaller solutes are highly permeable 
through the syncytial membranes (Brett et al., 2014; Lager and Powell, 2012; Smith 
et al., 1992). Most sites of known mechanisms of cellular transport are localized to the 
maternal- and fetal-facing plasma membrane surfaces of the syncytiotrophoblast 
(Sideri et al., 1984; Smith et al., 1992). Indeed, glucose, amino acids and lipids enter 
fetal circulation through nutrient-specific transport proteins located within the MVM 
and BM (Figure 1.3). Hence, it is commonly referred to as facilitated diffusion 
(Schneider, 1991; Brett et al., 2014; Lager and Powell, 2012). 
Glucose. Glucose is the main source of energy for both fetus and placenta (Hauguel et 
al., 1983). The vast majority of fetal glucose derives from mother (Kalhan et al., 2000; 
Staat et al., 2012). In vitro experiments demonstrate that almost 75% of glucose that 
enters the placenta reaches the fetal side unchanged (Hauguel-de Mouzon et al., 2001). 
Glucose transfer across the placenta occurs via specialized glucose transporters 
(GLUTs). The density of glucose transporter proteins is considerably greater within 
the MVM than within the BM of syncytiotrophoblast. This suggests that a consistent 
part of the glucose picked up from maternal circulation is used to fulfil placental 
metabolic needs (Illsley, 2000; Jansson et al., 1993). GLUT1 is the principal isoform 
involved in glucose transport across the placenta. Its expression is higher within MVM 
compared to BM (Baumann et al., 2002; Jansson et al., 1993). However, the density 
of GLUT1 in the BM increases significantly in the first half of pregnancy reaching a 
plateau from late second trimester onward suggesting increased fetal glucose demand 
toward term (Jansson et al., 1993). Interestingly, during the first trimester of 
pregnancy, placental glucose transport responds to insulin, while during the third 
trimester glucose uptake is not regulated by insulin (Castillo-Castrejon and Powell, 
2017; Anette Ericsson et al., 2005). This can be due to the fact that GLUT1 is the 
predominant placental glucose transporter expressed throughout pregnancy which 
increases toward term, while, on the contrary, the insulin-sensitive isoform GLUT4, 
is expressed during the first trimester but is downregulated in term placentas 
(Stanirowski et al., 2017). Insulin-like growth factor I (IGF-1), instead, increases the 
expression of GLUT1 in the BM enhancing transepithelial glucose transport 
(Baumann et al., 2014). Unlike GLUT1, which is ubiquitously expressed in all 
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placental cells, GLUT3 shows a more restricted expression pattern, which suggests 
specialized functions for this glucose transporter (Xu et al., 2015). The GLUT3 
isoform is expressed in cytotrophoblasts during early gestation but is localized 
primarily to the fetal vascular endothelium during late gestation (Brown et al., 2011). 
It seems to be mainly involved in positive regulation of glucose flux across the 
placenta by decreasing the umbilical arterial glucose concentration (Illsley, 2000). As 
for GLUT9, the placenta is one of the few tissues that express both splice variants, 
GLUT9a and GLUT9b, which are localized within the BM and MVM respectively 
(Augustin et al., 2004; Bibee et al., 2011).  
Amino acids. Amino acids provide the essentials for protein synthesis. Therefore, the 
concentration of amino acids results higher in fetal circulation compared to maternal 
circulation highlighting the great demand of the fetus for these macronutrients to grow 
(Jansson, 2001). Amino acids transport across syncytiotrophoblast is regulated by 15 
distinct families of transporters differently distributed between MVM and BM. The 
rate-limiting step in placental amino acids transport occurs across MVM (Glazier et 
al., 1997). The most well-characterized placental amino acid transport systems are 
System A and System L (Jansson, 2001). System A is more highly expressed in the 
MVM of the syncytiotrophoblast and regulates the transport of small neutral amino 
acids (SNAT) such as alanine, serine and glycine. Its activity is promoted by different 
hormones including insulin, leptin and IGF-1 (Jansson et al., 2003; Roos et al., 2009b). 
On the other hand, System L controls the placenta transport of large neutral amino 
acids (LAT) such as leucine and its activity is predominantly stimulated by glucose 
and insulin (Roos et al., 2009b).  
Fatty acids. In the maternal circulation, the fatty acids source is in the form of 
triglycerides (TGs). At the placenta barrier, specific placental TG lipases, such as 
endothelial lipase and lipoprotein lipase expressed at the MVM, break down TGs into 
free fatty acids (FFAs) to make them available for placental uptake (Duttaroy, 2009; 
Gauster et al., 2007). Three membrane systems have been implicated in placental 
FFAs transport and include a family of fatty acid transport proteins (FATPs) and fatty 
acid translocase (FAT/CD36), located on both MVM and BM, and a fatty acid binding 
protein (FABPpm) exclusively found within MVM (Campbell et al., 1998). Similarly 
to amino acid transporters, the expression and activity of placental fatty acid 
transporters is influenced by insulin, IGF-1 and leptin (Magnusson-Olsson et al., 2006; 
Mousiolis et al., 2012). 
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1.1.3.2 Protective function  
The syncytiotrophoblast constitutes a physical barrier against the invasion of a wide 
range of pathogens (Koi et al., 2002; Robbins et al., 2010; Zeldovich et al., 2013). 
Rupture or damage of syncytial barrier may constitute a portal for infectious agents to 
enter fetal compartment (Robbins et al., 2012, 2010). Along with physical barrier 
activity, the syncytiotrophoblast offers enzymatic defence against a vast variety of 
xenobiotics coming from maternal compartment thus preventing their cellular 
accumulation and transfer across the placenta (Myllynen et al., 2005). A crucial 
enzyme in the syncytiotrophoblast is 11β-HSD2 that offers protection to the fetus from 
an excess of maternal stress hormones, glucocorticoids, by catalysing the conversion 
of the human glucocorticoid, cortisol, to its inactive metabolite, cortisone (Yang, 
1997). Glucocorticoids are steroid hormones produced predominantly by the adrenal 
gland which mediate the response of the body to acute stress or daily life challenges 
(McEwen, 2007). During pregnancy, physiological levels of glucocorticoids guarantee 
the correct development for most fetal organs in preparation for extrauterine life 
including lung, heart, kidney, and gut (Seckl, 1998). However, elevation of maternal 
circulating glucocorticoids as a consequence of maternal stressors, including mood 
disorders (Conradt et al., 2013; O’Donnell et al., 2012; Ponder et al., 2011) and 
malnutrition (Bellisario et al., 2015; Chivers and Wyrwoll, 2017; Cottrell et al., 2012; 
Panchenko et al., 2016), leads to a failure in 11β-HSD2 barrier, including decreased 
enzyme levels or inhibition of the enzymatic ability to deactivate cortisol, resulting in 
increased exposure of the fetus to maternal glucocorticoids. Increased glucocorticoids 
exposure during in utero life induces fetal growth derangements with long-term 
consequences on the offspring’s health in both human and rodent models (Cottrell, 
2009; Maccari et al., 2003; Matthews, 2000; Seckl and Holmes, 2007).  
1.1.3.3 Endocrine function  
The syncytiotrophoblast is the primary source of placental hormones during much of 
pregnancy. The placental endocrine activity is involved in regulating many important 
aspects of gestation and post-parturition including regulation of maternal metabolism 
such as mobilization of nutrients, pregnancy maintenance, delivery and lactation 
(Costa, 2016; Napso et al., 2018) (Figure 1.4). Some placental hormones are secreted 
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into the fetal circulation to regulate also fetal development and growth (Murphy et al., 
2006).  
hCG: The first and best characterized protein hormone produced by the 
syncytiotrophoblast is the human chorionic gonadotropin (hCG). It belongs to the 
glycoprotein family and is constituted by a α-subunit, shared by all the family 
members, and a β-subunit characteristic of each hormone. Beta-hCG measurement in 
maternal blood and urine is commonly employed as a pregnancy test (Cole, 2012). 
Levels of β-hCG increase exponentially during early pregnancy followed by a plateau 
during the late first trimester and decline slowly until the end of pregnancy (Cole, 
1997). Throughout pregnancy, hCG has been shown to have numerous functions in 
the placenta, uterus and possible in the fetus (Cole, 2010). From the time of 
implantation until 3 to 4 weeks post-fertilization, hCG, produced by trophoblast cells, 
controls the production of progesterone from ovarian corpus luteal cells. As pregnancy 
progresses, the syncytiotrophoblast is mature enough to take over the production of 
progesterone (Tuckey, 2005). Progesterone, a steroid hormone synthesised from 
maternal cholesterol, in turn, is important in inhibition of myometrium contractility, 
promotion of uterine quiescence and decidualization of endometrium (Graham and 
Clarke, 1997). Besides controlling progesterone production, hCG promotes 
placentation by acting in an autocrine manner to stimulate syncytium formation thus 
participating in the generation and integrity of placental barrier (Shi et al., 1993; Yang 
et al., 2003). Moreover, hCG promotes the expression of 11β-HSD2 in the 
syncytiotrophoblast thus participating in maintaining the defence against maternal 
glucocorticoids excess (Ni et al., 2009). In the uterus, hCG promotes angiogenesis and 
vasculogenesis during pregnancy ensuring maximal blood supply to the developing 
placenta and nutrients to the growing fetus (Zygmunt et al., 2003). Furthermore, hCG 
takes part in regulating the immune response by reducing the macrophage activity at 
the placenta-uterine interface thus promoting maternal immune tolerance toward the 
forming fetal tissues (Schumacher, 2017). Finally, hCG contributes to myometrial 
relaxation during the course of pregnancy while its decrease prior the onset of labour 
(Edelstam et al., 2007), along with reduction in the number of myometrial hCG 
receptors (Zuo et al., 1994), suggest a role for hCG signalling in the onset of 
parturition.  
Estrogens: In addition to progesterone and hCG production, syncytiotrophoblast 
constitutes the major source of estrogens, synthetized from maternal cholesterol, 
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which include: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4). During the 
1st week of gestation, the estrogens are produced by ovarian corpus luteum under the 
stimulation of hCG. As pregnancy progress, the syncytiotrophoblast takes over the 
synthesis of these steroids producing around 100-120 mg/day at term 
(Chatuphonprasert et al., 2018). Estradiol is the most abundant steroid produced 
during pregnancy (Loriaux et al., 1972). Estrogens mainly promote blastocyst 
implantation by stimulating endometrial growth and differentiation (Groothuis et al., 
2007). In addition, estradiol stimulates the uteroplacental blood flow by promoting 
vasodilatation of uterine and placental arteries (Corcoran et al., 2014) and takes part 
in labour initiation by stimulating the contraction of human myometrial cells (Di et 
al., 2001).  
Hormones regulating maternal metabolism: A number of hormones produced by the 
syncytiotrophoblast, including human placenta lactogen (hPL) and human placenta 
growth hormone (hPGH), which share high homology and function, takes part in the 
regulation of maternal metabolism to ensure the mobilization of energy resources 
needed during pregnancy. Glucose is the main source of energy for both placenta and 
fetus and, for that reason, pregnancy has a major impact on glucose homoeostasis via 
insulin-mediated signalling (Butte, 2000; Leturque et al., 1987). Insulin secretion 
increases significantly during the first part of gestation to promote maternal lipid 
accumulation whereas insulin insensitivity arises during mid-gestation to promote 
hepatic gluconeogenesis and limit glucose uptake in maternal tissues thus providing 
higher levels of circulating glucose for the growing fetus (Bell and Bauman, 1997; 
Butte, 2000). Maternal serum levels of hPL rises in relation to the fetus and placenta 
size with maximum levels reached near term, suggesting a critical role of this hormone 
in placental and fetal growth (Bhagavan, 2002). Indeed, hPL reduces sensitivity to 
insulin in maternal peripheral tissues increasing glucose concentration in maternal 
circulation and promotes lipolysis of maternal fat storage to produce free fatty acids 
which, in part, become available fuel for the mother, utilized in substitution of glucose, 
and in part are converted in ketones which freely cross the placenta contributing to the  
formation of fetal brain (Bronisz et al., 2018; Handwerger and Freemark, 2000).  
Neuroendocrine hormones: During pregnancy, placenta becomes the main source of 
neuroendocrine hormones by replacing much of the mother’s pituitary and 
hypothalamic functions (Krieger, 1982; Voltolini and Petraglia, 2014). An example is 
the corticotropin-releasing hormone (CRH) secreted mainly by the paraventricular 
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nucleus (PVN) of the hypothalamus. CRH is synthesized in the syncytiotrophoblast 
from first to third trimester and maternal serum levels rise exponentially throughout 
pregnancy to peak at labour (Grammatopoulos, 2008; Petraglia et al., 1988; Riley et 
al., 1991). It targets multiple fetal–maternal tissues and is involved in the regulation 
of several functions throughout pregnancy including hormone secretion, immune 
response, glucose transport, vascular tonus and myometrial contractility (Gao et al., 
2012; Voltolini and Petraglia, 2014). Interestingly, in contrast to the hypothalamus, 
placental CRH release is positively regulated by glucocorticoids (Robinson et al., 
1988) suggesting increased demand for CRH biological functions near term (Petraglia 
et al., 2010). Indeed, at term, CRH regulates timing of parturition via estrogens and 
progesterone-mediated mechanisms which control the contractile properties of the 
myometrium (Majzoub and Karalis, 1999; Gangestad et al., 2012; Thomson, 2013). 
In addition, CRH stimulates cortisol and dehydroepiandrosterone sulphate (DHEAS) 
production from fetal adrenal gland at the end of pregnancy, suggesting a role in fetal 
lung maturation and adaptive mechanisms in response to the stress of parturition (Pepe 




Figure 1.4 Endocrine activity of the human placental trophoblast. The 
syncytiotrophoblast is the primary source of placental hormones during much of 
pregnancy. Placental hormones regulate many important aspects of gestation including 
mobilization of maternal nutrients for fetal growth, placentation, pregnancy 
maintenance and parturition.   
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1.1.4 Placental mechanisms of in utero programming: contribution of maternal 
overnutrition and stress 
According to the paradigm of the Developmental Origins of Health and Disease 
(DoHAD) postulated by Barker 27 years ago (Barker et al., 1993), perinatal exposure 
to suboptimal environmental conditions, including maternal metabolic alterations and 
stress, deranges fetal growth and “program” the offspring to develop chronic diseases, 
including cardiovascular disorders, obesity, and diabetes, later in life (Curhan et al., 
1996; Leon et al., 1998). It is now widely accepted that changes in fetal growth are the 
result of maladaptive placental responses to maternal environment which include 
aberrant placental development and function with major impact on placental size and 
morphology, alterations in the expression of nutrient transporters in the placental 
barrier and changes in the placental response to stress and epigenetic mechanisms 
(Fowden et al., 2006; Longtine and Nelson, 2011; Wu et al., 2004). Although it is now 
widely accepted that alterations in maternal physiology can be passed to the fetus via 
maladaptive changes in placenta development and function, the exact mechanisms 
through which the placenta acquires disease properties during maternal metabolic 
complications, especially overweight and obesity, and during distress states such as 
mood disorders, need further investigations.  
1.1.4.1 Epidemiologic evidence of in utero programming 
Maternal obesity: Obesity is the leading preventable cause of mortality in the 
developed countries classified as a disease by the American Medical Association in 
2013 (Barness et al., 2007; Mokdad et al., 2004). In 2015, 600 million adults (12%) 
and 100 million children were classified as obese among the world’s population (GBD 
2015 Obesity Collaborators, 2017). Likewise, the prevalence of obesity in women at 
the reproductive age, as well as the number of women entering pregnancy obese, have 
risen rapidly in the last two decades (Flegal et al., 2012; Heslehurst et al., 2010).  
Obesity is the most common problem in obstetrics that affects enormously both mother 
and child health in the short- and long-term (Catalano and Shankar, 2017). In 
particular, it is associated to spontaneous abortion, stillbirth and reduced likelihood of 
natural labour at term along with post-term pregnancy and occurrence of 
complications during delivery (Chu et al., 2007; Denison et al., 2008). In addition, 
maternal obesity significantly increases the risk for developing hypertensive disorders, 
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pre-eclampsia and gestational diabetes mellitus (GDM) during pregnancy as well as 
postpartum diabetes and hyperglycemia (Catalano and Ehrenberg, 2006; O’Brien et 
al., 2003; Weiss et al., 2004; Yogev and Langer, 2008). 
The consequences for the offspring born from obese mothers are also severe. 
Epidemiological studies showed that maternal obesity significantly deranges 
offspring’s growth increasing the risk for macrosomia (birthweight ≥4500 g), fat mass 
and fetal overgrowth (Ehrenberg et al., 2004; Metzger, 2010; Sewell et al., 2006). In 
addition, offspring born from pregnancy complicated by obesity and GDM are more 
likely to develop childhood and adult obesity and type 2 diabetes mellitus (Drake and 
Reynolds, 2010; Hochner et al., 2012; Reynolds et al., 2010). Macrosomia itself is a 
strong predictor of BMI at 1 year of age as well as obesity and cardiovascular risk at 
adulthood (Lindberg et al., 2012). Moreover, a strong association between maternal 
obesity and offspring neurodevelopmental and psychiatric morbidity has been 
reported (Edlow, 2017). In particular, children born from mothers with a metabolic 
condition, including obesity, are at risk for autism and developmental delay 
(Girchenko et al., 2018; Krakowiak et al., 2012; Li et al., 2016). In addition, maternal 
obesity has been associated with symptoms of attention-deficit hyperactivity disorder 
(ADHD) in the child and difficulty in the control of emotionality (Rodriguez, 2010; 
Rodriguez et al., 2008). Likewise, the risk for developing schizophrenia is increased 
up to 7.78-fold in children born from obstetric complications including diabetes and 
emergency cesarean section often associated to maternal obesity (Cannon et al., 2002; 
Chu et al., 2007). Finally, infants born larger than normal have a higher likelihood of 
developing anxiety and depression during adolescence and as adults (Colman et al., 
2012; Van Lieshout et al., 2020).  
Maternal stress and mood disorders: Epidemiological evidence shows that up to 13% 
of women experience depressive symptoms at some point during gestation or within 
one year from parturition (Gavin et al., 2005). Similarly, the prevalence for anxiety 
symptoms has been found to increase with the trimester of pregnancy reaching 24.6% 
in the third trimester as revealed recently by a meta-analysis study (Dennis et al., 
2017). Clinical studies show that symptoms of antenatal depression as well as 
moderate to severe life stress and maternal anxiety in women are associated with an 
increased risk for premature delivery, low birthweight and increased neonatal crying 
(Dunkel Schetter and Tanner, 2012). Moreover, it has been demonstrated that a 
distressed psychological state in the mother influences many aspects of fetal 
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physiology. For instance, perceived stress, depression and anxiety disorders during 
pregnancy, can change fetal heart rate (FHR) activity which, in turn, is a predictor of 
neurobehavioral disturbance in childhood (Kinsella and Monk, 2009). In addition to 
FHR, the fetal activity and sleep pattern have been shown to be influenced by maternal 
psychological states, suggesting that maternal mood exerts a major impact on the 
activity of the fetal nervous system (Kinsella and Monk, 2009). Indeed, clinical studies 
showed that maternal distress particularly affects fetal brain development and 
influences children’s long–term mental health. For instance, exposure to traumatic 
events and chronic stress during pregnancy have been associated with emotional and 
cognitive problems in the child, including an increased risk of attentional 
deficit/hyperactivity, anxiety, and language delay (Talge et al., 2007). Moreover, 
maternal mental disorders such as anxiety and depression are associated with 
increased risk for child emotional problems, depression in adolescence and low levels 
of general cognitive development in childhood (Stein et al., 2014). Two principal 
pathways have been proposed for the in utero transmission of maternal stress to the 
fetus and include the dysregulation of the maternal-fetal hypothalamic–pituitary–
adrenal (HPA) axis, which will be discussed later in this thesis Chapter, and disruption 
of placenta physiology and development due to variations in uterine artery flow 
(Kinsella and Monk, 2009). 
1.1.4.2 Role of placental nutrient transport in fetal programming 
Observation in humans showed that, a low caloric intake is associated to a lower 
placental weight and thickness (Roseboom et al., 2011) whereas higher maternal body 
weight correlated with larger placenta (Strøm-Roum et al., 2016; Thame et al., 2004). 
Early stages of gestation constitute a sensitive window during which placental 
structures are formed and the placenta is more susceptible to developmental 
alterations. For instance, the glucose transport system is particularly affected by 
changes in maternal metabolism as glucose uptake responds to insulin in primary 
villous during early pregnancy but not at term (Ericsson et al., 2005a; Ericsson et al., 
2005b). In addition, GLUT1 levels increase in early pregnancy representing a critical 
event since metabolic perturbations may further stimulate its expression (Jansson et 
al., 1999). Accordingly, placental glucose transporters along with amino acid 
transporters, respond to adverse maternal metabolic conditions including, obesity, 
diabetes and malnutrition (Das et al. 1998; Illsley 2000). In particular, pre-existing 
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diabetes and GDM are associated with increased expression of GLUT transporters in 
the BM of the syncytiotrophoblast and significantly higher uptake of glucose 
compared to normal pregnancies (Bibee et al., 2011; Gaither et al., 1999; Jansson et 
al., 1999). According to the Pedersen hypothesis, maternal hyperglycemia increases 
transplacental passage of glucose inducing fetal hyperglycemia and insulin secretion 
leading to increased fetal adipose mass accumulation and macrosomia at birth 
(Pedersen, 1971; Vambergue and Fajardy, 2011). Besides diabetes, recent 
observations showed that placental expression of GLUT1 is positively associated with 
maternal sugar intake in normal pregnancies (Brett et al., 2015). Furthermore, in obese 
women giving birth to large infants, placental GLUT1 expression and system A 
activity are up-regulated in BM and MVM respectively (Acosta et al., 2015; Jansson 
et al., 2013). Similarly, observations in animal models consuming high-fat diet 
periconceptionally showed fetal overgrowth along with up-regulation of transplacental 
glucose, increased expression of GLUT1 and SNAT2 amino acid transporter (Jones et 
al., 2009). 
1.1.4.3 Placental nutrient-sensing system in fetal programming 
According to the placental nutrient-sensing model, the placenta mediates the 
allocation of nutrients between mother and fetus by coordinating changes in maternal 
metabolism and physiology with fetal growth and requirements. This is possible due 
to the presence of sensors, expressed by the syncytiotrophoblast, which are able to 
detect maternal nutritional stimuli, such us glucose, fatty acids, amino acids and ATP, 
and adjust cell metabolism and placental transport in response to nutrients availability 
and fetal demand (Figure 1.5). Extreme conditions can activate or disactivate these 
nutrient-sensing mechanisms in the attempt to restore homeostasis with consequences 
on fetal development. The best characterized nutrient sensing pathways in the placenta 
are the mammalian target of rapamycin complex 1 (mTORC1) and the AMP-activated 
protein kinase (AMPK), but a novel candidate, the hexosamine biosynthetic pathway 
(HBP), has lately emerged (Díaz et al., 2014; Dimasuay et al., 2016; Hart et al., 2019; 







Figure 1.5 Representation of the placental nutrient-sensing model. The placenta 
integrates both maternal and fetal signals with information from nutrient-sensing 
signalling pathways to match fetal demand with maternal supply thus regulating 
pregnancy physiology, placental growth, and nutrient transport to the fetus.  
 
AMPK: AMPK activity as a cellular energy sensor is well known in different cell types 
(Hardie et al., 2012). In response to depletion of ATP and rise in AMP levels, AMPK 
maintains energy balance within the cell by switching off anabolic pathways, such as 
protein synthesis, and turning on processes generating ATP by increasing, for 
example, glucose uptake and fatty acid oxidation (Garcia and Shaw, 2017). According 
to its role as a placental nutrient sensor, AMPK is activated during maternal calorie 
restriction (Ma et al., 2011), whereas it is decreased in the placenta of over-nourished 
obese ewes (Zhu et al., 2009), in pregnant rats feeding high-fat diet (Gaccioli et al., 
2013) and in obese women (Jansson et al., 2013) all conditions associated with 
derangement in fetal growth and alterations of birth weight.  
mTORC1: mTOR is a ubiquitously expressed serine/threonine kinase constituted by 
two complexes, mTORC1 and mTORC2. In particular, mTORC1 controls cell growth, 
proliferation, and metabolism in response to nutrient availability and growth factor 
signalling by regulating protein synthesis via activation of the downstream targets, 
ribosomal S6 kinases (S6K1 and S6K2) and eukaryotic initiation factor 4E-binding 
proteins (4E-BP1 and 4E-BP2) (Ma and Blenis, 2009; Wang and Proud, 2006). In 
addition, it controls the transcription of metabolic gene network including genes 
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involved in amino acids, lipids and nucleotide metabolism (Düvel et al., 2010). In the 
placenta, mTORC1 is highly expressed in the syncytiotrophoblast (Roos et al., 2007) 
and its activation is regulated by glucose and amino acid concentrations (Roos et al., 
2009b) as well as insulin and IGF-1 (Shang and Wen, 2018; Taniguchi et al., 2006). 
In turn, mTORC1 stimulates both system A and L amino acid transporters thus 
regulating amino acids delivery to the fetus (Roos et al., 2009a). In agreement with its 
role as a placental nutrient sensor, mTORC1 is activated during maternal obesity 
associated with fetal overgrowth in both human (Jansson et al., 2013) and animal 
models of high-fat diet-induced obesity (Gaccioli et al., 2013; Rosario et al., 2016), 
whereas it is inhibited in human intrauterine growth restriction (IUGR) (Roos et al., 
2007; Yung et al., 2008) and in IUGR induced by a poor diet in animal models 
(Kavitha et al., 2014; Rosario et al., 2011). Importantly, AMPK exerts an inhibitory 
effect on mTORC1 and the two placental sensors have been found to be inversely 
activated in placentas from GDM pregnancies and in obese mothers giving birth to 
large babies (Jansson et al., 2013; Martino et al., 2016), suggesting the presence of a 
placental AMPK-mTORC1 interplay which regulates fetal growth.  
HBP: The nutrient-sensing HBP is activated in a nutrient-dependent fashion, 
especially by glucose, to produce the end product uridine diphosphate N-
acetylglucosamine (UDP-GlcNAc), the substrate for the O-GlcNAc transferase (OGT) 
which modifies post-translationally thousands of nucleocytoplasmic proteins thus 
controlling a myriad of cellular processes within multiple tissues (Love and Hanover, 
2005; Vaidyanathan and Wells, 2014). However, the role of the HBP and O-GlcNAc 
modification in nutrient-sensing within the placenta is less known. Preliminary studies 
showed that, HBP is active in first trimester human placenta and influences villous 
hormone production and IGF-stimulated trophoblast turnover (Acharya et al., 2012). 
In murine models, manipulation of HBP and O-GlcNAc signalling causes disturbance 
in the vasculature and shape of the placenta along with abnormal expression of GLUT1 
transporters and fetal growth restriction (Yang et al., 2015). Similarly, increased flux 
through the HBP, induced by stimulation with glucose and glucosamine, leads to 
aberrant placental physiology and fetal growth in rodent models suggesting a potential 
role of the HBP pathway and O-GlcNAc modification of proteins in placental growth 




1.1.4.4 Maternal hypothalamic–pituitary–adrenal (HPA) axis and 11β-HSD2 activity 
In humans, the HPA axis controls the synthesis and release of the stress hormone 
cortisol. Physical or emotional stress, but also metabolic stimuli such as 
hypoglycemia, induce the release of CRH from the hypothalamus, which stimulates 
the secretion of the adrenocorticotropic hormone (ACTH) from the anterior pituitary 
gland which, in turn, controls the synthesis and secretion of cortisol from the adrenal 
cortex (Figure 1.6) (Smith and Vale, 2006). In a physiological state, cortisol restores 
homeostasis after stress response. This occurs via activation of glucocorticoid 
receptors (GRs), which are present in almost every cell in the body. When the ligand-
receptor complex is formed, it translocates to the nucleus where it regulates the 
transcription of genes mainly associated to the anti-inflammatory response and 
regulation of metabolism (Sapolsky et al., 2000). The HPA axis activity changes 
significantly during pregnancy and lactation as an adaptive response to the 
modifications occurring in maternal physiology (Brunton et al., 2008). Moreover, in 
the fetus, cortisol plays a crucial role in the maturation of many organs contributing to 
the formation of respiratory, renal, and cardiovascular systems (Seckl, 1998). Normal 
pregnancy is a state of transient hypercortisolemia in part due to increased levels of 
placental CRH in the second half of pregnancy which stimulates the release of the 
ACTH from the anterior pituitary gland and consequently the release of cortisol from 
the adrenal (Mastorakos and Ilias, 2006) (Figure 1.6). Increases in plasma cortisol can 
be detected as early as the 11th week of gestation reaching almost 5-fold between the 
first trimester and delivery (Lindsay and Nieman, 2005). The fetus is protected from 
maternal hypercortisolism by the activity of placental 11β-HSD2 which inactivates 
cortisol by converting it into cortisone, while 11β-HSD1 drives the opposite reaction 
by converting cortisone into cortisol (Figure 1.6). During most of the pregnancy, the 
conversion of cortisol into cortisone by 11β-HSD2 predominates whereas, in late 
gestation, placental 11β-HSD2 activity markedly declines and maternal glucocorticoid 
concentrations rise to favour fetal organ maturation (Agnew et al., 2018; Fowden et 
al., 1998). However, the protection offered by the 11β-HSD2 barrier in early gestation 
can be weakened by maternal disease and mood disorders such as anxiety or 
depression (Ponder et al., 2011), metabolic disorders (McTernan et al., 2001), 
infection and inflammation (Chapman et al., 2013; Chisaka et al., 2005). These 
conditions lead to an increase in maternal circulating cortisol along with decreased 
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expression of placental 11β-HSD2, promoting increased transfer of maternal 
glucocorticoids to the fetus. Because maternal cortisol levels are much higher than 
fetal levels, even moderate variations in placental 11β-HSD2 expression or activity 
can significantly alter fetal cortisol exposure (Duthie and Reynolds, 2013). As the 
forming fetal organs, particularly brain, liver and kidney, highly express GRs, 
increased exposure to cortisol impinges on the basic structure of immature organs 
affecting, subsequently, their functions and predisposing the offspring to an increased 
risk for neurodevelopmental and cardiometabolic problems in adulthood (Duthie and 
Reynolds, 2013; Lindsay and Nieman, 2005). 
 
 
Figure 1.6 Placental barrier to maternal stress hormones. The secretion of 
maternal cortisol is controlled by the HPA axis and the majority of this hormone is 
inactivated in the placenta by the 11β-HSD2 enzyme which converts cortisol into 
cortisone. In normal pregnancies, only a little portion of cortisol reaches the fetus to 
ensure organ maturation. In this respect, glucocorticoids program in utero many 
aspects of the offspring’s physiology at adulthood including metabolism and brain 
functions (Adapted from Duthie and Reynolds, 2013).   
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1.1.4.5 Fetal programming and placental epigenetics 
Epigenetic mechanisms may also contribute to transmit maternal alterations to the 
growing fetus. The term “epigenetics” refers to inheriting mechanisms of variation in 
gene expression which are not associated to changes in the DNA nucleotide sequence 
such as DNA methylation and histone acetylation. One proposed mechanism via 
which maternal nutritional status may alter placental epigenetic modifications is by 
altering the availability of methyl donors, such as folate (Waterland and Jirtle, 2003). 
Observations in humans showed that, maternal glucose metabolism dysregulation 
preferentially affects DNA methylation of placental genes involved in energy and 
glucose metabolism along with genes regulating fetal and placental growth (Bouchard 
et al., 2010; Lesseur et al., 2014; Ruchat et al., 2013). Recent studies conducted in 
both humans and murine models showed that the placental epigenetic machinery is 
also sensitive to maternal obesity associated with adverse pregnancy outcomes 
(Mitsuya et al., 2017; Panchenko et al., 2016). In humans, the methylation status of 
specific subsets of genes, including genes controlling energy homeostasis and genes 
associated with cardiometabolic risk, is particularly affected in the placenta of babies 
born with abnormal birth weight (Chen et al., 2018; Díaz et al., 2017). These data 
suggest that changes in DNA methylation may provide a molecular mechanism to 
explain the impact of maternal nutrition and metabolism on fetal programming of 
diseases.  
Maternal stress and mood disorders can also induce changes in placental gene 
expression via epigenetic mechanisms particularly affecting the expression of genes 
involved in the regulation of placental glucocorticoid pathway with potential 
implications for fetal neurodevelopment. For instance, maternal anxiety and perceived 
stress have been linked to increased placental methylation of the gene encoding the 
11β-HSD2 enzyme (Monk et al., 2016; Conradt et al., 2013) while maternal depression 
has been associated with increased placental methylation of the gene encoding 
glucocorticoid receptors, NR3C1 (Conradt et al., 2013). Recent studies have also 
found that levels of war trauma and chronic stress were associated with placental DNA 
methylation levels of four key genes regulating the HPA axis activity including CRH, 
CRH binding protein (CRHBP), which binds CRH to regulate its actions, NR3C1, and 
FKBP5, a co-chaperone protein which modulates glucocorticoid receptor activity 
(Kertes et al., 2016).   
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1.2 O-GlcNAc signalling 
1.2.1 The hexosamine biosynthetic pathway (HBP) and O-GlcNAc modification 
An increasing body of evidences point to a key regulatory role for glucose in mediating 
cellular signalling. Although most cellular glucose is metabolized by glycolysis to 
release energy in the form of ATP, almost 1–5% enters the HBP where it is converted 
to the final product UDP-GlcNAc, a nucleotide sugar extensively involved in cell 
signalling (Marshall et al., 1991). The UDP-GlcNAc formed in the HBP is the 
substrate for the downstream UDP-N-acetylglucosamine-peptide N-
acetylglucosaminyltransferase, also known as O-linked β-N-acetylglucosamine 
transferase or O-GlcNAc transferase (OGT) which catalyses the addition of a single 
N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser and Thr residues on 
thousands of nucleocytoplasmic proteins through an O-glycosidic linkage (O-
GlcNAc), while the O-glycoprotein 2-acetamino-2-deoxy-β-glucopyranosidase or O-
GlcNAcase (OGA) catalyses the removal of O-GlcNAc from the target proteins (Ma 
and Hart, 2014). In the HBP, the glutamine:fructose-6-phosphateamidotransferase 
(GFAT), which converts fructose-6-phosphate to glucosamine-6-phosphate (GlcN-6-
P), is sensitive to UDP-GlcNAc levels and represents the rate-limiting step to HBP 




Figure 1.7 Representation of the hexosamine biosynthetic pathway (HBP) and 
protein O-GlcNAcylation. In addition to glycolysis and glycogen synthesis, 1–5% of 
glucose which enters cells is converted in the nucleotide sugar UDP-GlcNAc in the 
HBP. GFAT, mediates the conversion of fructose-6-P to glucosamine-6-P and is 
considered the rate-limiting step of the HBP activity. UDP-GlcNAc is the substrate of 
OGT which catalyses the transfer of O-GlcNAc on Ser and Thr residues of 
nucleocytoplasmic proteins, while OGA catalyses the removal of the sugar. Amino 




 1.2.2 OGT and OGA enzymes  
OGT and OGA alone control the O-GlcNAc cycling of thousands of 
nucleocytoplasmic and mitochondrial proteins. This is possible due to a finely 
controlled regulation of these two enzymes which includes alternative splicing, 
cellular compartmentalization, high structural adaptability and post-translational 
modifications.  
OGT was found in all mammalian tissues but it is particularly abundant in insulin-
sensitive and high-energy tissues including pancreas, brain, liver, heart and skeletal 
muscle (Gao et al., 2001; Lubas et al., 1997; Nolte and Müller, 2002). This enzyme 
is encoded by the Ogt gene (~43 kb) and the transcript is alternatively spliced to 
generate three different isoforms: 1) a nucleocytoplasmic isoform (ncOGT or OGT, 
110 kDa), which constitutes the most studied OGT isoform containing a putative 
nuclear localization sequence (NLS) and mainly expressed within the nucleus but also 
abundant in the cytoplasm; 2) a mitochondrial isoform (mOGT, 103 kDa) and 3) a 
short isoform (sOGT, 75 kDa) both linked to apoptosis (Hanover et al., 2003) (Figure 
1.8). The three isoforms contain a variable number of tetratricopeptide (34-amino 
acid) repeats (TPRs) on the N-terminal domains and a common C-terminal domain 
with two catalytic regions (Wrabl and Grishin, 2001). The TPR motifs are packed into 
anti-parallel α-helices and contain conserved “asparagine ladder” and “hinge-like” 
domains enabling the enzyme to adapt and promiscuously bind to a large variety of 
different substrate proteins (Jínek et al., 2004; Lazarus et al., 2011). Deletion studies 
demonstrated that the TPRs is important in the O-GlcNAcylation of many substrates 
including nucleoporins (Lubas and Hanover, 2000) and RNA Polymerase II C-
terminal domain (Comer and Hart, 2001) as well as in the homo-dimerization and 
auto-glycosylation of OGT associated with an attenuated O-GlcNAcylation of 
specific targets (Jínek et al., 2004; Whisenhunt et al., 2006). 
Less is known about OGA. The enzyme is a monomeric hexosaminidase (~130 kDa) 
which is encoded by the human Mgea5 gene (~34 kb). There are two isoforms, the 
full-length (OGA-L) and the short isoform (OGA-S). OGA-L is localized to the 
cytosol and nucleus whereas OGA-S was found primarily in lipid droplets (Figure 
1.8) (Keembiyehetty et al., 2011; Wells et al., 2002). OGA cleaves the β-linked 
GlcNac at neutral pH. Interestingly, the catalytic efficiency for OGA is similar across 
different protein substrates, suggesting that O-GlcNAc itself, rather than the structure 
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of the target protein, modulates OGA’s specificity (Shen et al., 2012). OGA contains 
an N-terminal N-acetyl-β-D-glucosamindase domain and, within its C-terminal 
domain, a region which shares sequence homology with histone acetyltransferase 




Figure 1.8 Representation of the OGT and OGA isoforms and cellular functions 
controlled by the OGT/OGA interplay. There are three isoforms for the OGT 
enzyme with different molecular weights. The ncOGT (110 kDa) is the most studied 
and well-known isoform and is characterized by the presence of a nuclear localization 
sequence (NLS). The OGA-L isoform can also localize to the nucleus via its HAT 
domain. The ncOGT and OGA-L isoforms can control alone the O-GlcNAc cycling 





1.2.3 Diverse roles of O-GlcNAcylation in biological processes  
Protein O-GlcNAcylation is one of the most abundant post-translational modifications 
within the cell and is conserved among all metazoans. It is ubiquitously found in all 
cellular compartments and occurs on proteins belonging to almost all the functional 
classes, with the highest density on nucleoporins, transcription factors and chromatin 
remodelling proteins. The discovery of the O-GlcNAc modification is relatively recent 
and occurred by chance in 1980 when Torres and Hart noticed that most of the 3H-Gal 
used to label proteins on the cell surface of lymphocytes, was unexpectedly 
incorporated on intracellular proteins (Torres and Hart, 1984). Indeed, O-
GlcNAcylation differs from the canonical protein glycosylation for many aspects. 
First, it occurs on nuclear and cytoplasmic proteins and is independent from the 
endoplasmic reticulum (ER) and the Golgi apparatus where, instead, secreted and cell 
surface proteins are glycosylated. Secondly, unlike the very complex pattern of 
glycans found on extracellular proteins, the O-GlcNAc modification is constituted by 
only one sugar unit which is not further elongated or modified. Finally, the O-GlcNAc 
modification is reversible and its cycling occurs very quickly in response to a variety 
of stimuli due to the dynamic interplay occurring between OGT and OGA (Hart et al., 
2007). Consistent with the above mentioned characteristics, the role of O-
GlcNAcylation is to regulate nearly all the aspects of cellular processes and 
physiology. In particular, the O-GlcNAc modification is enriched in the nucleus where 
regulates transcription and epigenetics and is abundantly present on nucleoporins at 
the nuclear pore complex (NPC) where mediates bidirectional trafficking between 
cytoplasm and nucleus. Besides transcription, O-GlcNAcylation regulates translation 
and ribosome biogenesis although much more work is needed in this area. 
Interestingly, the O-GlcNAc modification widely regulates cell signalling dynamics 
and protein degradation often in interplay with other post-translational modifications 
and, as a cellular stress sensor, protects cells from acute stress including heat, high 
salt, ultraviolet light and hypoxia. Importantly, the O-GlcNAc modification is at the 
nexus of macronutrients metabolism and works as a nutrient sensor by coupling 
fluctuations in the availability of nutrients including glucose, amino acids and lipids, 
with adaptation of downstream signalling pathways (Copeland et al., 2008; Groves et 
al., 2013; Hart, 2015; Lewis and Hanover, 2014; Ruan et al., 2013; Zhu et al., 2016).  
49 
 
The vast majority of the cellular functions mentioned above, particularly the control 
of transcription and signalling, are regulated by a finely tuned interplay between O-
GlcNAcylation and phosphorylation which occurs with three principal mechanisms: 
1) many proteins, including the RNA polymerase II, are reciprocally modified at the 
same Ser and Thr sites under different conditions, suggesting that phosphorylation and 
O-GlcNAcylation are mutually exclusive modifications (Du et al., 2001; Kelly et al., 
1993); 2) in other cases, they can occur at proximal sites. For example, in order to get 
activated, the calcium/calmodulin-dependent protein kinase type IV (CAMKIV) is 
first de-O-GlcNAcylated and then phosphorylated on a residue close to the de-O-
GlcNAcylated site. Mutation of the major site of O-GlcNAcylation on CAMKIV 
results in a constitutively active enzyme (Dias et al., 2009); 3) O-GlcNAcylation and 
phosphorylation may exist simultaneously at different sites such as on the insulin 
receptor substrate (IRS) proteins (Ball et al., 2006) (Figure 1.9). 
Consistently with its extensive regulatory role of key cellular functions, dysregulation 
in O-GlcNAcylation levels is directly associated to the aetiology of the major chronic 
diseases including metabolic disorders, cancer, cardiovascular diseases and 




Figure 1.9 Cross-talk between O-GlcNAcylation and phosphorylation. The three 
main mechanisms occurring during modification of the nucleocytoplasmic proteins 






1.2.3.1 O-GlcNAcylation and signalling 
O-GlcNAcylation is particularly important for kinases regulation and vice versa. 
Studies employing protein arrays showed that, O-GlcNAc modification occurs on 
almost all families of kinases with over one-half of all kinases being modified by the 
sugar (Dias et al., 2012). On the other hand, OGT and OGA are regulated by 
phosphorylation (Bullen et al., 2014; Song et al., 2008) and both enzymes have been 
found in protein complex containing both kinases and phosphatases indicating that 
phosphorylation and glycosylation occur dynamically on protein targets (Zeidan and 
Hart, 2010). The reciprocal regulation between O-GlcNAcylation and phosphorylation 
is particularly evident for metabolic signalling pathways. In cell responsive to insulin, 
upon insulin stimulation, the OGT associates with phosphoinositides at the plasma 
membrane where it is directly phosphorylated and activated by insulin receptor (IR). 
Once activated, OGT modifies other components of the insulin signalling cascade to 
turn off insulin signalling (Whelan et al., 2008; Yang et al., 2008). OGT can be also 
phosphorylated by AMPK, the major energy sensing kinase within cells as previously 
discussed. Phosphorylation by AMPK can influence OGT substrate binding. On the 
other hand, the activity of AMPK is positively regulated by O-GlcNAcylation (Bullen 
et al., 2014; Xu et al., 2014) (Figure 1.10). A dynamic interplay exists also between 
OGT and the insulin-regulated mitotic protein glycogen synthase kinase (GSK3). 
GSK3 mediates the phosphorylation of OGT at Ser3 or Ser4 enhancing its activity. 
Treatment with a GSK3 inhibitor alters global protein O-GlcNAcylation in 
mammalian cells (Kaasik et al., 2013; Wang et al., 2007). On the contrary, GSK3 is a 
substrate for OGT and its activity is perturbed by altering the O-GlcNAc cycling 
(Kazemi et al., 2010). These findings strongly suggest an extensive cross-talk between 
essential nutrient-sensitive enzymes which dynamically regulate each other to control 
cellular metabolism (Figure 1.10).  
Importantly, the interplay between O-GlcNAcylation and phosphorylation can 
influence the nuclear localization of OGT itself along with the activity of many 
transcription factors involved in cell growth. Indeed, for many proteins including c-
Myc, Sp1 and mTOR, the nuclear form is more O-GlcNAcylated than the cytoplasmic 
form and their re-localization to the cytoplasm can be induced by silencing OGT gene 




Figure 1.10 Reciprocal regulation of OGT and kinases. OGT modifies and 
activates AMPK whereas inhibits GSK3. On the other hand, OGT can be 
phosphorylated and activated by GSK3 whereas AMPK phosphorylation occurring on 
Thr-444 can regulate OGT activity by altering its substrate selectivity, nuclear 
localization and gene transcription. 
 
1.2.3.2 O-GlcNAcylation in transcription and epigenetics 
Recently, O-GlcNAcylation has emerged as fundamentally important for nutrient 
regulation of gene expression.  
Nearly all factors associated with RNA polymerase II transcription are modified by 
O-GlcNAc in mammals (Vaidyanathan et al., 2014). More importantly, O-
GlcNAcylation is highly present on the carboxy-terminal domain (CTD) of RNA 
polymerase II and regulates the pre-initiation complex assembly and initiation of 
transcription in interplay with phosphorylation thus controlling the expression of a 
multitude of genes in higher eukaryotes (Bond and Hanover, 2013; Lu et al., 2016). 
Accordingly, OGT and OGA are highly localized at the transcription initiation sites of 
thousands of genes. In vitro studies showed that inhibition of OGT and OGA blocked 
transcription prior to initiation, but not after elongation (Lewis and Hanover, 2014; 
Ranuncolo et al., 2012).  
In addition, it has been demonstrated that OGT and OGA are localized to the 
chromatin-remodeling complexes where they contribute to regulate both activation 
and repression of transcription by modifying histones and chromatin-remodeling 
enzymes (Hanover et al., 2012; Sakabe et al., 2010). Indeed, O-GlcNAc is part of the 
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histone code and all the four subunits of the histone core are O-GlcNAcylated in their 
tail regions (Sakabe et al., 2010). Furthermore, O-GlcNAcylation controls DNA 
methylation and thus gene repression. As an example, the ten-eleven translocation 
(TET) family of enzymes responsible for DNA demethylation, target OGT to 
chromatin and are regulated by O-GlcNAcylation themselves (Chen et al., 2012; 
Deplus et al., 2013; Vella et al., 2013). Moreover, OGA and OGT co-localize at 
repressed promoters with mSin3A, a core component of a large multiprotein 
corepressor complex with histone deacetylase activity, suggesting another mechanism 
via which O-GlcNAc cycling can dynamically intervene in epigenetic regulation 
(Whisenhunt et al., 2006; Yang et al., 2002).  
Finally, OGT is a polycomb gene. Members of this gene family encode for a group of 
proteins which repress the expression of large sets of genes, including HOX genes, 
and are responsible for regulating tissue patterning during development further 
supporting a central role played by protein O-GlcNAcylation in controlling 





1.2.4 O-GlcNAcylation in the pathogenesis of chronic disorders 
1.2.4.1 O-GlcNAcylation in diabetes 
Pathologies including diabetes, diabetes-related complications and obesity are all 
associated, directly or indirectly, with alterations in the nutritional status of the 
organism.  
Due to its ability to regulate several cellular processes in relation to the flux of 
nutrients entering the HBP, especially glucose, alterations in O-GlcNAc modification 
are involved in the pathophysiology of diabetes. Accordingly, in both humans and 
animal models, glucose toxicity and hyperglycemia-induced insulin resistance, two 
major hallmarks of type 2 diabetes, have been directly linked to abnormal O-
GlcNAcylation (Buse, 2005; Copeland et al., 2008; Dias and Hart, 2007; Lehman et 
al., 2005; Slawson et al., 2010). O-GlcNAc modification is abundant on proteins 
belonging to the insulin signalling pathway and increased O-GlcNAcylation, induced 
by hyperglycemia, affects particularly insulin-sensitive organs including pancreatic 
islets, liver, adipose and muscle tissue. Accordingly, overexpression of even moderate 
levels of OGT (20%) in mice, specifically targeted to adipose and muscle tissue, was 
sufficient to cause insulin resistance (McClain et al., 2002). Similarly, overexpression 
of OGT in liver resulted in impairment of insulin-responsive genes and the 
establishment of insulin resistance (Copeland et al., 2008; Yang et al., 2008).  
The molecular mechanisms underlying the onset of insulin resistance during 
hyperglycemic conditions, have been widely investigated. Studies suggest that 
increase of O-GlcNAcylation at the expense of phosphorylation on key transcription 
factors and components of insulin signalling pathway perturbs the response to insulin 
resulting in diminished glucose uptake in the muscle and fat tissues and increased 
gluconeogenesis in the liver (Copeland et al., 2008; Ma and Hart, 2013).  
In adipocytes, increased O-GlcNAc reduces the phosphorylation of the 
phosphoinositide 3-kinase (PI3K) p85 binding motif of insulin receptor substrate 1 
(IRS1) resulting in a concomitant reduction in tyrosine phosphorylation of IRS-1 and 
insulin signalling (Whelan et al., 2010).  
In the liver, O-GlcNAcylation regulates insulin signalling in physiologic conditions. 
The binding of insulin to its tyrosine kinase receptor activates the intracellular 
substrates IRS1/2 thus initiating PI3K-Akt pathways to increase glucose uptake and 
metabolism in cells. PI3K activation gives rise to phosphatidylinositol 3,4,5 
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trisphosphate (PIP3) which recruits OGT to the plasma membrane where, O-
GlcNAcylation of specific components, leads to the attenuation of insulin signalling. 
However, upon chronic hyperglycemia, abnormally high O-GlcNAcylation leads to 
abnormal diminishing of insulin sensitivity (Figure 1.11). In parallel, hyper-O-
GlcNAcylation increases the activity of many transcription factors and co-activators 
involved in promoting gluconeogenic/lipogenic gene transcription. As an example, 
FoxO1 responds to hyperglycemia through elevated O-GlcNAcylation in the liver. 
Diabetes-induced O-GlcNAcylation of hepatic FoxO1, in turn, increases the 
expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase), two rate-limiting enzymes in gluconeogenesis (Ma and Hart, 
2013; Housley et al., 2008) (Figure 1.11). Similarly, the carbohydrate-responsive 
element-binding protein (ChREBP), a central regulator of lipid synthesis in the liver, 
is hyper-O-GlcNAcylated during hyperglycemia and translocates to the nucleus to 
initiate the transcription of lipogenic genes (Ma and Hart, 2013) (Figure 1.11).  
Furthermore, O-GlcNAcylation of the ubiquitously expressed transcription factor Sp1 
contributes to the development of diabetes-related complications. Studies showed that 
hyper-O-GlcNAcylation occurs at multiple sites on Sp1 during acute hyperglycemia 
and diabetes leading to its nuclear accumulation, increased DNA binding, enhanced 
transcriptional activity and protein stability (Kudlow, 2006; Solomon et al., 2008; 
Copeland et al., 2008). Increased transcriptional activity of hyper-O-GlcNAcylated 
Sp1 has been associated with the development of diabetic atherosclerosis via 
enhancement in the transcription of the transforming growth factors TGF-α, TGF-β, 
and plasminogen activator inhibitor (PAI)-1, all involved in the atherosclerotic process 
(Özcan et al., 2010). Moreover, O-GlcNAc modification of Sp1 mediates 
hyperglycemia-induced upregulation of the vascular endothelial growth factor A 
(VEGF-A), a proangiogenic protein whose expression contributes significantly to 
retinal lesions and neovascularization in diabetic retinopathy in both human and rat 
retinal cells (Donovan et al., 2014). 
All together these studies suggest that a chronically sustained flux through the HBP 
and increased O-GlcNAcylation of key proteins regulating metabolic pathways may 
represent one mechanism via which hyperglycemia promotes insulin resistance and 





Figure 1.11 O-GlcNAc modification regulates insulin signalling in the liver. In 
physiological conditions (black), insulin binding to its tyrosine kinase receptor 
activates the intracellular substrates IRS1/2, initiating PI3K-Akt signalling which 
leads to increased glucose uptake. OGT is recruited to the plasma membrane, where 
the O-GlcNAcylation of several components of the insulin signalling pathway (green 
circles) leads to an attenuation of insulin response. Upon chronic hyperglycemia (red), 
the UDP-GlcNAc pool increases leading to high O-GlcNAcylation of proteins, 
including elements of the insulin signalling pathway and some key transcription 
factors, diminishing insulin sensitivity and stimulating gluconeogenic/lipogenic gene 
transcription (Adapted from Ma and Hart, 2013).  
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1.2.4.2 O-GlcNAcylation in cancer metabolism 
Many cancer types exhibit enhanced O-GlcNAcylation levels and abnormal 
expression of OGT and OGA. In many cases, the histological grade of the tumor and 
cancer progression correlate with higher levels of OGT and O-GlcNAc and reduced 
levels of OGA (Ferrer et al., 2016; Yehezkel et al., 2012), whereas downregulation of 
OGT via RNA interference (RNAi) or pharmacological inhibition blocked cell growth 
in in vitro studies using different cancer cells (Ferrer et al., 2014).  
The repromming of cellular metabolism and stress response by O-GlcNAc-mediated 
mechanisms is thought to enable cancer cells to resist stressful microenvironments and 
promote tumor growth. For instance, O-GlcNAcylation regulates cancer metabolism 
and sustains cellular survival via regulation of the hypoxia-inducible factor (HIF-1) 
pathway (Ferrer et al., 2014). HIF-1 promotes adaptive responses of the tumor cells to 
their environment by activating the transcription of downstream genes important to 
maintain tumor survival and progression such as GLUT1 (Masoud and Li, 2015). 
Human breast cancer cells display high levels of HIF-1 and OGT, and low OGA levels 
which correlate with poor patient outcome. Downregulation of O-GlcNAcylation in 
these cells promotes HIF-1 proteasomal degradation and leads to endoplasmic 
reticulum-mediated apoptosis whereas overexpression of a stable form of HIF-1 or 
GLUT1 prevents these effects (Ferrer et al., 2014). Cross-talk between O-
GlcNAcylation and the AMPK/mTOR pathway is also emerging as a key mechanism 
regulating cellular metabolism and growth in normal physiology as well as in cancer. 
The mTOR pathway plays a major role in coordinating cell growth and for that reason 
is critical to cancer biology. Indeed, it is hyperactivated in human cancers due to 
activation and inactivation of its positive and negative regulators respectively. For 
instance, LKB1 negatively regulates mTOR signalling via its substrate AMPK. Loss 
of LKB1 mediates mTOR activation promoting cell growth in human cancers (Zhou 
et al., 2013). It has been shown that downregulation of O-GlcNAcylation in cancer 
cells enhanches LKB1 and AMPK activity decreasing activation of mTOR effectors. 
On the contrary, overexpression of the glucose transporter GLUT1 reversed LKB1 
and AMPK activation (Ferrer et al., 2014, 2016). Taken together these findings 
suggest that OGT can regulate the major pathways controlling cellular metabolism and 
stress response in cancer cells including HIF-1, GLUT1 and AMPK/mTOR pathway.  
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1.2.5 O-GlcNAc modification and pregnancy 
1.2.5.1 O-GlcNAc modification during pre-implantation, implantation, and embryo 
development 
Both OGT and OGA are extremely conserved from worm to humans and are essential 
for embryonic implantation, development and survival (Gao et al., 2001; Kreppel et 
al., 1997). During pre-implantation, OGT mediates  blastocyst formation and cell 
proliferation which are both impaired by hyperglycemic conditions in early mouse 
embryos (Pantaleon et al., 2010). Moreover, OGT regulates the timing of 
differentiation in mouse embryonic stem cells by maintaining the undifferentiated 
state (Miura et al., 2018; Shi et al., 2013). In addition, O-GlcNAcylation may intervene 
in fetal immune tolerance by modulating the activity of natural killer (NK) cells at the 
maternal-fetal interface (Lima et al., 2018; Yao et al., 2004). 
As for embryo development, knockdown of OGT results in morphological defects, 
impaired embryonic growth and decreased cell survival in zebrafish embryos (Webster 
et al., 2009). Similarly, in murine models carrying OGT deletion, the embryogenesis 
is blocked at day five (O’Donnell et al., 2004; Shafi et al., 2000), while knock-out of 
OGA led to impaired cellular division, embryonic growth and early post-natal death 
(Yang et al., 2012). Interestingly, another study showed that, the negative effects 
displayed by mouse embryos carrying a mutation for GlcNAc-6-phosphate 
acetyltransferase (EMeg32), a crucial enzyme of the HBP involved in de novo UDP-
GlcNAc synthesis, were prevented by nutritional restoration of UDP-GlcNAc levels 
suggesting that aberrations in the embryonic development can be mediated by 
decreased efficiency of the HBP via reduced O-GlcNAcylation (Boehmelt et al., 
2000). On the other end, increased O-GlcNAcylation induced by maternal 
hyperglycemia may impact negatively on fetal neurodevelopment. In vivo inhibition 
of OGT and reduction of O-GlcNAcylation in diabetic pregnant mice decreased the 
rate of neural tube defects (NTDs) in the embryos, suggesting that OGT and O-
GlcNAcylation can be suitable candidate targets to prevent birth defects in 







1.2.5.2 O-GlcNAc modification and placental programming 
Both OGT and OGA are extensively expressed in placentas (Lubas et al., 1997; Gao 
et al., 2001). The main role of the O-GlcNAc modification in the regulation of placenta 
function has emerged in relation to its role as a cellular sensor of stress. In several cell 
types, O-GlcNAc modification acts as a sensor of stress which rapidly increases in 
response to different stressors and cellular injuries to promote cell survival (Groves et 
al., 2013; Martinez et al., 2017). Recently, studies conducted in rodents identified 
OGT as a placental marker of prenatal stress and demonstrated that, the placental 
expression of OGT changes according to the type and intensity of stress experienced 
by the mother, affecting the offspring’s development in a sexually dimorphic manner 
(Howerton et al., 2013; Lima et al., 2018; Olivier-Van Stichelen et al., 2014; Pantaleon 
et al., 2017). Indeed, OGT is a X-linked gene which escapes X-inactivation as 
demonstrated in mouse trophoblast cells. This means that OGT remains more 
expressed in placentas from female fetuses compared to males. It has been suggested 
that the differences observed in the placental OGT dosage may account for sex-
specific sensitivity to the intrauterine environment thus contributing to gender-
dependent susceptibility to in utero programming of chronic disease (Olivier-Van 
Stichelen et al., 2014).  
The role of placental OGT as a nutrient sensor is poorly explored in human 
pregnancies. Nevertheless, data on rodents point toward a role for O-GlcNAcylation 
as a good candidate to link maternal diet and offspring development. Accordingly, 
maternal diet, either poor or high in fat content, increases the gene expression of OGT 
preferentially in the placenta of female mice (Mao et al., 2010). In addition, severe 
and mild maternal hyperglycemia in rats, resulted in increased O-GlcNAcylation of 
kappa-light-chain-enhancer of activated B cells (NF-kB) which was associated with 
augmented production of proinflammatory cytokines, placental morphometric 
alterations and reduced placental index (Dela Justina et al., 2018, 2017). Furthermore, 
in the human choriocarcinoma BeWo cell line and in first trimester explants, 
stimulation of HBP flux with glucosamine was associated to increased protein O-
GlcNAcylation, enhanced distribution of O-GlcNAc modified proteins in the nuclear 
speckles as well as reduced trophoblast proliferation and placental secretion of leptin, 
a key regulator of placental amino acid uptake. In agreement with these in vitro data, 
59 
 
placentas from mice treated with glucosamine throughout pregnancy were 
significantly smaller than those from control mice (Palin et al., 2013). 
Although evidence emerging from studies in rodent models strongly suggest a link 
between O-GlcNAc signalling and key pathways regulating placental adaptation to 
maternal environment and fetal growth, including mechanisms of placental stress 
response and nutrient transport, few efforts have been made to investigate the role of 
OGT and its biochemical signatures in human placenta in relation to maternal health 




1.3 Thesis aims 
Little is known about the placental molecular mechanisms governing the transmission 
of maternal metabolic stimuli to the growing fetus. Less is known about the role of 
protein O-GlcNAcylation in the human placenta. However, an increasing number of 
studies have linked O-GlcNAc signalling to the alterations of cellular metabolism 
underlying the pathophysiology of chronic disorders including diabetes, cancer and 
neurodegenerative diseases, highlighting the urgent need to elucidate the role of this 
recently identified post-translational modification also in the human placenta. It is 
widely accepted that a healthy placenta is crucial to guarantee the well-being of the 
mother and in programming the health of the future generation. Thus, the overall aim 
of this thesis is to investigate the role played by OGT and O-GlcNAcylation in some 
aspects of placenta physiology. In particular, the main objectives of this research work 
are:  
- developing a method to characterize global O-GlcNAc-modified proteins in the 
human trophoblast cell line BeWo. This part of the study will allow to acquire a 
broader overview of potential OGT targets with a pivotal role in regulating trophoblast 
physiology. 
- investigating the roles played by OGT in regulating the molecular mechanisms 
underlying the formation of the syncytiotrophoblast using BeWo cells. The pathways 
governing trophoblast differentiation are well-characterized and include the activation 
of a phosphorylation cascade involving several protein kinases. The evaluation of a 
potential interplay between phosphorylation and O-GlcNAcylation in the regulation 
of key kinases involved in mediating the differentiation process will allow to obtain a 
clearer understanding of the mechanisms underlying the formation of 
syncytiotrophoblast. 
- evaluating ex-vivo, in human term placental biopsies, the potential association 
between O-GlcNAc signalling and maternal alterations, including obesity and 
depression, and exploring the effects on placental nutrient-sensing and stress response 















Pregnant women were recruited at the Chelsea and Westminster Hospital in London 
where informed written consent and approval of the ethics committee were obtained 
(REC No: 14/LO/0592). All the procedures were conducted in accordance with the 
Helsinki Declaration. Study subjects were 34 healthy women aged 21 to 45 years with 
BMI ranging from 19 to 45.4 (kg/m2) related to the first trimester of pregnancy (11-
14 weeks) and giving birth to infants with a birth weight (BW) ranging from 2630 to 
4440 g. The inclusion criteria for this study were good general health, normal gestation 
length (˃37 weeks), mother age above 20 years old, while women with diabetes, 
chronic diseases, or pregnancy complications such as preeclampsia were excluded. 
Samples were randomly selected. Three women giving birth to small for gestational 
age babies (SGA, birth weight centile (BWC)˂10) and 5 mothers giving birth to large 
for gestational age (LGA, BWC˃90) were not excluded from the cohort study. 
Maternal depressive symptoms were assessed in early pregnancy (11-14 weeks) at the 
time of recruitment, using the Edinburgh Postnatal Depression Scale (EPDS) which 
was validated for assessing depression also during pregnancy by Cox and colleagues 
(Cox et al., 1996). A value ≥13, on a scale ranging from 0 (low depression) to 30 (high 
depression), is used in the test to identify maternal depression (Cox et al., 1996). 
2.2 Oral glucose tolerance test (OGTT) and HbA1c measurement 
At 28-30 weeks of gestation all women underwent full oral glucose tolerance test 
(OGTT) and haemoglobin A1c (HbA1c) test as part of standard clinical care at the 
Chelsea and Westminster Hospital where samples collection and analysis were 
performed. For the OGTT, used as a diagnostic tool for gestational diabetes, blood 
glucose levels were measured at fasting and 2 h after 75 g of oral glucose load. The 
OGTT measures the concentration of blood glucose after fasting for 8 h and the body's 
ability to metabolise glucose at 2 h after consuming a glucose drink. Individuals 
without diabetes display glucose levels below 5.6 mmol/L at fasting and below 7.8 
mmol/L after 2 h from glucose administration. The HbA1c test is employed to measure 
the average blood glucose carried by the red blood cells over the last 2–3 months and, 





2.3 Placenta collection and sample preparation for immunoblotting 
Placentas were collected and processed at the Chelsea and Westminster Hospital. Soon 
after delivery, placentas were collected and immediately placed on ice for dissection. 
Small pieces of villous tissue were then snap frozen in liquid nitrogen and stored for 
further analysis. For immunoblotting sample preparation, 5 mg of frozen tissue was 
homogenized still frozen in 200 µl of ice-cold Pierce™ RIPA buffer with the following 
composition: 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS (Thermo Scientific Pierce) supplemented with 1% of Halt™ 
Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scientific). 
Samples were then clarified by centrifugation at 14000 g for 10 min at 4 °C and the 
supernatant was collected in sterilized 0.5 ml Eppendorf tubes and kept at -80 °C until 
immunoblotting analysis.  
2.4 Cell culture and treatments 
2.4.1 Storage, reviving and propagation of BeWo cells 
BeWo cells (American Type Culture Collection) were stored in liquid nitrogen in 2 
ml cryogenic vials with a mixture 1:9 of dimethyl sulfoxide (DMSO, Sigma-Aldrich) 
and fetal bovine serum (FBS, Sigma-Aldrich). For each experiment, cells were revived 
by thawing at 37 °C in a water bath, resuspended by gentle pipetting and transferred 
to a 15 ml centrifuge tube with 5 ml of culture medium and centrifuged to eliminate 
DMSO. Cells were resuspended in growing medium Ham's F-12K medium 
supplemented with 10% FBS and 1% of 1:1 penicillin-streptomycin 10000 U/mL 
sterilized solution (VWR International), transferred to a T75 sterilized flask and grown 
at 37 °C under a humidified atmosphere of 5% CO2. Medium was changed every two 
days. At confluence cells were trypsinized to dissociate using a solution of 0.5% 
trypsin-EDTA (Gibco, Thermo Fisher Scientific), resuspended in fresh medium and 
centrifuged at 200 rpm at 37 °C for 5 min to eliminate trypsin. For each experiment, 
the number of cells seeded was determined using a hemocytometer (Hirschmann 
Instruments).  
2.4.2 Protein extraction from BeWo cells 
At the end of each experiment, cells were washed in ice-cold PBS and total protein 
content was extracted by lysing cells in 100  μL/well of ice-cold RIPA buffer (25 mM 
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Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with 1% of Halt™ Protease and Phosphatase Inhibitor Single-Use 
Cocktail for 5  min on ice. Samples were then clarified by centrifugation at 14000 g 
for 10 min at 4 °C and the supernatant was collected in sterilized 0.5 ml Eppendorf 
tubes and analysed by immunoblotting.  
2.4.3 Treatments  
2.4.3.1 Trophoblast differentiation forskolin-induced 
Forskolin (Cayman Chemical) was dissolved in DMSO and used at a concentration of 
100 µM to induce differentiation of BeWo cells as previously described (Delidaki et 
al., 2011). Briefly, Bewo cells were seeded at a density of 0.3 x 106 in a 6-well plate 
and grown as a monolayer of mononucleated cells (cytotrophoblast) at 37 °C under a 
humidified atmosphere of 5% CO2 in Ham's F-12K medium supplemented with 10% 
FBS and 1% pen/strep until they reached 70% of confluence. Afterwards, BeWo cells 
were treated with forskolin to activate the cAMP/PKA pathway and induce 
syncytialization or with the same volume of DMSO used as a control for 48 h.  
2.4.3.2 Experimental hyperglycemia  
Glucose treatment was used to create hyperglycemic conditions to study the response 
of global protein O-GlcNAcylation and the role of AMPK as a cellular energy sensor. 
Bewo cells were grown in a 6-well plate and the growing medium, formulated with a 
concentration of 5 mM, was supplemented with glucose powder suitable for cell 
culture (Sigma Aldrich) to a final concentration of 15 mM which was applied to the 
cells to mimic hyperglycaemic exposure to glucose for 48 h.  
2.4.3.3 Enhancement of protein O-GlcNAcylation with PUGNAc  
To increase global protein O-GlcNAcylation in BeWo cells, PUGNAc (O-(2-
acetamido-2deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate) (Sigma-
Aldrich), an inhibitor of OGA, the enzyme which removes O-GlcNAc moieties from 
Ser and Thr residues, was used. PUGNAc was dissolved in sterilized water (vehicle) 
and used at a concentration of 100 µM as suggested in the literature (Park et al., 2005). 




2.4.3.4 Inhibition of PKA with H89 
H89 (Tocris Biotechne) was dissolved in sterilized water and used at a concentration 
of 5 µM to specifically inhibit PKA. The dose was chosen on the basis of a cell titration 
experiment consisting of 1 h pretreatment of BeWo cells with 0, 1, 5 or 10 µM of H89 
followed by stimulation with 100 µM of forskolin for 10 min, the time needed to have 
the maximum forskolin-induced activation of PKA in BeWo cells (Delidaki et al., 
2011). The activation of PKA was estimated by determining the activation of the well-
known PKA downstream targets, CREB and ERK, and was measured as the 




Figure 2.1 Dose-dependent inhibition of PKA by H89 in BeWo cells. BeWo cells 
were pretreated for 1 h with different doses of H89 before inducing activation of PKA 
with 100 µM of forskolin for 10 min. Activation of PKA downstream targets CREB 
and ERK was measured by immunoblotting. N=3. Data are expressed as mean ± SEM; 




2.4.3.5 Transient gene silencing using short interfering RNA  
BeWo cells were transiently transfected with Silencer® Select small interfering 
(si)RNAs for OGT (s16093), GLUT1 (s12925) and negative control (4390844). 
siRNAs used in this study were designed, validated and purchased from Thermo 
Fisher Scientific. BeWo cells were seeded at a density of 0.3 x 106 in a 6-well plate 
and treated when they reached 60% of confluence with 10 µM of siRNA against OGT 
or GLUT1 and siRNA control prepared as follow. Five nmol of lyophilized siRNA 
were resuspended using 50 µL of nuclease-free water for a final concentration of 100 
µM and further diluted to make a 10 µM working solution. For each well, 3 µL of 
siRNA 10 µM solution were diluted with 150 µL of Opti-MEM® medium (Thermo 
Fisher Scientific) and mixed 1:1 with a solution made with 9 µL of Lipofectamine® 
RNAiMAX (Thermo Fisher Scientific) diluted with 150 µL of Opti-MEM® medium. 
A volume of 250 mL of the mixture were added to each well and cells were incubated 
at 37 oC for the duration of the experimental procedure. 
2.5 Fluorescence microscopy 
Microscope glass coverslips 0.17 mm thick (Thermo Scientific), were sterilized in 
100% ethanol and let to dry under a sterile hood before to be transferred to a 12-well 
plate. Cells were then seeded to a density of 0.1 x 106 cells/well and incubated at 37 
°C under a humidified atmosphere of 5% CO2 until they reached a confluency of 60%. 
Cells were then treated according to the experimental design. At the end of treatment, 
the culture medium was removed and the coverslips transferred to a new sterile well 
plate to be washed 3 times with PBS. Cells were fixed with 100% ice-cold methanol 
for 20 min at -20 oC. Each coverslip was then washed 3 times with PBS and blocked 
for 1 h in 5% bovine serum albumin (BSA, VWR Chemicals) and 0.3% Triton X-100 
(Sigma Aldrich) prepared in PBS. After blocking, the coverslips were incubated 
overnight with the primary rabbit polyclonal antibody against the membrane protein 
E-cadherin (sc-7870, Santa Cruz) diluted 1:200 in an antibody buffer solution 1% BSA 
and 0.3% Triton X-100 prepared in PBS. The day after, coverslips were rinsed 3 times 
with PBS and incubated with the goat anti-rabbit IgG (H+L) conjugated to DyLight™ 
800 4X PEG (#5151, Cell Signaling) diluted 1:800 in the antibody buffer solution in 
the dark for 1 h at room temperature. The coverslips were then rinsed 3 times with 
PBS and incubated with the blue-fluorescent DNA stain DAPI (sc-3598, Santa Cruz) 
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for 10 min at room temperature, washed 3 times with PBS, mounted on a microscope 
slide in DPX Mounting medium (Sigma-Aldrich) and dried overnight at +4 oC. Images 
were collected at a magnification of 20X on an Olympus IX71 fluorescence 
microscope (Olympus Optical).  
2.6 RNA extraction  
Total RNA was extracted using the kit GenElute RTN70-1kt (Sigma Aldrich) 
according to the manufacturer’s instructions. RNase- and DNase-free barrier tips were 
used in the procedure to avoid contaminations. All the reagents used in this process 
were provided with the kit except for 70% ethanol solution. Cells grown in 6-well 
plate to 90-100% confluence, were washed with PBS at room temperature and lysed 
using 250 µL of the Lysis Solution provided and prepared with 1% 2-mercaptoethanol. 
The lysate was then transferred to a GenElute filtration column and spinned down by 
centrifugation at 14000 g for 2 min to remove cellular debris and shears DNA. An 
equal volume of 70% ethanol solution was then added to the filtered lysate and the 
mixture was transferred to a GenElute binding column to isolate the RNA from the 
lysate/ethanol mixture by centrifugation. Afterwards, the binding column was washed 
with 500 μL of Wash Solutions 1 and 2 and transferred to a clean collection tube. The 
RNA was released from the column using 50 µL of Elution Buffer and 1 min 
centrifugation at 14000 g.  
2.7 RNA quantification and quality control 
The concentration and quality of the total RNA isolated was determined by 
spectrophotometric analysis using a NanoDrop ND-1000 (Thermo Fisher Scientific). 
Only samples with a ratio of absorbance A260/A280 between 1.8 and 2.1 were used 
as a ratio appreciable lower than ~2.0 may indicate contamination with proteins or 
ethanol used for the extraction which absorb at or near 280 nm. 
2.8 Protein quantification  
Total proteins content was quantified in BeWo cells and term placenta extracts using 
the Thermo Scientific™ Pierce™ BCA Protein Assay kit (Thermo Fischer Scientific) 
based on the bicinchoninic acid (BCA) assay. The kit provides: 1) BCA Reagent A 
containing sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 M sodium hydroxide; 2) BCA Reagent B containing 4% cupric sulfate; 
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3) BSA at a concentration of 2 mg/mL in 0.9% saline and 0.05% sodium azide. Briefly, 
a standard curve was prepared by diluting the BSA standard with RIPA buffer as the 
diluent according to Figure 2.2, A. The BCA Working Reagent (WR) was prepared 
by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B (50:1, Reagent 
A:B). Ten μL of each standard or unknown sample were then pipetted in a 96-well 
polystyrene microplates in replicates and 200 μL of BCA WR were added to each 
well. The plate was thoroughly mixed and incubated at 37°C for 30 min. Proteins 
reduce the cupric ion present in Reagent B from Cu+2 to Cu+1 whereas the BCA in 
Reagent A reacts with Cu+1 resulting in a purple colour whose intensity is 
proportional to protein concentration. The absorbance was read at 562 nm on a Tecan 
Sunrise microplate Reader using a Magellan® Software. Figure 2.2 B shows a typical 
standard curve obtained with this assay. The derived equation was used to calculate 






Figure 2.2 Albumin standard for protein determination. A) Preparation of diluted 
BSA standards. B) Typical standard curve obtained after reading absorbance at 562 
nm. The x axis represents known protein concentration in the BSA standard. The linear 
equation of the calibration curve is used to calculate the unknown concentration of 




2.9 Sample preparation for immunoblotting 
After protein concentration assay, samples were boiled for 5 minutes at 95°C in 
Laemmli SDS sample buffer (Thermo Fisher Scientific) to be denatured. The buffer is 
composed by 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol 
blue and 0.125 M Tris HCl. The 2-mercaptoethanol reduces the molecular disulfide 
bonds between the thiol groups of cysteines destabilizing the protein. The SDS 
detergent coats and denatures proteins giving an overall negative charge which allows 
proteins to move through an electrical field towards the anode during electrophoresis. 
The bromophenol blue facilitates sample loading in the electrophoresis gel. 
2.10 Immunoblotting 
An amount of 10-20 µg protein along with 5-10 µl of PageRuler™ Prestained Protein 
Ladder (Thermo Fischer Scientific), were loaded in 1D SDS-PAGE gel prepared 
according to a Bio-RAD® recipe (Table 1) and were separated by electrophoresis 
according to their size using a TRIS-glycine-SDS running buffer pH 8.3 (Alfa Aesar) 
with a constant current setting of 50 mA. The separated proteins were transferred from 
the gel to a nitrocellulose membrane in cold Western Blot transfer buffer (Thermo 
Scientific) supplemented with 20% of methanol in a vertical mini-gel electrophoresis 
tank (Bio-Rad) under a constant voltage of 100 V applied for 1 h. Membranes were 
then blocked with Odyssey Blocking Buffers (LI-COR Biosciences) at room 
temperature for 1 h and incubated overnight at 4°C with primary antibodies diluted in 
5% BSA at different concentrations depending on the antibody efficiency (Table 2). 
After washing 3 times in Tris-buffered saline (TBS) supplemented with 0.1% 
Tween™ 20 (Fisher BioReagents™) (TBST), membranes were incubated at room 
temperature for 1 h with 1:15000 secondary anti-mouse IgG (HL) (DyLight 680 
Conjugate) or anti-rabbit IgG (HL) (DyLight 800 4X PEG Conjugate) antibody (Cell 
Signaling) followed by other 3 washes in TBST. Fluorescence emission was detected 





Table 1. Recipes for stacking and resolving gels 
The letter A designates the volume of 30% Acrylamide/Bis solution required to produce the specified 










2.11 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR was performed in two separate reactions: first, total RNA was reverse 
transcribed into cDNA, then the cDNA was amplified by PCR and the product 
quantified using fluorescent dyes. In this thesis work, RT-qPCR was performed to 
quantify gene expression after transfection with siRNAs as well as the expression of 
specific markers of differentiation in BeWo cells.  
2.11.1 Genomic DNA removal 
Before performing cDNA synthesis, the extracted RNA samples underwent DNA 
removal using the Invitrogen™ DNase I, Amplification Grade kit (Thermo Fisher 
Scientific) to digest any residual genomic DNA. One µg of RNA was diluted in DEPC-
treated water up to 8 µL and mixed with 1 µL of 10X DNase I Reaction Buffer and 1 
µL of DNase I Amp Grade provided with the kit. Samples were then incubated for 15 
min at room temperature and 1 µL of EDTA was added to initiate the DNA removal. 
The reaction was conducted at 65 °C for 10 min. 
2.11.2 cDNA synthesis 
cDNA was synthesized by reverse transcription using the High-Capacity RNA-to-
cDNA™ kit (Applied Biosystems™) according to the manufacturer’s instructions. 
The kit provides: 1) 50 µL of 20X Enzyme mix containing the reverse transcriptase 
MuLV and RNase inhibitor protein; 2) 500 µL of 2X RT Buffer Mix which includes 
dNTPs, random octamers, and oligo dT-16. Reagents were mixed and diluted as 
described in Table 3 for a final volume of 20 µL. To start the reverse transcription 
reaction, samples were incubated at 37°C for 60 min followed by 95°C for 5 min and 
finally hold at 4°C. 
Table 3. cDNA synthesis using High-Capacity RNA-to-cDNA™ Kit 
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2.11.3 SYBR® Green-based quantitative RT-qPCR 
Following reverse transcription, RT-qPCR was performed in duplicates using the 
SensiFAST SYBR Lo-ROX kit (Bioline) in a 96-well PCR plate. One µL of cDNA 
solution, 1 µL of reverse and forward primer (Sigma-Aldrich), 7 µL of nuclease-free 
water (Invitrogen) and 10 µL of SYBR® Green were mixed and added to each well. 
Primers were purchased commercially (Sigma-Aldrich), and the amplicon length was 
22 base pairs. The primer sequences used are listed in Table 4. RT-qPCR was 
performed using the Applied Biosystems™ 7500 Real-Time PCR machine and the 
setting conditions used are shown in Table 5. The mRNA expression for each target 
gene was normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
reference gene. Fold changes in the mRNA expression levels were calculated using 
the ΔΔCt quantitation method. 
 
Table 4. Sequences of forward and reverse primers used for RT-qPCR 
 
 




2.11.3.1 Melting curve analysis 
The SYBR® Green I dye is a double-stranded DNA binding dye which detects PCR 
products as they accumulate during PCR cycles. The method enables the melting curve 
analysis which allows to check for nonspecific product formation. The melting curve 
is generated when double-stranded DNA, with the incorporated dye, is heated and 
melts to generate a single-stranded DNA. In the process, a sudden decrease in 
fluorescence is detected when the melting temperature is reached as a consequence of 
the dissociation of the DNA strands and subsequent release of the fluorescent dye 
giving origin to the melting curve. As the melting temperature of nucleic acids is 
affected by factors such as their length or the presence of base mismatches, the 
presence of PCR artifacts can be detected by analysing the shape of the melting curve 
thus reducing the need for time-consuming gel electrophoresis. A single-peaked melt 
curve chart is interpreted as representing a pure, single amplicon whereas additional 
peaks in the melting curves indicate the presence of nonspecific products such as 
primer dimerization. The melting curves generated from RT-qPCR experiments in this 




2.12 Immunoprecipitation and co-immunoprecipitation assay 
The immunoprecipitation was performed using the anti-O-GlcNAc antibody RL2 
(Thermo Fisher Scientific) to isolate O-GlcNAc-modified proteins from a complex 
mixture of proteins extracted from BeWo cells. The co-immunoprecipitation assay 
was used to study the physical interaction between OGT protein and PKA or 11β-
HSD2 in BeWo extracts (Figure 2.3). Cell lysates were diluted using PBS to reduce 
the concentration of the detergents present in the protein extraction buffer RIPA and 
300 µg of total protein, corresponding to approximately 300-350 µL of cell lysate, 
were incubated overnight under gentle rotation at 4 °C with primary antibodies anti-
OGT or anti-O-GlcNAc added at a concentration of 1:50. The day after, 20 µL of A/G 
protein agarose beads (Santa Cruz) were added in each tube and incubated under gentle 
rotation for 4 h at 4 °C followed by centrifugation at 2000 g for 5 min at 4 °C to spin 
down the beads. The supernatant was then collected to evaluate the 
immunoprecipitation efficiency whereas beads were washed 3 times with 200 µl of 
ice-cold PBS followed by centrifugation after each washing. Beads were finally 
resuspended in 20 µL of Laemmli buffer, boiled for 5 min at 95 °C in order to 
dissociate the immunocomplex from the beads and centrifuged to collect the 
supernatant containing the proteins of interest. Samples were further analyzed by 
immunoblotting to detect the protein of interest using specific antibodies or SDS-





Figure 2.3 Schematic procedure of the agarose beads-based immunoprecipitation 
and co-immunoprecipitation assay. The O-GlcNAc-modified proteins were 
immunoprecipitated using a specific antibody against O-GlcNAc (RL2) while anti-
OGT antibody was used to pull down proteins physically associated with OGT in the 
co-immunoprecipitation assay. Agarose beads were used to bind specifically to the 
antibody. Once coupled to agarose beads, centrifugation was used to pull down and 
purify the antibody/protein complex. O-GlcNAc-modified proteins isolated by 
immunoprecipitation were visualized by immunoblotting using anti-O-GlcNAc 
antibody while anti-PKA/11β-HSD2 antibodies were used to evaluate protein-protein 
interaction with OGT after co-immunoprecipitation.   
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2.13 Coomassie blue staining 
After isolation of O-GlcNAcylated proteins by immunoprecipitation and separation 
by SDS-PAGE electrophoresis, proteins on the gel were visualized using the Bio–
Safe™ Coomassie Stain (Bio-Rad) to confirm that the immunoprecipitation was 
successful before processing samples for proteomic analysis. The gel was first washed 
in double-distilled water (ddH2O) to remove running buffer residues before being 
incubated in the Coomassie staining solution for 1 h at room temperature under gentle 
shaking. The gel was then washed for 30 min in ddH2O and gel lanes were cut and 
stored in ddH2O at 4 °C until processing for proteomic analysis. 
2.14 In-gel protein digestion for proteomics 
Each step was conducted at room temperature under shaking at 650 rpm unless 
otherwise specified. The whole gel lane was cut in small pieces and destained in 50% 
ethanol prepared in 50 mM ammonium bicarbonate (ABC) buffer for 20 min until the 
Coomassie was completely removed from the gel. After dehydrating the gel using 
100% ethanol for 5 min, a reduction/alkylation step was performed by adding 10 mM 
of tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) and 40 mM of 2-
chloroacetamide (CAA) for 5 min at 70 °C with gentle vortex. The gel pieces were 
then washed 3 times using 50% ethanol in 50 mM ABC for 20 min and underwent a 
second dehydration in 100% ethanol for 5 min. The tryptic digestion was then 
performed using 2.5 ng/µL trypsin solution and incubating samples overnight at 37 
°C. The day after, trypsin was collected in a clean tube and peptides were further 
extracted from the gel by sonication in bath in a solution 25% acetonitrile 5% formic 
acid for 10 min. Peptides in solution were concentrated using a vacuum evaporator to 
bring the volume down to 20 µL and were resuspended in 2.0% acetonitrile + 0.1% 
trifluoroacetic acid solution to a final volume of 50 µL. Samples were then transferred 
to a mass spec vial and stored at -20 °C until mass spectrometry (MS) analysis.  
2.15 MTT assay  
The MTT assay kit (Sigma-Aldrich) was used to measure cellular metabolic activity 
as an indicator of cell viability after performing OGT gene silencing. The MTT assay 
is based on the conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) compound to insoluble purple formazan crystals by 
metabolically active cells. The formazan is then solubilized and the concentration is 
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determined by measuring the optical density at 570 nm (Figure 2.4). BeWo cells were 
seeded at 1×103 cells/well in a 96-well culture plate, allowed to attach and stabilize 
for 24 h and treated with siRNA or control siRNA for 24 h and 48 h. At the end of the 
siRNA treatment, the medium was replaced with 100 µL of fresh culture medium and 
10 μL of MTT reagent was added to each well at a concentration of 0.5 mg/mL. The 
plate was incubated for 3 h at 37°C before adding 100 μL of the MTT solubilization 
solution to each well followed by a second incubation at 37°C for 4 h in a humidified 
chamber. Finally, absorbance was measured at 570 nm with a microplate Tecan 




Figure 2.4 Schematic representation of the MTT assay procedure. The MTT 
solution was added to BeWo cells at 0, 24 and 48 h after treatment with siOGT or 
control siRNA. A group of untreated cells was also included in the experiment. After 
incubating MTT-treated cells for 3 h at 37 °C to allow the formation of the formazan 
crystals, a solubilizing solution was added followed by incubation for 4 h at 37 °C. 
Absorbance was measured at 570 nm. The amount of absorbance is proportional to the 




2.16 Assessment of β-hCG and cortisol in the culture media 
The culture media of BeWo cells was collected at the end of each experiment and 
stored at -20 °C for the measurement of β-hCG, a marker of human trophoblast 
differentiation, and cortisol, a steroid hormone belonging to the glucocorticoid class 
which regulates placental response to stress and fetal growth. Briefly, 200 µL of 
culture media were collected in a polypropylene test tubes and analyzed using 
electrochemiluminescence immunoassay (Roche Diagnostics) by the Department of 
Biochemistry (University Hospitals Coventry and Warwickshire NHS Trust).  
2.17 In silico analysis for proteomics study 
Three biological replicates of peptides from O-GlcNAc-enriched and non-enriched 
BeWo extracts, were subjected to fractionation using high performance liquid 
chromatography (HPLC) and analyzed by an Orbitrap Fusion with UltiMate 3000 
RSLCnano System (Thermo Scientific) using a combination of two “softer” 
fragmentation methods, Higher energy Collisional Dissociation (HCD) and Electron-
Transfer Dissociation (ETD). HCD has the advantage to generate a distinct HexNAc 
oxonium ion (m/z 204) and a series of HexNAc fragments (m/z 186, m/z 168, m/z 
144, m/z 138 and m/z 126) which serve as diagnostic tools for O-GlcNAc modification 
whereas ETD produces sufficient fragmentation ions for confident peptide 
identification and preserves, at the same time, the O-GlcNAc-modified residues for 
accurate site assignment (Zhao et al., 2011). Data file analysis for N-acetylhexosamine 
(HexNAc) peptides and peptide fragment assignation used search against the 
Uniprot_Human database and was performed using the MaxQuant software (version 
1.6.10.43). Protein abundance analysis was performed by a two-sided t-test, and 
significance was determined on the basis of a false discovery rate (FDR) of <0.05 and 
hyperbolic curve threshold of S0=0.1 using the Perseus software (version 1.6.2.2). S0 
is defined as the “artificial within groups variance” and controls the relative 
importance of the t-test p value and difference between means (Tusher et al., 2001). 
The significantly O-GlcNAc-enriched proteins were further analysed using the 
publicly-available annotation platform Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7 to perform a Gene Ontology (GO) analysis to 
identify biological and functional categories. A predictive model was applied to the 
identified O-GlcNAc sites using the web-based tool OGTsite 
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(http://csb.cse.yzu.edu.tw/OGTSite/) and an interacting network analysis was 
conducted using the Search Tool for the Retrieval of Interacting Genes (STRING) 
database (https://string-db.org/). The proteomics analysis presented in this thesis has 
been mainly performed by the staff members at the Proteomics Research Technology 
Platform at the University of Warwick with the exception of the analysis conducted 
using DAVID, OGTsite and STRING. 
2.18 Statistical analysis 
Data were analysed using a Student t-test to compare two groups or 1-way and 2-way 
analysis of variance (ANOVA) to compare more than two groups. Multiple 
comparison tests were performed in case of ANOVA analysis using a Tukey’s post-
hoc test. A linear regression model was applied to evaluate linear relationships 
between two variables. The StatView software (version 5.0.1.0, Abacus Concepts, 
CA, USA) was used to carry out statistical analysis. A level of probability set at p<0.05 











Identification and site mapping of O-GlcNAc-





The main goal of the work presented in this Chapter was to identify O-GlcNAc-
modified proteins in human placental trophoblast BeWo cells using MS. The approach 
used to achieve the Chapter’s aim is summarised in the workflow diagram in Figure 
3.1. O-GlcNAc signalling is emerging as a major regulator of cellular functions in 
response to a variety of stressful and metabolic stimuli. Thus, identifying O-GlcNAc-
modified proteins in the human trophoblast can be crucial to better understand the 
molecular basis underlying the pathophysiological adaptations occurring in the 
placenta during pregnancy complications. One major challenge when studying O-
GlcNAcylation is associated to low abundance and substoichiometric occupancy of 
O-GlcNAc sites which requires the application of enriching methods upstream MS 
(Ma and Hart, 2014). In addition, the O-GlcNAc site mapping is limited by the 
susceptibility of the β-O-glycosidic bond which anchors the GlcNAc moiety to the 
amino acid chain and is easily lost during the conventional fragmentation methods 
employed in proteomics such as the Collision-Induced Dissociation (CID) (Chalkley 
and Burlingame, 2001). By taking advantage of the recently identified O-GlcNAc 
monoclonal antibodies and the combination of two “softer” fragmentation methods, 
Higher energy Collisional Dissociation (HCD) and Electron-Transfer Dissociation 
(ETD), O-GlcNAcylated proteins were first enriched from BeWo protein extracts, 
then characterized and O-GlcNAc sites were mapped. HCD has the advantage to 
generate a distinct HexNAc oxonium ion (m/z 204) and a series of HexNAc fragments 
(m/z 186, m/z 168, m/z 144, m/z 138 and m/z 126) which are used as diagnostic tools 
for identifying O-GlcNAc-modified sites whereas ETD produces sufficient 
fragmentation ions for confident peptide identification and preserves, at the same time, 
the O-GlcNAc-modified residues for accurate site assignment (Zhao et al., 2011). 
Following enrichment and MS, a Gene Ontology (GO) analysis was performed in 
order to assign biological and functional roles to the proteins characterized as O-
GlcNAc-modified, in the attempt to identify single proteins or clusters with a pivotal 
role in trophoblast physiology. This is the first study which combines O-GlcNAc-
specific antibody enrichment followed by HCD/ETD analysis for profiling O-





Figure 3.1 Workflow diagram summarizing the approach used to characterize 
O-GlcNAcylated proteins in BeWo cell extracts. Proteins were extracted and O-
GlcNAc-enriched by IP with a specific antibody. The IP efficiency was verified by 
immunoblotting and both enriched and not enriched samples underwent MS analysis 
using a combined HCD/ETD fragmentation method. MS data were searched against 
the Uniprot_Human database using the MaxQuant software (version 1.6.10.43) and 
statistically analysed using Perseus (version 1.6.2.2). A Gene Ontology (GO) and a 
protein-protein association network analysis were performed on O-GlcNAc-enriched 
proteins in order to assign biological roles and functional interconnection. Finally, a 




3.2 Sample processing for HCD/ETD MS analysis  
3.2.1 Antibody specificity validation before O-GlcNAc enrichment of BeWo protein 
extracts 
The pharmacological inhibition of OGT is still a major challenge due to the lack of 
specificity and poor cell permeability showed by many inhibiting agents (Trapannone 
et al., 2016). As OGT is the unique enzyme responsible for protein O-GlcNAcylation, 
a siRNA was used here to perform specific silencing of endogenous OGT. Afterwards, 
OGT protein expression and the corresponding amount of O-GlcNAcylation was 
measured by immunoblotting at 4, 9, 24 and 48 h after transfection with siOGT, 
control siRNA or no treatment (NT) (Figure 3.2, A). Results showed that after 9 h 
onward, siOGT significantly reduced both OGT protein expression and global protein 
O-GlcNAcylation compared to both NT and control siRNA (Figure 3.2. B and C, 
siOGT vs control siRNA or NT, OGT protein expression: 9 h: p˂0.05, 24 h: p˂0.01 
and 48 h: p˂0.001; O-GlcNAcylation: 9 h: p˂0.05; 24 and 48 h: p˂0.001). By 
performing an MTT assay after 24 and 48 h post-transfection, cell viability was 
significantly reduced in siOGT or control siRNA compared to NT (p˂0.001) possibly 
due to the toxic effects of the reagent used for transfection. However, there was no 
difference in cell survival between siOGT and control siRNA treatment suggesting 












Figure 3.2 Validation of the anti-O-GlcNAc antibody (RL2) using siRNA against 
OGT in BeWo cells. A) Representative immunoblotting showing OGT and O-
GlcNAcylation protein levels in NT, control siRNA and siOGT-treated cells at 4, 9, 
24 and 48 h post-transfection. B) Relative density for OGT and C) protein O-
GlcNAcylation. Normalization to β actin. N=3. D) MTT assay showing cell viability 
at 24 and 48 h post-transfection. Data are expressed as mean ± SEM; ns=non-
significant, *p<0.05, **p<0.01, ***p<0.001. 
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3.2.2 Antibody-based enrichment of O-GlcNAcylated proteins in BeWo extracts  
The enrichment of O-GlcNAcylated protein is a fundamental step before applying MS 
detection due to the substoichiometric site occupancy of O-GlcNAc. After testing its 
specificity against O-GlcNAc proteins, the antibody RL2 was used to purify O-
GlcNAcylated proteins from BeWo whole extracts using IP before applying MS 
analysis (Figure 3.3). The immunoprecipitates were analysed using fluorescent 
immunoblotting to verify the efficiency and specificity of IP. In Figure 3.3 O-GlcNAc-
modified proteins in whole extracts (lane 1), whole extracts after IP (lane 2), IgG 
control (lane 3) and purified O-GlcNAcylated proteins (lane 4) are shown. O-
GlcNAcylated proteins are almost 3 times more represented after purification with the 
anti-O-GlcNAc antibody (lane 4) compared to the not-enriched whole extracts in lane 
1 indicating a robust enrichment after IP; on the contrary, O-GlcNAc proteins are 
almost 3 times lower after IP in the supernatant (lane 2). The intensities for all the 
lanes are reported in the table in Figure 3.3.  After IP validation, proteins from both 
whole extracts and O-GlcNAc-enriched samples derived from three biological 
replicates were separated by SDS-PAGE, stained with Coomassie blue for protein 
visualization and gel lanes were cut out. After destaining and in-gel trypsin digestion 
of proteins, samples underwent MS analysis for protein identification and 






Figure 3.3 Representation of the antibody-based enrichment method used to 
purify O-GlcNAcylated proteins upstream MS analysis in BeWo extracts. O-
GlcNAcylated proteins were purified from BeWo extracts using a specific antibody 
(RL2) against O-GlcNAc-modified proteins. The IP efficiency was checked by 
visualizing O-GlcNAcylated proteins using immunoblotting in whole extract (lane 1), 
whole extracts after IP (lane 2), IgG control (lane 3) and O-GlcNAc-enriched proteins 
in the immunoprecipitate (lane 4). The density of the signal was measured for each 
lane using the Odyssey software and is reported in the table. Whole extracts and O-
GlcNAc-purified proteins only were run on agarose gel, stained with Coomassie blue 
to be visualized and gel lanes were excised, proteins digested with trypsin and 
identified by MS. 
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3.3 In silico analysis 
3.3.1 Characterization and cellular localization of O-GlcNAc-modified proteins 
enriched from BeWo extracts  
A two-stage HCD/ETD fragmentation method was applied to analyse non-enriched 
extracts and O-GlcNAc-enriched proteins. The acquired data were searched against 
the Uniprot_Human database using MaxQuant software. A total of 2334 proteins was 
identified by MS, 210 of which were significantly more represented in the O-GlcNAc-
enriched samples compared to the non-enriched ones as graphed in the volcano plot in 
Figure 3.4, A. Data were analysed by two-sided t-test using Perseus software. The 
hyperbolic lines in the volcano plot represent a statistical cut-off based on FDR 
(p<0.05) and S0=0.1. The S0 controls the relative importance of the t-test p value 
taking into account the difference between means (Tusher et al., 2001) so the 
hyperbolic lines in the graph are based on both the p value and “within groups 
difference of means”. The significantly enriched proteins represent with high 
confidence O-GlcNAc-modified proteins and are listed in Table 6 according to their p 
values for the significance of enrichment. However, there is the possibility that some 
of the 210 O-GlcNAc-enriched proteins here identified by MS may have been co-
purified during the co-immunoprecipitation assay because tightly associated to O-
GlcNAcylated proteins, for example as a part of multiproteic complexes and may not 
be O-GlcNAc-modified themselves. For that reason, a manual database (neXtProt, 
PhosphoSitePlus®) and literature search (Zhao et al., 2011; Lund et al., 2016; Kang 
et al., 2013; Ahmad et al., 2011; Ha and Lim, 2015; Zeidan et al., 2010; Hiromura et 
al., 2003; Duan et al., 2018; Liu et al., 2016; Ruan et al., 2013; Gurel et al., 2014) were 
performed to verify which of the O-GlcNAc-enriched proteins, identified in this study, 
were already characterized as O-GlcNAc-modified. Results showed that 99/210 (47%) 
proteins were already identified as O-GlcNAcylated according to the literature and 
database search (shown in blue in Table 6), while 106/210 (50%) were found to 
interact with OGT in interactome studies (shown in yellow in Table 6) for a total of 
60 proteins (shown in green in Table 6) which both interact with OGT and are O-
GlcNAcylated representing with high probability O-GlcNAc-modified proteins. 
Finally, 61/210 proteins (shown in grey in Table 6) were found to be neither O-
GlcNAc-modified nor interacting with OGT and, for that reason, they might represent 
novel O-GlcNAcylated or co-purified proteins (Figure 3.4, B). Finally, of the 210 O-
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GlcNAc-enriched proteins identified in this study, 36% is located exclusively in the 
nucleus, 21% is cytoplasmic and 33% is shared between nucleus and cytoplasm as 
predicted by GO analysis. Interestingly, a significant amount of these proteins (10%) 
belong to the nuclear envelope (Figure 3.5, A). These data are further confirmed by 
immunocytochemistry analysis using anti-O-GlcNAc antibody RL2 which showed 
higher fluorescence inside and surrounding the nucleus (Figure 3.5, B and C).  
 
 
Figure 3.4 Characterization of putative O-GlcNAcylated proteins enriched from 
BeWo extracts and identified by HCD/ETD analysis. A) Volcano plot showing, in 
black, the 210 proteins which were significantly enriched by immunoprecipitation 
with anti-RL2 and representing putative O-GlcNAc-modified proteins. Data are 
plotted as significance (-log10 of the p value) versus fold change of the enrichment 
(Log2) on the y and x axes, respectively. Statistical analysis was performed by two-
sided t-test using Perseus. The black hyperbolic curved lines represent the threshold 
for statistical significance with FDR of 0.05 and S0 (minimal fold change) of 0.1. B) 
Schematic representation of results originated from manual literature and database 
search for proteins already known to interact with OGT or be O-GlcNAc-modified. 






Figure 3.5 Cellular compartmentalization of O-GlcNAcylated proteins in BeWo. 
A) Pie chart showing the subcellular localization of the 210 O-GlcNAc-enriched and 
identified proteins in BeWo extracts as predicted by GO analysis. B) 
Immunocytochemistry showing cellular localization of O-GlcNAcylated proteins 
recognized by the anti-O-GlcNAc antibody, RL2 (green) in BeWo cells. C) Two-
dimensional graph displaying changes in pixel intensity along a line drawn across a 
cell stained with anti-O-GlcNAc antibody. The analysis was performed with ImageJ 
1.49v software on different cells and a representative example is shown here. The X-
axis of the graph represents distance along the drawn line and the Y-axis is the 




Table 6. Putative O-GlcNAcylated proteins purified from BeWo and identified by 
MS 
Gene ID Protein Name -Log10(p value) 
NUP62 Nuclear pore glycoprotein p62 5,87 
NUP54 Nucleoporin p54 5,68 
NUP98 Nuclear pore complex protein Nup98-Nup96 4,80 
TFG Protein TFG 4,53 
HIST1H1B Histone H1.5 4,37 
SEC24B Protein transport protein Sec24B 3,80 
RPL3 60S ribosomal protein L3 3,72 
SETD1A Histone-lysine N-methyltransferase SETD1A 3,65 
RPSA 40S ribosomal protein SA 3,62 
HSPA1B Heat shock 70 kDa protein 1B 3,55 
RPS14 40S ribosomal protein S14 3,32 
PRPF40A Pre-mRNA-processing factor 40 homolog A 3,29 
RBM25 RNA-binding protein 25 3,27 
HSPA9 Stress-70 protein, mitochondrial 3,14 
HSPA5 Endoplasmic reticulum chaperone BiP 2,95 





PRPF19 Pre-mRNA-processing factor 19 2,58 
SFPQ Splicing factor, proline- and glutamine-rich 2,22 
RPL27 60S ribosomal protein L27 2,13 
HNRNPA2B1 




Probable global transcription activator 
SNF2L2 
1,94 
WDR5 WD repeat-containing protein 5 1,89 
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 1,86 
RPL11 60S ribosomal protein L11 1,83 
HSPA4 Heat shock 70 kDa protein 4 1,82 
YBX1 Nuclease-sensitive element-binding protein 1 1,55 
HUWE1 E3 ubiquitin-protein ligase HUWE1 1,52 
RANBP2 E3 SUMO-protein ligase RanBP2 1,50 
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YY1 Transcriptional repressor protein YY1 1,50 
NUP153 Nuclear pore complex protein Nup153 5,97 
TRIM21 E3 ubiquitin-protein ligase TRIM21 5,04 
NUP214 Nuclear pore complex protein Nup214 5,02 
QSER1 Glutamine and serine-rich protein 1 4,77 
CSNK2A1 Casein kinase II subunit alpha 4,59 
BAP1 Ubiquitin carboxyl-terminal hydrolase BAP1 4,54 
OGT 
UDP-N-acetylglucosamine--peptide N-
acetylglucosaminyltransferase 110 kDa 
subunit 
4,45 
TET3 Methylcytosine dioxygenase TET3 4,08 
HNRNPU Heterogeneous nuclear ribonucleoprotein U 3,90 
KANSL3 KAT8 regulatory NSL complex subunit 3 3,84 
HIVEP1 Zinc finger protein 40 3,64 
DMAP1 
DNA methyltransferase 1-associated protein 
1 
3,53 
HCFC1 Host cell factor 1 3,39 
RAE1 mRNA export factor 3,34 
DIDO1 Death-inducer obliterator 1 3,24 
HCFC1 Host cell factor 1 3,12 
TET2 Methylcytosine dioxygenase TET2 3,12 
AHNAK 




Nuclear envelope pore membrane protein 
POM 121 
2,92 
SPEN Msx2-interacting protein 2,64 
NUP160 Nuclear pore complex protein Nup160 2,30 
CARM1 Histone-arginine methyltransferase CARM1 2,13 
CAD CAD protein 2,07 
NUP205 Nuclear pore complex protein Nup205 1,87 
RTN4 Reticulon 1,72 
NUP50 Nuclear pore complex protein Nup50 1,70 
NUP188 Nucleoporin NUP188 homolog 1,69 
ASXL1 Putative Polycomb group protein ASXL1 1,18 
ASXL2 Putative Polycomb group protein ASXL2 1,07 
PROSER1 Proline and serine-rich protein 1 4,25 
RPS3 40S ribosomal protein S3 4,20 
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FLG2 Filaggrin-2 4,04 
SLC25A5 ADP/ATP translocase 2 3,88 
PHF12 PHD finger protein 12 3,83 
ALB Serum albumin 3,67 
SLC16A1 Monocarboxylate transporter 1 3,17 
RAB14 Ras-related protein Rab-14 3,16 
PSPC1 Paraspeckle component 1 3,16 
DSG1 Desmoglein-1 3,15 
ZC3H18 
Zinc finger CCCH domain-containing protein 
18 
2,99 
DCD Dermcidin 2,79 
NXF1 Nuclear RNA export factor 1 2,78 
FAM208B Protein FAM208B 2,75 
DDX54 ATP-dependent RNA helicase DDX54 2,72 
HRNR Hornerin 2,72 
TUBB4B Tubulin beta-4B chain 2,68 
RPS16 40S ribosomal protein S16 2,68 
CSNK2B Casein kinase II subunit beta 2,61 
DHX9 ATP-dependent RNA helicase A 2,36 
PSMD3 
26S proteasome non-ATPase regulatory 
subunit 3 
2,34 
RPLP0 60S acidic ribosomal protein P0 2,15 
RPN1 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
2,06 
GTF3C3 General transcription factor 3C polypeptide 3 1,98 
COPA Coatomer subunit alpha 1,97 
LMNB1 Lamin-B1 1,93 
ARCN1 




Solute carrier family 2, facilitated glucose 
transporter member 3 
1,90 
TUBA1C Tubulin alpha-1C chain 1,88 
ZNF326 DBIRD complex subunit ZNF326 1,84 
MRPS26 28S ribosomal protein S26, mitochondrial 1,70 
TMEM33 Transmembrane protein 33 1,68 
RAB35 Ras-related protein Rab-35 1,61 
XPO1 Exportin-1 1,57 
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RPS10 40S ribosomal protein S10 1,49 
KDM1B Lysine-specific histone demethylase 1B 1,46 





IQGAP1 Ras GTPase-activating-like protein IQGAP1 1,36 





COPB2 Coatomer subunit beta' 1,18 
SCAF11 Protein SCAF11 1,14 
ATP2A2 
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 
1,12 
AHCTF1 Protein ELYS 1,08 
EIF2B3 
Translation initiation factor eIF-2B subunit 
gamma 
1,07 
RBM27 RNA-binding protein 27 3,54 
POU2F1 POU domain, class 2, transcription factor 1 5,29 
UBAP2 Ubiquitin-associated protein 2 5,17 
TET1 Methylcytosine dioxygenase TET1 5,08 
POM121C 
Nuclear envelope pore membrane protein 
POM 121C 
4,58 
RUVBL1 RuvB-like 1 4,48 
SP3 Transcription factor Sp3 4,34 
PRRC2C Protein PRRC2C 4,10 
SRCAP Helicase SRCAP 3,61 
UBAP2 Ubiquitin-associated protein 2 3,60 
RAN GTP-binding nuclear protein Ran 3,51 
HSPA8 Heat shock cognate 71 kDa protein 3,40 
EWSR1 RNA-binding protein EWS 3,17 
NUP88 Nuclear pore complex protein Nup88 2,75 
UBAP2 Ubiquitin-associated protein 2 2,73 
JMJD1C 
Probable JmjC domain-containing histone 
demethylation protein 2C 
2,62 
NFRKB 
Nuclear factor related to kappa-B-binding 
protein 
2,41 
SEC23IP SEC23-interacting protein 2,20 
RACK1 Receptor of activated protein C kinase 1 1,42 
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WNK1 Serine/threonine-protein kinase WNK1 6,36 
CIC Protein capicua homolog 4,69 
ANKHD1 
Ankyrin repeat and KH domain-containing 
protein 1 
4,63 
ANKRD17 Ankyrin repeat domain-containing protein 17 4,46 
BASP1 Brain acid soluble protein 1 4,19 
NUP58 Nucleoporin p58/p45 4,05 
EMSY 
BRCA2-interacting transcriptional repressor 
EMSY 
3,98 
TCERG1 Transcription elongation regulator 1 3,96 
ATP5F1A ATP synthase subunit alpha, mitochondrial 3,76 
SP1 Transcription factor Sp1 3,65 
NUP93 Nuclear pore complex protein Nup93 3,06 
SAP30BP SAP30-binding protein 2,66 
LUZP1 Leucine zipper protein 1 2,32 
MEF2D Myocyte-specific enhancer factor 2D 2,28 
MARK2 Serine/threonine-protein kinase MARK2 1,95 
UBAP2L Ubiquitin-associated protein 2-like 1,83 
CLASP2 CLIP-associating protein 2 1,20 
PRRC2B Protein PRRC2B 1,13 
WNK2 Serine/threonine-protein kinase WNK2 1,07 
CDK12 Cyclin-dependent kinase 12 1,07 
MARK3 




Histone deacetylase complex subunit 
SAP130 
0,95 
KRT1 Keratin, type II cytoskeletal 1 5,21 
SIX4 Homeobox protein SIX4 5,13 
SEC23B Protein transport protein Sec23B 4,52 
NFYA Nuclear transcription factor Y subunit alpha 4,41 
KRT14 Keratin, type I cytoskeletal 14 4,38 
RUVBL2 RuvB-like 2 4,32 
LYZ Lysozyme 3,99 
SS18 Protein SSXT 3,97 
KRT9 Keratin, type I cytoskeletal 9 3,73 
YEATS4 YEATS domain-containing protein 4 3,69 
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ACTR6 Actin-related protein 6 3,49 
KRT2 Keratin, type II cytoskeletal 2 epidermal 3,38 
TBC1D4 TBC1 domain family member 4 3,14 
KRT10 Keratin, type I cytoskeletal 10 3,14 
GDPD3 Lysophospholipase D GDPD3 3,04 
KRT6A Keratin, type II cytoskeletal 6A 3,01 
FBXO22 F-box only protein 22 2,85 
KRT5 Keratin, type II cytoskeletal 5 2,76 
DHCR7 7-dehydrocholesterol reductase 2,74 
MYOF Myoferlin 2,65 
GRN Progranulin 2,64 
H1F0 Histone H1.0 2,59 
CDK11B Cyclin-dependent kinase 11B 2,26 
DARS Aspartate--tRNA ligase, cytoplasmic 2,20 
PFKL 




Vacuolar protein sorting-associated protein 
72 homolog 
2,15 
ACTL6A Actin-like protein 6A 2,12 
PTHLH Parathyroid hormone-related protein 2,08 
SLC7A5 
Large neutral amino acids transporter small 
subunit 1 
2,02 
CAV1 Caveolin-1 2,02 
NSRP1 Nuclear speckle splicing regulatory protein 1 1,95 
PRKD2 Serine/threonine-protein kinase D2 1,95 
PHKB 
Phosphorylase b kinase regulatory subunit 
beta 
1,95 
HEXB Beta-hexosaminidase subunit beta 1,93 
ATP2B4 
Plasma membrane calcium-transporting 
ATPase 4 
1,87 
FERMT2 Fermitin family homolog 2 1,86 
KPRP Keratinocyte proline-rich protein 1,84 
KRT16 Keratin, type I cytoskeletal 16 1,82 
SNTB2 Beta-2-syntrophin 1,77 
STX18 Syntaxin-18 1,77 
COBLL1 Cordon-bleu protein-like 1 1,66 




Search for OGT interactome studies was performed on https://www.nextprot.org/ and on Zhao 
et al., 2011. Search for protein O-GlcNAcylation was performed on 
https://www.phosphosite.org/ and on literature (Zhao et al., 2011; Lund et al., 2016; Kang et 
al., 2013; Ahmad et al., 2011; Ha and Lim, 2015; Zeidan et al, 2010; Hiromura et al., 2003; 
Duan et al., 2018; Liu et al., 2016; Ruan et al., 2013; Gurel et al., 2014).  
According to the literature and database search, proteins that both interact with OGT and are 
known to be O-GlcNAcylated are shown in green in the table; proteins that only interact with 
OGT are shown in yellow; proteins that are known to be O-GlcNAc-modified are shown in 
blue; novel putative O-GlcNAcylated proteins are shown in grey at the bottom of the table.  
RAB8A Ras-related protein Rab-8A 1,58 
BCAP31 B-cell receptor-associated protein 31 1,53 
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1 1,51 
GSTZ1 Glutathione transferase zeta 1 1,48 
STT3B 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 
1,44 
SERPINH1 Serpin H1 1,43 
ATP6V1H V-type proton ATPase subunit H 1,40 
PRKCH Protein kinase C eta type 1,35 
CPVL Probable serine carboxypeptidase CPVL 1,33 
AAMP Angio-associated migratory cell protein 1,28 
KRT77 Keratin, type II cytoskeletal 1b 1,27 
FHL2 Four and a half LIM domains protein 2 1,23 
DNMT3B DNA (cytosine-5)-methyltransferase 3B 1,21 
CEMIP2 Cell surface hyaluronidase 1,20 
SEC23A Protein transport protein SEC23 1,17 
LEO1 RNA polymerase-associated protein LEO1 1,17 
RABGAP1 Rab GTPase-activating protein 1 1,17 
ZNF384 Zinc finger protein 384 1,10 
COL4A1 Collagen alpha-1(IV) chain 1,08 
SURF4 Surfeit locus protein 4 1,06 
REXO4 RNA exonuclease 4 1,00 
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3.3.2 Mapping of O-GlcNAcylation sites  
For the identification of the O-GlcNAc sites, each raw spectral file originated from the 
HCD/ETD fragmentation of BeWo proteins, was searched against the Uniprot_Human 
database using the MaxQuant software allowing for HexNAc modification on 
serine/threonine (+203.079 Da). Indeed, once fragmented, peptides containing O-
GlcNAcylation sites show a distinctive fragmentation profile characterized by the 
HexNAc oxonium ion with a specific mass-to-charge ratio (m/z) of 204 (m/z 204). A 
series of HexNAc fragments are also produced at high intensity (m/z 186, m/z 168, 
m/z 144, m/z 138 and m/z 126) in the HCD/ETD fragmentation spectra (Figure 3.6) 
(Zhao et al., 2011). A total of 114 O-GlcNAc sites on 22 proteins, 4 of which were 
novel O-GlcNAc-modified proteins, were identified in BeWo extracts using the 
HCD/ETD fragmentation method and engine search (Table 7). Not surprisingly, O-
GlcNAc sites were found mainly on the 210 proteins significantly enriched by the O-
GlcNAc antibody suggesting that primarily O-GlcNAcylated proteins were purified 
with the antibody-based enrichment method used in this study. By comparison with 
the literature and database search, 69 sites, were not previously reported and might 
constitute novel O-GlcNAcylation sites (marked in bold in Table 7). A predictive 
model analysis, based on the computational evaluation of the amino acids motif 
surrounding the O-GlcNAcylation sites as substrate for the OGT enzyme, was also 
applied to the novel identified O-GlcNAc sites using the web-based tool OGTsite (Wu 
et al., 2014). Studies have demonstrated that OGTsite predicts O-GlcNAcylation by 
providing a ~84% accuracy (Kao et al., 2015). Results showed that 10/69 O-GlcNAc-
modified sites identified in this study are predicted as O-GlcNAc-modified by the 
OGTsite tool and are shown in red in Table 7. Interestingly, this analysis revealed that 
the most pronounced feature surrounding the O-GlcNAc modification site is the 
abundance of hydrophobic amino acids Proline (P), Valine (V), and Alanine (A), 





Figure 3.6 Typical ion spectra generated by the fragmentation of an O-
GlcNAcylated peptide. The spectrum shows the fragmentation of HCF-1 on the 
peptide (K)TIPmsAIITQAGATGVTSSPGIK(S). The HexNAc oxonium ion (m/z 
204) and its fragments (m/z 186, m/z 168, m/z 144, m/z 138, and m/z 126) are 




Table 7. O-GlcNAc sites identified in BeWo extracts 
 
Gene ID Protein name Modification sites Substrate motif  
ERP44 Endoplasmic reticulum 
resident protein 44 
T367, T369     
TLDC1 TLD domain-containing 
protein 1 
S425   
POLDIP3 Polymerase delta-
interacting protein 3 
T138   
UBQLN2 Ubiquilin-2 S116   
UBAP2L Ubiquitin-associated 
protein 2-like 
S445, T446   
UBAP2 Ubiquitin-associated 
protein 2 
T336, T338, S368, 
T389, T391, S421, S485, 
T487, T1010, T1009  
  
RBM27 RNA-binding protein 27 T539   
ANKRD17 Ankyrin repeat domain-
containing protein 17  




POM121 Nuclear envelope pore 
membrane protein POM 
121 
T686, T688     
SRCAP Helicase SRCAP T2229, T2235, S2239, 
T2406, T2412, S2416  
  
 
PRRC2C Protein PRRC2C T2244, T2242   
HCFC1 Host cell factor 1 T495, T498, S518, T566, 
S569, T579, T583, T586, 
T619, S620, T625, T627, 
T642, T651, T652, T689, 
T698, T771, S775, T779, 
T797, T800, T801, T805, 
S806, T808, T861, S863, 







KRT1 Keratin, type II 
cytoskeletal 1 
S502    
NUP98 Nuclear pore complex 
protein Nup98-Nup96 
T223   
SEC24B Protein transport protein 
Sec24B 
S315, S342   
POM121C Nuclear envelope pore 
membrane protein POM 
121C 






T283, S284      
QSER1 Glutamine and serine-
rich protein 1 
S51, S52, T233, S715   
NUP153 Nuclear pore complex 
protein Nup153 
T515, S543, S544, T548, 
S564, T630, S764, T890, 
S891, S895, S911, S912, 
S937, S938, S1023, 
T1112, S1113, T1114, 
S1115, S1154, T1156 
 
PROSER1 Proline and serine-rich 
protein 1 
S595, S596, T597, T601  
 
NUP214 Nuclear pore complex 
protein Nup214 
T598, S1044, S1045, 
T1051, T1134, S1136, 
T1137, T1201, S1207, 








T1600, T1848   
 
All the O-GlcNAcylation sites showed in this table have been identified in this study using 
HCD/ETD fragmentation and search engine for the HexNAc ion in the Uniprot_Human 
database. In bold are indicated the potentially novel O-GlcNAc sites which are not reported 
in literature, while in red are shown the modified sites predicted in this study using the 
OGTsite tool with the corresponding OGT substrate motifs. The manual search for O-
GlcNAcylation sites was performed on https://www.phosphosite.org/ and on literature (Zhao 
et al., 2011; Lund et al., 2016; Kang et al., 2013; Ahmad et al., 2011; Ha and Lim, 2015; 
Zeidan et al, 2010; Hiromura et al., 2003; Duan et al., 2018; Liu et al., 2016; Ruan et al., 
2013; Gurel et al., 2014).   
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3.3.3 Gene Ontology (GO) analysis of O-GlcNAc-enriched proteins identified by MS 
In order to assign a putative molecular and biological function to the 210 O-GlcNAc-
enriched proteins identified in this study, a GO analysis was performed using the web-
accessible program DAVID. By agglomerating information on tens of millions GO 
annotation terms from a variety of public bioinformatics databases, DAVID provides 
significantly enriched biological and functional annotation terms and condenses large 
input lists of genes which share the same annotations into single functional groups 
(Dennis et al., 2003). To quantify the degree of enrichment for each functional group, 
DAVID compares the annotations associated to the user’s list of genes with the 
distribution of the annotations among the whole human genome background assigning 
a p value of annotation enrichment to each group of genes sharing the same annotation 
term. A p value ≤0.05 indicates that a certain group of genes is specifically associated 
(enriched) with a specific biological or functional category more than a random chance 
as compared to human background. As graphed in Figure 3.7 A, the GO molecular 
functions analysis identified “protein binding”, “RNA binding”, “DNA binding” and 
“chromatin binding” as the most significantly enriched annotations, suggesting that 
the O-GlcNAcylated proteins identified in this study might be involved in epigenetic 
regulation at level of both DNA and RNA. Indeed, the top-ranked categories in terms 
of percentage of genes for the GO biological functions analysis (Figure 3.7, B), are 
associated with transcription and regulation of transcription, in agreement with the GO 
molecular function analysis, followed by terms associated to transport across the 
nucleus.  
A gene functional classification analysis was also performed in DAVID for the 210 
O-GlcNAc-enriched proteins. This type of analysis classifies the user’s list of genes 
into functionally related gene groups based on their GO term annotations and has the 
advantage of ranking the importance of different gene groups by assigning them an 
enrichment score. A higher score for a certain group indicates that the gene members 
in that group are involved in more important (enriched) terms in a given study, 
therefore more attention should go to them (Huang et al., 2009). An enrichment score 
of 1.3 is equivalent to non-log scale 0.05. Groups with scores ≥1.3 are statistically 
significantly enriched and are shown in Table 8 for this study. Results indicated that 
56/210 of the O-GlcNAc-enriched proteins identified in this study were allocated in 5 
functional clusters with a significant enrichment score ranging from 15.8 to 3.5. 
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Interestingly, the top ranking group of genes, in terms of statistical significance, 
belong to components of nuclear envelope involved in the transport across the nucleus, 
followed by proteins involved in regulation of transcription, translation and a group of 
protein kinases (Table 8) suggesting that these groups of genes may play major 





Figure 3.7 Gene Ontology (GO) analysis for the O-GlcNAc-enriched proteins 
identified by MS in BeWo extracts. Statistically significantly enriched annotation 
terms are displayed for A) GO molecular functions and B) GO biological functions 








Table 8. Gene functional classification analysis 
 
Group 1 Enrichment Score: 15.8 Enriched GO terms 
NUP50 nucleoporin 50 
GO:0016925 protein 
SUMOylation       
GO:0031047 gene 
silencing by RNA     
GO: 0006406 mRNA 
export from nucleus                                                              
GO: 0007077 mitotic 
nuclear envelope 
disassembly  
NUP58 nucleoporin 58 
NUP214 nucleoporin 214 
POM121 POM121 transmembrane nucleoporin 
RAE1 ribonucleic acid export 1 
RANBP2 RAN binding protein 2 
NUP62 nucleoporin 62 
NUP153 nucleoporin 153 
NUP54 nucleoporin 54 
NUP98 nucleoporin 98 
NUP88 nucleoporin 88 
NUP93 nucleoporin 93 
NUP188 nucleoporin 188 
NUP205 nucleoporin 205 
NUP160 nucleoporin 160 
POM121C POM121 transmembrane nucleoporin C 
Group 2 Enrichment Score: 10.9   




EMSY BRCA2 interacting transcriptional repressor 
SAP30BP SAP30 binding protein 
CIC capicua transcriptional repressor 
VPS72 vacuolar protein sorting 72 homolog 
NFRKB nuclear factor related to kappaB binding protein 
Group 3 Enrichment Score: 9.9   





of ribosome                                         
GO:0006412 
translation  
RPL27 ribosomal protein L27 
RPL3 ribosomal protein L3 
RPSA ribosomal protein SA 
RPLP0 ribosomal protein lateral stalk subunit P0 
RPS14 ribosomal protein S14 
RPS16 ribosomal protein S16 
RPS10 ribosomal protein S10 
Group 4 Enrichment Score: 9.4   
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 
GO:003676 nucleic 
acid binding 
SFPQ splicing factor proline and glutamine rich 
RBM25 RNA binding motif protein 25 
PSPC1 paraspeckle component 1 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 
SPEN spen family transcriptional repressor 




Enrichment score of 1.3 is equivalent to non-log scale 0.05. Groups with scores ≥1.3 are 
statistically significantly enriched and here represented. Only clusters having at least 6 
members are shown. 
  
Group 5 Enrichment Score: 3.5   




WNK2 WNK lysine deficient protein kinase 2 
PRKCH protein kinase C eta 
PRKD2 protein kinase D2 
WNK1 WNK lysine deficient protein kinase 1 
MARK2 microtubule affinity regulating kinase 2 
CSNK2A1 casein kinase 2 alpha 1 
CDK12 cyclin dependent kinase 12 
MARK3 microtubule affinity regulating kinase 3 
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3.3.4 Protein-protein interaction network analysis  
To further investigate the relationship between the O-GlcNAc-enriched proteins 
identified in BeWo, a protein-protein interaction network analysis was constructed 
using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), a 
freely available database based on known and predicted protein-protein interactions. 
The results confirmed what observed in the GO analysis, showing that the majority of 
the O-GlcNAc-enriched proteins identified by MS in this study, are physically and 
functionally associated and are mainly involved in regulation of transcription (23%) 
(yellow), translation (10%) (red) and nucleocytoplasmic transport (13%) (green) 
(Figure 3.8). This analysis has also predicted that OGT is in a direct protein-protein 
interaction with 21 of the 210 O-GlcNAc-enriched proteins identified here (Figure 
3.9) many of which are involved in chromatin modification (blue area, Figure 3.8) and 
regulation of transcription. Interestingly, 18 of the 21 proteins identified in this 
analysis were already found to interact with OGT following a manual search as 
described in paragraph 3.3.1. However, by manual search a total of 106 proteins were 
identified suggesting that, of the two methods used to predict which proteins are in a 







Figure 3.8 Protein-protein association network analysis of the O-GlcNAc-
enriched proteins in BeWo using STRING database. The four functional classes 
identified in this analysis are highlighted with different colours. The lines connecting 
the spheres represent known or predicted protein-protein interactions according to the 




Figure 3.9 Protein-protein interaction network analysis for the OGT enzyme. 
OGT is among the O-GlcNAc-enriched proteins in BeWo extracts and interacts with 
21/210 of the identified proteins as predicted by the STRING model. The majority of 




As described in Chapter 1-Introduction, protein O-GlcNAcylation controls most 
cellular processes. As a “cellular sensor” it is highly dynamic and changes rapidly in 
response to many stimuli including stress and metabolic variations (Zachara and Hart, 
2004). Abnormal levels of O-GlcNAcylation on nucleocytoplasmic proteins are 
associated with chronic diseases including cancer, diabetes and neurodegenerative 
disorders (Yang and Suh, 2014). Thus, identifying new OGT targets and O-GlcNAc 
modification sites is crucial to evaluate the impact that changes in O-GlcNAc cycling 
may produce on cellular processes especially in the human placenta where functional 
adaptations can program the health of future generations (Sferruzzi-Perri and Camm, 
2016).  
By using an antibody-based enrichment method followed by the HCD/ETD peptide 
fragmentation, 210 putative O-GlcNAc-modified proteins were significantly enriched 
by the anti-O-GlcNAc antibody and identified in BeWo cell line, 61 of which are 
potentially novel. In addition, 114 O-GlcNAc sites on 22 proteins were identified, 69 
of which may constitute putative novel sites. A GO and protein-protein association 
network analysis predicted that the identified proteins are functionally interconnected 
and regulate common biological processes within the cell including regulation of 
transcription, mainly via control of chromatin structure, regulation of translation, 
protein degradation and transport across the nucleus. In the context of trophoblast 
physiology, these proteins are involved at different levels in both placentation and fetal 
development (Figure 3.10).  
One of the most significantly enriched cluster of O-GlcNAcylated proteins found in 
this study includes many nucleoporins, components of the nuclear pore complex 
(NPC), a fundamental barrier between nucleus and cytoplasm which controls virus 
replication, nuclear envelope disassembly during mitosis, gene expression and 
SUMOylation (Texari and Stutz, 2015; Flatt and Greber, 2015). Nucleoporins are 
among the most O-GlcNAcylated proteins and loss of O-GlcNAc modification leads 
to their increased ubiquitination, proteasomal degradation and downstream 
malfunction of the nuclear pore which explains why O-GlcNAcylation of the NPC is 
highly conserved among metazoans (Y. Zhu et al., 2016). The high content in O-
GlcNAc moieties on nucleoporins justifies why they are highly enriched by the anti-
O-GlcNAc antibody in this study and explains the abundance of modification sites, 26 
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of which novel, identified by MS on Nup214, Nup153, Nup98, POM121 and 
POM121C. In human reproduction, NCP marks the implantation window in human 
endometrium (Guffanti et al., 2008), regulates trophoblast differentiation from 
cytotrophoblast into syncytiotrophoblast (Mayhew et al., 1999) and is involved in fetal 
development since several nucleoporins are mutated in some inherited diseases 
(Schreiber and Kennedy, 2013). Moreover, alterations in protein SUMOylation, a 
post-translational modification which occurs copiously at the NPC, are associated with  
preeclampsia, growth restriction and inflammation (Baczyk et al., 2013; Baczyk et al., 
2018). 
Many proteins, known to regulate gene transcription and chromatin structure, were 
also significantly O-GlcNAc-enriched and identified in this study. The majority of 
them are known to be in a physical stable interaction with the OGT enzyme. An 
example is the transcriptional coregulator host cell factor-1 (HCF-1), encoded by the 
gene HCFC1 and one of the most heavily O-GlcNAcylated protein. Up to 32 sites 
were identified here for HCF-1, 7 of which are potentially novel. OGT is required for 
HCF-1 maturation whereas the latter is required for stabilizing OGT in the nucleus 
(Daou et al., 2011). In this way, they regulate the activity of protein complexes 
involved in epigenetic control via chromatin modifications. In the SET1/COMPASS 
complex, for example, OGT is assisted by the two methylcytosine dioxygenases TET2 
and TET3 in sustaining, via O-GlcNAcylation of HCF-1, the tri-methylation of histone 
H3 Lys4 (H3K4me3), an epigenetic modification involved in early mammalian 
development (Deplus et al., 2013). Moreover, OGT and HCF-1 are part of the 
polycomb repressive complex PR-DUB and, together with the lysine-specific histone 
demethylase 1B (KDM1B), the transcriptional regulators ASXL1 and ASXL2 and the 
deubiquitinating enzymes BAP1, all significantly enriched by the anti-O-GlcNAc 
antibody in this study, regulate the ubiquitination status and activity of H2A, one of 
the five main histones involved in the structure of chromatin in eukaryotic cells (Dey 
et al., 2012). A mutation that disrupts the catalytic activity of the PR-DUB complex, 
abolishes H2A deubiquitination in vitro and HOX genes repression in vivo. The latter 
are master regulators of embryonic development (Scheuermann et al., 2010; 
Deschamps and van Nes, 2005), also involved in placentation and trophoblast 
syncytialization (Murthi et al., 2012; Novakovic et al., 2017). Furthermore, 8 of the 
10 components of the SRCAP complex (SRCAP, DMAP1, VPS72, RUVBL1, 
RUVBL2, ACTL6A, ACTR6, ACTIN, YEATS4 and ZNHIT1) (Feng et al., 2018), 
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were found among the O-GlcNAc-enriched proteins identified in this study and 6 
novel O-GlcNAc sites were identified for SRCAP. This chromatin remodelling 
complex controls the deposition of the histone variant H2A.Z at promoters of 
transcription factors, including SP1, during replication (Wong et al., 2007). Both 
SRCAP and H2A.Z are essential for normal gene expression via recruitment of RNA 
polymerase II and TATA-binding protein (Adam et al., 2001). In mammal 
reproduction, H2A.Z is essential for both embryonic development and trophoblast 
differentiation (Kafer et al., 2015) while SRCAP serves as a coactivator for CREB and 
the glucocorticoid receptors, both crucial for a fully functional placenta and fetal 
development (Gupta et al., 2016; Turkay et al., 2012). Taken together these findings 
suggest a central role played by OGT in regulating the histone code and controlling 
different multiprotein complexes within the nucleus (Sakabe et al., 2010). 
Besides transcription and epigenetic mechanisms, gene regulation may occur also at 
level of ribosomes as suggested by differences existing between expression of 
transcriptome and proteome (Schwanhüusser et al., 2011). It has been demonstrated 
that O-GlcNAcylation of ribosomal proteins influences the role of these cellular 
components with implications on ribosome performance (Dierschke et al., 2019). 
However, much more research is required in this field. In the present study many core 
ribosomal proteins were found to be O-GlcNAc-modified in agreement with literature 
(Zeidan et al., 2010), suggesting a second mechanism via which protein O-
GlcNAcylation might control gene expression in human trophoblast.  
Protein O-GlcNAcylation is often in interplay with phosphorylation and ubiquitination 
(Ruan et al., 2013; Guinez et al., 2008). Here, many proteins involved in ubiquitination 
were found to be O-GlcNAcylated including UBAP2, UBAP2L, UBQLN2, TRIM21, 
BAP1, HUWE1, PRPF19 and 9 novel O-GlcNAcylation sites were identified for 
UBAP2 and UBAP2L. Ubiquitination influences protein localization and activity and 
marks misfolded and damaged proteins for proteasomal degradation thus maintaining 
cellular homeostasis. For this reason, suboptimal ubiquitination of proteins is involved 
in the pathophysiology of a broad range of human diseases including cancer, viral 
infection, neurodegenerative disorders, diabetes and inflammation (Petroski, 2008). In 
the placenta of both rodents and humans, alterations in the ubiquitination system are 
associated with intrauterine growth retardation (Harbers et al., 1996; Chen et al., 
2015). Another important cluster of proteins identified here as O-GlcNAc-enriched 
proteins belong to a group of kinases involved in trophoblast physiology, identifying 
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the potential of O-GlcNAcylation to modify kinase networks. In particular, the casein 
kinase 2 (CK2), highly expressed in the syncytiotrophoblast, is known to be regulated 
on its catalytic subunit by O-GlcNAc on Ser347 (Chen et al., 2015). Inhibition of CK2 
decreases proliferation, invasion and syncytialization of trophoblast cells and is 
associated to preeclampsia in human placenta (Abi Nahed et al., 2020). In addition, 
WNK1 kinase, highly expressed in the placenta (O’Reilly et al., 2003), is the most 
represented protein enriched by the anti-O-GlcNAc antibody in this study. Although 
its role has not yet been well explored, WNK kinases are known for being positive 
regulators of canonical Wnt/β-catenin signalling (Serysheva et al., 2013) which 
regulates many aspects of mammalian reproduction including placentation (Tepekoy 
et al., 2015; Knöfler and Pollheimer, 2013).  
In conclusion, the findings presented in this Chapter demonstrated that, the antibody-
based enrichment method, followed by HCD/ETD analysis, is a valid approach for the 
detection and site assignment of O-GlcNAc modification and, in combination with 
GO analysis, it offers a global perspective for studing the function of a broad range of 
O-GlcNAcylated proteins involved in the regulation of placenta physiology and 
diseases. Furthermore, what has strongly emerged from this study is that the OGT 
enzyme is highly versatile and able to modify different classes of proteins involved in 
diverse biological processes. More importantly, these data position OGT and O-
GlcNAcylation at the “front-stage” in the epigenetic control of human trophoblast and 
support further research to dissect placental OGT roles as the cellular sensor linking 











Figure 3.10 Schematic representation of O-GlcNAc-modified proteins in BeWo 
trophoblast cells and their biological function. The scheme summerizes the main 
findings emerged in this thesis Chapter and shows the potential mechanisms through 














Role of OGT and O-GlcNAcylation in the 







The formation of syncytiotrophoblast is a critical step in placentation, fetal 
development and pregnancy success. The syncytial layer establishes a feto-maternal 
interface around the highly vascular placental villi and facilitates the passive exchange 
of nutrients and gases between the mother and the embryo (Knöfler et al., 2019). 
Moreover, the syncytiotrophoblast produces important placental hormones throughout 
pregnancy including hCG which is crucial for placental maturation, pregnancy 
establishment and maintenance as well as fetal growth (Cole, 2010; Murphy et al., 
2006). The in vivo fusion process, which gives origin to the syncytiotrophoblast in the 
human placenta, can be reproduced in vitro using the human choriocarcinoma cell line, 
BeWo. This cell line grows in culture as a monolayer of mononucleated 
cytotrophoblast cells which can be induced to aggregate and fuse to form a non-
proliferative and endocrine active multinucleated syncytium by activating the 
AC/cAMP cascade. The molecular mechanisms underlying trophoblast differentiation 
into syncytiotrophoblast are well-established. The intracellular increase of cAMP 
activates the PKA-CREB axis along with ERK1/2 and p38 MAPKs signalling in a 
PKA-dependent manner leading to increased expression of markers of differentiation, 
such as the fusogenic proteins syncytin-1 and syncytin-2, and enhanced secretion of a 
panel of placental hormones including hCG (Daoud et al., 2005; Delidaki et al., 2011; 
Wice et al., 1990).  
The aim of this thesis Chapter was to investigate to which extent OGT and its 
biochemical mark O-GlcNAcylation are important in regulating trophoblast 
differentiation in BeWo cells. To achieve this, the OGT-depleted BeWo cell line was 
generated using siRNA against OGT and was induced to differentiate using forskolin, 
an AC activator. Expression levels of the fusogenic proteins syncytin-1 and syncytin-
2 were investigated by RT-qPCR whereas immunohistochemistry was used to detect 
morphological changes and areas of cell fusion. The secretion of β-hCG was detected 
by chemiluminescence while differences in signalling pathways downstream PKA 







4.2 Forskolin-induced differentiation in BeWo cells as a model to study 
syncytiotrophoblast formation 
4.2.1 Morphological and biochemical differentiation in forskolin-treated BeWo cells 
In order to set up a suitable in vitro model of trophoblast differentiation using BeWo 
cells, a previously validated protocol was applied in this study (Delidaki et al., 2011). 
Undifferentiated choriocarcinoma BeWo cells were grown as a monolayer of 
mononucleated cells to 80% of their confluence before being treated with 100 μM of 
forskolin or DMSO for 48 h. Forskolin activates AC and enhances the intracellular 
cAMP levels thus activating PKA and its downstream targets involved in the 
trophoblast differentiation process. In Figure 4.1 A, the effect of forskolin or DMSO 
on cellular morphology is captured with immunofluorescence microscope. Nuclei are 
stained with blue-fluorescent DNA stain DAPI and cellular membranes with anti-E-
cadherin antibody. In absence of forskolin, the cytotrophoblast maintains a contiguous 
monolayer with prominent E-cadherin staining at the borders of each cell (Figure 4.1 
A, upper panel). In contrast, after 48 h of forskolin treatment, clustered nuclei 
appeared along with loss of E-cadherin integrity (Figure 4.1 A, lower panel, yellow 
arrows). Reduced E-cadherin protein expression in forskolin-treated cells compared 
to DMSO treatment was further confirmed by immunoblotting analysis of cell lysates 
(p˂0.01, Figure 4.1 B). Gene expression of the fusogenic proteins syncytin-1 and 
syncytin-2 was also significantly increased in forskolin-treated cells compared to 
DMSO (p˂0.001, Figure 4.1 C) along with levels of secreted β-hCG as measured in 
the culture media by chemiluminescence (p˂0.001, Figure 4.1 D). Phosphorylation at 
Thr202/Tyr204 and Thr180/Tyr182, the activation sites of ERK1/2 (p˂0.01) and p38 
(p˂0.05) respectively, was significantly higher after 48 h of forskolin treatment 
compared to DMSO, whereas phosphorylation of CREB at Ser-133 was 
downregulated in forskolin-treated cells compared to controls (p˂0.05) (Figure 4.1, E 
and F).  
It has been shown that in BeWo cells, the maximum activation of CREB, p38 and 
ERK1/2 is reached 10 min after stimulation with 100 μM forskolin (Delidaki et al., 
2011) as also shown in Figure 4.2 where the activation of CREB (p˂0.01, A), ERK1/2 
(p˂0.001, B) and p38 (p˂0.01, C) is represented as significantly increased in forskolin-
treated cells compared to DMSO. In contrast, 1 h pre-treatment with H89, an inhibitor 
of PKA, significantly prevented the activation of CREB, ERK1/2 or p38, compared to 
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vehicle treatment (p˂0.01 for p38 and CREB; p˂0.001 for ERK1/2). As expected, 
prolonged H89 treatment (48 h) reduced by 80% β-hCG secretion forskolin-induced 
compared to DMSO treatment (p˂0.001, Figure 4.2 D), confirming that trophoblast 
differentiation in BeWo is PKA-dependent. 
Taken together these results demonstrated that forskolin treatment induces 
morphological and endocrine differentiation in BeWo cells via PKA-dependent 






Figure 4.1 Morphological and biochemical profiling of forskolin-induced 
differentiation in BeWo cells. BeWo cells were grown as a mononucleated 
monolayer (cytotrophoblast) until approximately 80% of confluence before being 
treated with 100 µM forskolin for 48 h to differentiate into syncytiotrophoblast or with 
DMSO as a control. A) Double-label immunofluorescence microscopy of BeWo 
cytotrophoblast (upper) and syncytiotrophoblast (lower). Cells were fixed and stained 
with DAPI (blue) or an antibody against the membrane protein E-cadherin (red). 
Representative immunoblot and densitometry analysis of B) E-cadherin normalized 
against β actin and E-F) phosphorylated activation sites of p38, ERK1/2 and CREB 
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normalized against their total protein. C) RT-qPCR analysis of relative amounts of 
syncytin-1 and syncytin-2 gene expression normalized to GAPDH mRNA levels. D) 
Relative concentration of secreted β-hCG measured in the media by 
chemiluminescence and normalized to total protein content. N=3. Data are expressed 





Figure 4.2 Effect of PKA inhibition on forskolin-induced downstream signalling 
initiation and differentiation in BeWo cells. Representative immunoblots and 
densitometry analysis of phosphorylation and activation of p38 (A), ERK1/2 (B) and 
CREB (C) measured by immunoblotting and normalized against total protein forms in 
BeWo cells pre-treated with 5 μM of H89 or vehicle for 1 h followed by 100 μM of 
forskolin or DMSO for 10 min. D) Relative concentration of secreted β-hCG 
normalized to the total protein content and measured by chemiluminescence in the 
media of BeWo cells pre-treated with 5 μM of H89 or vehicle for 1 h followed by 
forskolin or DMSO for 48 h. N=3. Data are expressed as mean ± SEM; *p<0.05, 




4.2.2 The O-GlcNAc system is downregulated during forskolin-induced 
differentiation in BeWo cells 
It has been reported that, global O-GlcNAc modification and OGT levels are 
downregulated when pluripotent embryonic stem cells (ESCs) are induced to 
differentiate (Jang et al., 2012; Kim et al., 2009; Miura et al., 2018). Indeed, O-
GlcNAcylation of key signalling components works as a biochemical checkpoint that 
prevents the onset of differentiation and maintains ESCs in their undifferentiation state 
(Miura et al., 2018). To see whether a similar regulatory mechanism controls BeWo 
differentiation, levels of OGT, OGA and global O-GlcNAcylation were measured by 
immunoblotting after 48 h of forskolin or DMSO treatment (Figure 4.3 A). Results 
showed that, in forskolin-treated cells, the levels of global O-GlcNAcylation (p˂0.01) 
and protein expression of OGT (p˂0.01) were significantly downregulated compared 
to DMSO treatment (Figure 4.3 B). Surprisingly, also the protein levels of OGA, the 
enzyme responsible for the removal of O-GlcNAc, were downregulated in forskolin-
differentiated cells compared to DMSO (p˂0.001), suggesting that the reduction in 
global O-GlcNAcylation during BeWo differentiation is associated to OGT 
downregulation only rather than to enhanced OGA activity.  
These data are in agreement with what observed during ESCs differentiation and 
suggest that downregulation of OGT and its biochemical mark O-GlcNAcylation 






Figure 4.3 Downregulation of the O-GlcNAc system in forskolin-induced 
differentiation of BeWo cells. Representative immunoblot (A) and densitometry 
analysis (B) of global O-GlcNAcylation, OGA and OGT protein expression in 
differentiated BeWo cells treated for 48 h with forskolin and non-differentiated cells 
treated with DMSO. N=3. Data are expressed as mean ± SEM. *p<0.05, **p<0.01, 





4.2.3 Knockdown of OGT recapitulates the effects of forskolin inducing spontaneous 
differentiation in undifferentiated BeWo cells 
As demonstrated in paragraph 4.2.2 of this Chapter, the OGT system is downregulated 
during forskolin-induced differentiation from cytotrophoblast into 
syncytiotrophoblast in BeWo cells suggesting that reduced O-GlcNAc protein 
modification might constitute a biochemical mechanism important for the 
differentiation process. To further investigate this aspect, OGT was knocked down 
using siRNA in undifferentiated BeWo cells and markers of differentiation were 
measured afterwards. After 48 h from transfection, global O-GlcNAc levels (p˂0.001) 
and OGT protein expression (p˂0.01) were significantly lower in OGT-depleted cells 
compared to control siRNA treatment. Interestingly, OGA protein levels were also 
significantly downregulated in siOGT cells compared to control treatment (p˂0.01) 
(Figure 4.4 B) suggesting that the OGA activity is regulated by cellular O-
GlcNAcylation levels as already demonstrated in several human cell lines (Zhang et 
al., 2014) and in paragraph 4.2.2 of this Chapter. In presence of 48 h siOGT treatment, 
clustered nuclei and derangement of the cell membrane appeared (Figure 4.4 A, lower 
panel, yellow arrows), in contrast with the well-organized monolayer of 
mononucleated cytotrophoblast observed in control siRNA treatment (Figure 4.4 A, 
upper panel). Accordingly, E-cadherins were downregulated in siOGT lysates 
compared to controls as shown by immunoblotting (p˂0.01) (Figure 4.4 C). Moreover, 
gene expression of the fusogenic proteins syncytin-1 and syncytin-2 (p˂0.01, Figure 
4.4 D) and β-hCG secretion (p˂0.01, Figure 4.4 F) were significantly up-regulated in 
OGT-depleted cells compared to siRNA controls. However, there was no difference 
in the activation of signalling pathways downstream of PKA between the two 
treatments (Figure 4.4 E) suggesting that the expression of markers of differentiation 
observed in the OGT-depleted cytotrophoblast cells could be PKA-independent. 
Taken together these observations demonstrated that OGT depletion in 
undifferentiated BeWo cells induced spontaneous differentiation suggesting that O-








Figure 4.4 Markers of differentiation after 48 h knockdown of OGT in 
undifferentiated BeWo cells. A) Double-label immunofluorescence microscopy of 
BeWo cytotrophoblast treated with control siRNA (upper panel) and siOGT (lower 
panel) for 48 h, fixed and stained with DAPI (blue) or anti-E-cadherin antibody (red). 
Representative immunoblot and densitometry analysis of B) O-GlcNAcylation, OGT 
and OGA protein and C) E-cadherin levels in BeWo extracts from control siRNA or 
siOGT treatment. Protein levels are normalized against β actin. D) RT-qPCR analysis 
of relative amounts of syncytin-1 and syncytin-2 gene expression normalized to 
GAPDH mRNA levels. E) Densitometry analysis of phosphorylated forms of p38, 
ERK1/2 and CREB normalized against their total protein and F) relative concentration 
of secreted β-hCG measured in the culture media and normalized to the total protein 







4.3 Role of OGT and O-GlcNAcylation in forskolin-induced differentiation in BeWo 
cells 
4.3.1 O-GlcNAc up-regulation reduces differentiation in forskolin-treated BeWo cells 
As shown in paragraph 4.2.2, OGT and protein O-GlcNAcylation were downregulated 
during forskolin-induced differentiation in BeWo cells. In order to examine whether 
the attenuation of O-GlcNAc signalling is important in syncytiotrophoblast formation, 
BeWo cells were differentiated in presence of 100 μM PUGNAc, an OGA inhibitor, 
or vehicle. PUGNAc treatment significantly increased the global O-GlcNAc 
modification levels compared to vehicle (p˂0.05) without modifying OGT protein 
levels confirming that inhibition of OGA promotes the accumulation of O-GlcNAc 
modification on nucleocytoplasmic proteins. On the contrary, both OGA gene and 
protein expression (p˂0.01) were significantly increased by PUGNAc treatment 
compared to vehicle (Figure 4.5 A and B) probably in response to the inhibitory effects 
of PUGNAc on OGA activity as already observed in studies on pancreatic β cells 
(Filhoulaud et al., 2019). In parallel, PUGNAc significantly reduced ERK1/2 
activation in forskolin-treated cells (p˂0.01) while there was only a tendency toward 
decrease for the activation of p38 (p=0.056) (Figure 4.5 C). Instead, β-hCG secretion 
levels were strongly suppressed by PUGNAc by almost 50% compared to vehicle 
(p˂0.01) (Figure 4.5 D). Similarly, the gene expression of both syncytins along with 
GCM1 and DUSP23, two key factors in promoting placental cell fusion via 
PKA/cAMP-mediated mechanisms (Lin et al., 2011), was significantly reduced by 
PUGNAc treatment compared to vehicle (p˂0.01) (Figure 4.5 E). 
All together, these results demonstrated that the attenuation of O-GlcNAc signalling 
is critical for forskolin-induced differentiation in BeWo cells and that inhibition of 
OGA using PUGNAc shifts the balance of the OGT/OGA interplay towards increased 






Figure 4.5 Markers of differentiation in forskolin-treated BeWo cells underwent 
pharmacological up-regulation of O-GlcNAcylation. Cells were induced to 
differentiate with 100 μM of forskolin for 48 h in presence of 100 μM of the OGA 
inhibitor PUGNAc or vehicle. A) Representative immunoblot and B) densitometry 
analysis of global levels of O-GlcNAcylation and OGT and OGA protein levels as 
well as gene expression of OGA in PUGNAc- or vehicle-treated cells. C) 
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Densitometry analysis of phosphorylated forms of ERK1/2 and p38 normalized 
against their total protein as measured by immunoblotting in protein lysates and D) 
relative concentration of secreted β-hCG normalized to total protein content and 
measured in the culture media. E) RT-qPCR analysis of relative amounts of syncytin-
1, syncytin-2, GCM1 and DUSP23 gene expression normalized to GAPDH mRNA 






4.3.2 Knockdown of OGT enhances forskolin-induced differentiation in BeWo cells 
As demonstrated previously in this Chapter, O-GlcNAc signalling is attenuated during 
forskolin-induced differentiation in trophoblast BeWo cells. Therefore, the 
differentiation response to forskolin was investigated in OGT-depleted BeWo cells 
and results are reported in this paragraph. BeWo cells were treated with control siRNA 
or siOGT and induced to differentiate 48 h later using 100 µM forskolin. After 48 h 
of stimulation with forskolin, extensive areas of syncytialization were observed in 
OGT-depleted cells compared to control siRNA (Figure 4.6 A, bottom panel, yellow 
arrows). Interestingly, these areas are characterized by small nuclei. A regression in 
the nuclear size has already been described in the syncytialized areas of human term 
placentas and represents the morphological feature of syncytiotrophoblast turnover 
characterized by shrinkage of the nuclei, nucleolar regression and chromatin 
condensation typical of cells in late apoptosis (Mayhew et al., 1999, 2014). In parallel 
to morphological changes, secreted levels of β-hCG were significantly increased in 
OGT-depleted cells compared to control siRNA in response to forskolin (p˂0.001, 
Figure 4.6 C). As for the signalling pathways, the forskolin-induced activation of both 
p38 (p˂0.001) and ERK1/2 (p˂0.01) was enhanced in siOGT treatment compared to 
control siRNA (Figure 4.6 B). 
Together, these data demonstrate that the effect of forskolin in inducing differentiation 
in BeWo cells is potentiated in presence of reduced levels of OGT suggesting that O-
GlcNAc signalling may exert a regulatory role on the PKA-mediated molecular 






Figure 4.6 Morphological and endocrine forskolin-induced differentiation in 
OGT-depleted BeWo cells. BeWo cells were treated with control siRNA or siOGT 
for 48 h and induced to differentiate with 100 μM of forskolin for 48 h or treated with 
DMSO. A) Double-label immunofluorescence microscopy showing DAPI (blue) or 
anti-E-cadherin (red) immunostaining of differentiated BeWo cells treated with 
siOGT or control siRNA. B) Representative immunoblot and densitometry analysis of 
phosphorylated sites of activation for ERK1/2 and p38 normalized against the total 
protein form in protein lysates and C) relative concentration of secreted β-hCG 
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measured in the culture media of BeWo cells pre-treatment with control siRNA or 
siOGT for 48 h and induced to differentiate with forskolin for 48 h or treated with 
DMSO. β-hCG levels are normalized to the total protein content. N=3. Data are 
expressed as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 vs DMSO. ## p<0.01, 





4.3.3 Restoration of O-GlcNAcylation prevents up-regulation of forskolin-induced 
differentiation observed in OGT-depleted BeWo cells  
To test whether restoration of O-GlcNAcylation prevents the enhancement of 
forskolin-induced differentiation observed when OGT is silenced, BeWo cells were 
treated with siOGT or control siRNA in presence of PUGNAc, to inhibit OGA activity 
and enhance O-GlcNAcylation, or vehicle as control for 24 h before being induced to 
differentiate with forskolin for 48 h. PUGNAc treatment partially restored the pool of 
O-GlcNAcylated proteins in siOGT cells compared to vehicle (p˂0.05) with no impact 
on OGT protein levels (Figure 4.7 B) suggesting that a residual O-GlcNAc activity 
was still present in the cells after OGT silencing. The large areas of syncytialization 
observed in OGT-depleted cells (Figure 4.7 A, middle panel) are no longer detected 
in cells treated with PUGNAc (bottom panel) which morphologically resemble more 
to control cells (upper panel). Accordingly, the up-regulation of β-hCG levels and gene 
expression of both syncytins observed in siOGT cells treated with vehicle were 
significantly downregulated in PUGNAc treatment (p˂0.001) (Figure 4.7 C and D). 
Moreover, the activation status of ERK1/2 (p˂0.01) and p38 (p˂0.05) observed in 
OGT-depleted cells treated with vehicle was returned to baseline levels by PUGNAc 
treatment, whereas no significant effects were exerted by PUGNAc on CREB 
activation (Figure 4.7 E).  
Taken together, these results confirm that downregulation of O-GlcNAc signalling 
facilitates forskolin-induced differentiation in BeWo cells and further corroborate the 
possibility of a repressive role played by O-GlcNAc signalling on mechanisms 







Figure 4.7 Effects of O-GlcNAc restoration on morphological and biochemical 
forskolin-induced differentiation in OGT-depleted BeWo cells. Cells were treated 
with siOGT or control siRNA for 48 h in presence of PUGNAc or vehicle and induced 
to differentiate for 48 h with 100 μM forskolin. A) Double-label immunofluorescence 
microscopy. Cells were fixed and stained with DAPI (blue) or anti-E-cadherin 
antibody (red) after treatments. Representative immunoblot and densitometry analysis 
of B) O-GlcNAcylation and OGT protein normalized against β-actin and E) 
phosphorylation of the activation sites for ERK1/2, p38 and CREB normalized against 
the corresponding total protein measured in the cell lysates. C) Relative concentration 
of secreted β-hCG measured in the culture media and normalized to the total protein 
content. D) RT-qPCR analysis of relative amount of syncytin-1 and syncytin-2 gene 
expression normalized to GAPDH mRNA levels. N=3. Data are expressed as mean ± 






4.4 Cross-talk between PKA and O-GlcNAc signalling during BeWo differentiation 
4.4.1 PKA partially mediates the up-regulation of forskolin-induced differentiation 
observed in OGT-depleted BeWo cells  
In paragraph 4.3.2 of this Chapter, it was demonstrated that the effect of forskolin on 
BeWo differentiation was significantly potentiated when O-GlcNAc was depleted by 
siRNA against OGT. On the contrary, up-regulation of global O-GlcNAcylation by 
PUGNAc reduced forskolin-induced differentiation suggesting that O-GlcNAcylation 
might exert an inhibitory effect on signalling pathways controlling trophoblast 
differentiation. It is well-established that cAMP/PKA signalling is the major route to 
trigger trophoblast differentiation. Moreover, it has been reported that, in neurons, 
OGT and PKA are functionally associated (Griffith and Schmitz, 1999). However, it 
is not known whether a similar interaction occurs also in trophoblast cells. Using co-
immunoprecipitation, here it is shown that PKA and OGT physically interact in BeWo 
cells (Figure 4.8 A). Furthermore, pre-treating siOGT BeWo cells with the PKA 
inhibitor H89 before inducing differentiation with forskolin partially prevented the up-
regulation of gene expression of both syncytins (p˂0.01) and GCM1 (p˂0.05) 
observed in OGT-depleted cells treated with vehicle only (Figure 4.8 B) suggesting 
that the increased expression of genes promoting differentiation observed in OGT-
depleted cells occurs via PKA potentiation rather than an unrelated pathway. 
Similarly, an almost complete suppression in the forskolin-induced secretion of β-hCG 
was observed in OGT-depleted cells treated with H89 compared to vehicle (p˂0.001) 
(Figure 4.8 C) suggesting that the up-regulation of β-hCG production observed in 
OGT-depleted cells is also controlled by PKA-mediated mechanisms. 
Taken together, these findings suggest that PKA and OGT are physically associated 
and that PKA mediates in part the abnormal differentiation induced by forskolin when 





Figure 4.8 Inhibition of PKA in differentiated OGT-depleted BeWo cells. A) 
Association of OGT and PKA shown by co-immunoprecipitation assay. BeWo lysates 
were immunoprecipitated with IgG or anti-OGT antibody and blots were probed with 
antibodies against OGT and PKA. B) RT-qPCR analysis of relative amounts of 
syncytin-1, syncytin-2 and GCM1 gene expression normalized to GAPDH mRNA 
levels and C) relative concentration of secreted β-hCG normalized to total protein 
content. For the data shown in B) and C) BeWo cells were treated with siOGT or 
control siRNA for 48 h and induced to differentiate with 100 μM forskolin for 48 h in 
presence of 1 h pre-treatment with H89 or vehicle. N=3. Data are expressed as mean 
± SEM; *p<0.05, **p<0.01, ***p<0.001 vs vehicle. #p<0.05, ##p<0.01, ###p<0.001 
vs control siRNA.  
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4.4.2 Depletion of OGT alters the activation profile of targets downstream of PKA in 
BeWo cells  
As shown in paragraph 4.2.1 of this Chapter, ERK1/2, p38 and CREB are activated 
downstream of PKA within 10 min of forskolin treatment and selective inhibition of 
PKA with H89 prevented their activation and downstream endocrine differentiation of 
BeWo cells. To test whether the knockdown of OGT changes the activation dynamics 
of signalling downstream of PKA, siOGT and control siRNA BeWo cells were 
stimulated for 30 min with 100 μM of forskolin and phosphorylation of ERK1/2, p38 
and CREB on their activation sites was measured at 0, 10, 20 and 30 min after 
forskolin treatment by immunoblotting (Figure 4.9 B-D-F). The 30-min stimulation 
was selected in order to obtain a more complete activation profile of targets 
downstream of PKA after reaching their maximal activation within 10 min of forskolin 
treatment. In control siRNA cells, forskolin significantly increased CREB activation 
10 min after treatment remaining sustained at 20 and 30 min as compared to baseline 
(p˂0.01). In contrast, in OGT-depleted cells, the basal CREB activation was increased 
and forskolin had no additional effect compared to control siRNA curve (Two-way 
ANOVA: interaction Time x siRNA treatment: p˂0.01, Figure 4.9 A-B). As for 
ERK1/2, the enzyme activation was increased of approximately 6-fold 10 min after 
forskolin in both siOGT and control cells and decreased steadily over the next 20 min 
remaining still higher 30 min after stimulation compared to baseline in both siRNA 
treatments. However, at baseline (p˂0.01) and 30 min after forskolin treatment 
(p˂0.05), the activation of ERK1/2 was significantly higher in siOGT cells compared 
to control siRNA (Figure 4.9 C-D). Finally, in control siRNA, forskolin significantly 
upregulated p38 activation 10 min after treatment which remained sustained at 20 and 
30 min compared to baseline (p˂0.01). In siOGT cells, however, p38 activation was 
significantly upregulated compared to control siRNA at baseline (p˂0.001) as well as 
10 and 20 min after forskolin treatment (p˂0.01) (Figure 4.9 E-F). 
These data suggest that OGT may alter the dynamics of PKA mechanisms affecting 





Figure 4.9 Activation kinetics of targets downstream of PKA in OGT-silenced or 
control siRNA-treated BeWo cells. Undifferentiated BeWo cells were treated for 48 
h with siOGT or control siRNA before being stimulated with 100 μM forskolin for 30 
min. Activation of CREB (A-B), ERK1/2 (C-D) and p38 (E-F) was measured by 
immunoblotting at 0, 10, 20 and 30 min after forskolin treatment. N=3. Data are 
expressed as mean ± SEM. A two-way ANOVA with Time and siRNA treatment as 
independent variables was used followed by Tukey’s post-hoc test. *p<0.05, 





In human placenta, the syncytiotrophoblast, which takes origin from the fusion of 
cytotrophoblast cells forming the inner layer of trophoblast, supplies the fetus with 
nutrients, gases and protection and constitutes the primary source of pregnancy 
hormones. Therefore, the integrity and functionality of the syncytiotrophoblast layer 
is vital for pregnancy success. Defective syncytialization of cytotrophoblast cells 
during placentation may result in the occurrence of clinical pregnancy complications 
such as preeclampsia, in utero fetal growth restriction and Down’s syndrome (Massin 
et al., 2001; Roland et al., 2016; Ruebner et al., 2010). For these reasons, a deeper 
understanding of signalling pathways regulating trophoblast differentiation in human 
placenta is crucial to target molecular mechanisms that might trigger placental 
dysfunctions. 
The formation of syncytiotrophoblast is under a precise control and coordinated 
activity of multiple factors (Gauster and Huppertz, 2008). Some of these mechanisms 
have been well-characterized in both cell lines and primary cells. In BeWo as well as 
in primary trophoblast cells, the interplay between cAMP-PKA and downstream 
MAPK pathways regulates hCG secretion and expression of fusogenic genes 
promoting cytotrophoblast differentiation into syncytiotrophoblast (Delidaki et al., 
2011; Daoud et al., 2005). In this Chapter, the role of the interplay of OGT and OGA 
in regulating syncytiotrophoblast formation was investigated in trophoblast BeWo 
cells by enhancing or depleting protein O-GlcNAcylation using the OGA inhibitor 
PUGNAc or a specific siRNA against OGT respectively. Results showed that OGT is 
a negative regulator of differentiation in BeWo cells. Accordingly, O-GlcNAc 
signalling was downregulated during differentiation while pharmacological increase 
of O-GlcNAcylation by OGA inhibition reduced BeWo differentiation as evidenced 
by suppression of syncytiotrophoblast markers such as β-hCG, GCM1 and syncytins. 
On the contrary, downregulation of OGT by gene silencing reduced protein O-
GlcNAcylation and OGA expression promoting spontaneous differentiation in 
cytotrophoblast BeWo cells and potentiating the effects of forskolin (Figure 4.10). 
As demonstrated here, OGT is physically associated to the catalytic subunit of PKA 
and depletion of OGT enhanced PKA response to forskolin leading to increased β-
hCG secretion, syncytin-1 and syncytin-2 gene expression and increased areas of 
syncytialization. These effects were prevented by specific inhibition of PKA 
141 
 
suggesting that OGT may control trophoblast differentiation via PKA-mediated 
mechanisms. Although this study has generated novel evidence that depletion of OGT 
alters PKA-induced signalling dynamics, it did not clarify the exact mechanism via 
which OGT controls PKA activity. It is well-established that O-GlcNAc modification 
competes with phosphorylation for the occupancy of Ser/Thr residues. It is also known 
that, phosphorylation of Thr197 on the catalytic subunits of PKA by pyruvate 
dehydrogenase kinase 1 (PDK1) is essential for its activation (Cheng et al., 1998). 
Although more evidence is needed, it is attractive to postulate that O-GlcNAcylation 
of Thr197 on PKA might constitute a possible mechanism via which OGT regulates 
PKA activation during differentiation of BeWo cells.  
The forskolin-mediated activation of PKA-CREB-syncytin-1 axis is one of the most 
well-characterized pathways involved in the fusion of trophoblast BeWo cells 
(Malhotra et al., 2015). In neurons, O-GlcNAcylation of PKA promotes its 
translocation to the nucleus and enhances CREB activation (Xie et al., 2016). In the 
present study, however, O-GlcNAcylation may exert a negative effect on the PKA-
CREB axis as in OGT-depleted BeWo cells CREB activation is sustained even in 
absence of the PKA activator, forskolin. Up-regulation of PKA-CREB signalling may 
then lead to increased expression of downstream targets including β-hCG and 
syncytins thus enhancing differentiation as observed in siOGT cells compared to 
controls. The discrepancy in this study and the one mentioned above is likely to be 
due to functional differences existing between trophoblast and neuronal cells.  
ERK1/2 and p38 kinases are also activated downstream of cAMP/PKA and both play 
a critical role in regulating trophoblast differentiation as demonstrated in BeWo cells 
and cytotrophoblast explants (Daoud et al., 2005; Delidaki et al., 2011; Shu et al., 
2014). In BeWo cells, both kinases are involved in hCG release and syncytin-2 
expression via independent mechanisms. In addition, p38 controls gene expression of 
syncytin-1 via GCM1 (Delidaki et al., 2011). As shown here, the activation of both 
p38 and ERK1/2 is maximal after 10 min from forskolin treatment and it is 
significantly upregulated also after 48 h from the treatment suggesting a mechanism 
of long-term activation induced by forskolin. Interestingly, the activation kinetics of 
both ERK1/2 and p38 changes in OGT-depleted cells following forskolin stimulation, 
with p38 showing more pronounced forskolin-induced activation in siOGT BeWo 
cells compared to control siRNA. In agreement with that, enhancing global O-
GlcNAcylation using PUGNAc significantly affected the gene expression of the two 
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targets downstream of p38, syncytin-1 and GCM1, whereas their expression was 
significantly upregulated in OGT-depleted cells in a PKA-dependent manner.  
However, OGT might interact directly with p38 to regulate BeWo differentiation. 
Studies showed that OGT interacts and regulates p38 activation in a manner dependent 
on cell type and experimental conditions (Goldberg et al., 2011; Moriwaki and Asahi, 
2017). Future studies will be dedicated to further investigate the functional importance 
of p38/OGT association in the context of trophoblast differentiation.  
Overall, the findings presented in this Chapter provide novel evidence supporting a 
central role for protein O-GlcNAcylation as a negative regulator of trophoblast 
differentiation via PKA-dependent mechanisms and demonstrate that unbalance in 
OGT/OGA interplay can alter trophoblast syncytialization with pronounced effects on 
syncytiotrophoblast morphology and hCG secretion in BeWo cells. Interestingly, cells 
respond to OGT depletion by adjusting OGA levels accordingly (Figure 4.10). This 
observation has been already reported in studies conducted on several human cell lines 
suggesting an adapting mechanism probably aimed to restore O-GlcNAc homeostasis 
(Zhang et al., 2014).  
 
Figure 4.10 OGT/OGA interplay in the regulation of trophoblast differentiation. 
In BeWo trophoblast cells, blocking OGA activity with PUGNAc prevents the 
removal of O-GlcNAc modification from the nucleocytoplasmic proteins enhancing 
global protein O-GlcNAcylation which, in turn, inhibits the expression of markers of 
differentiations including fusogenic proteins and hCG. On the contrary, depletion of 
OGT using a specific siRNA induces overexpression of markers of differentiation and 
increased areas of syncytialization in a PKA-dependent manner. Cells respond to OGT 












Role of O-GlcNAc signalling in placental 




It is well established that high pre-pregnancy BMI is strongly associated with fetal 
overgrowth (Gaudet et al., 2014) and that changes in the growth trajectories during in 
utero development increase the risk for chronic diseases later in life (Barker et al., 
1993).  
As discussed in Chapter 1 - Introduction, a suboptimal maternal milieu, including 
metabolic alterations, can interfere with placental physiology by altering placental 
gene expression, signalling and morphology with dramatic consequences on nutrients 
transport and fetal growth (Connor et al., 2020; Lewis et al., 2013; M. Li et al., 2011). 
The majority of the studies have been focusing on maternal diabetes. However, it is 
emerging that glucose transport across the placenta plays a critical role in regulating 
fetal growth even in absence of maternal diabetes. Indeed, maternal glucose levels 
below those diagnostic of diabetes are strongly associated with increased birth weight 
(HAPO Study Cooperative Research Group, 2002). Moreover, GLUT1, which in 
humans controls placental glucose transport capacity, is associated with maternal 
BMI. It has been shown that heavier babies born from obese mothers are exposed to 
increased glucose levels during in utero life via changes in GLUT1 transporters, 
regardless maternal glucose levels (Acosta et al., 2015). Nevertheless, studies 
investigating the molecular mechanisms underpinning placental dysfunctions and fetal 
overgrowth in relation to maternal BMI remain still very limited.  
Protein O-GlcNAcylation is a good candidate signalling pathway to mediate maternal 
metabolic disfunctions to the fetus via regulation of placenta physiology. First, OGT 
is extensively expressed in the human placenta (Gao et al., 2001). Second, O-GlcNAc 
cycling regulates almost all the biological processes within cells and the O-GlcNAc 
modification is present on a wide range of proteins belonging to a variety of functional 
classes in trophoblast cells, as demonstrated in Chapter 3. Finally, OGT activity 
depends on the concentration of the donor substrate, the UDP-GlcNAc, which is 
produced from nutrients flowing through the HBP, especially glucose (Hart and 
Akimoto, 2009). Accordingly, O-GlcNAc cycling is perturbed in many tissues and 
organs during chronic diseases characterized by alterations in glucose metabolism 
including obesity, diabetes and cancer (Ma and Hart, 2013; Slawson et al., 2010).  
Therefore, it is plausible to hypothesize that changes in nutrient flux through the 
placenta, particularly glucose, can affect placental OGT activity and protein O-
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GlcNAcylation thus altering placental physiology. To date, however, there are only 
two studies conducted in hyperglycemic rats which investigates the consequences of 
perturbations in protein O-GlcNAcylation on placenta (Dela Justina et al., 2017, 
2018). The present study sought to examine the impact of maternal BMI on placental 
OGT and protein O-GlcNAcylation levels and characterize, in the trophoblast cell line 
BeWo, interactions between OGT and AMPK, one of the placental nutrient sensor 
extensively involved in the regulation of fetal growth.  
5.2 Maternal BMI is positively associated with circulating blood glucose levels and 
birth weight 
Women were divided into two groups, lean (BMI˂30, n=8) or obese (BMI˃30, n=18), 
based on their BMI (p˂0.0001), calculated by taking into account maternal body 
weight and height (kg/m2) at 11-14 weeks of gestation. Maternal age, gestational age 
and plasma levels of protein-A (PAPP-A), a pregnancy marker of adverse perinatal 
outcomes, were not different between the two groups (Table 9). Although BW showed 
no statistical differences between maternal groups (p=0.28), BWC was significantly 
higher for babies born to obese mothers compared to those born to normal weight 
mothers (p=0.038) (Table 9). Indeed, both BW (p=0.0349, R2=0.172) and BWC 
(p=0.013, R2=0.231) were positively correlated to maternal BMI (Table 10). As for 
the OGTT, glucose blood levels at fasting and 2 h after the oral glucose load were 
below the diagnostic threshold for diabetes which is defined as a fasting value below 
5.6 mmol/L and below 7.8 mmol/L at 2 h (Table 9). However, both maternal fasting 
glucose (p=0.049) and HbA1c (p=0.0085) levels were significantly higher in obese 
women compared to normal weight subjects (Table 9) and positively correlated each 
other (p=0.0058, R2=0.287; Table 10). Furthermore, a positive correlation was found 
between maternal BMI and both maternal fasting glucose (p=0.0177, R2=0.221) and 
HbA1c (p=0.0156, R2=0.229) (Table 10). 
Taken together these data suggest that, although non-diabetic, obese mothers showed 





Table 9. Clinical characteristics of the population study 
 
#  The BMI (kg/m2) refers to the first trimester of pregnancy (11-14 weeks). 
## HbA1c, maternal fasting glucose and 2 h glucose levels refer to the third trimester of pregnancy (28-
30 weeks).  
Data are expressed as mean ± SEM. Differences between groups were analyzed using a t-test. * p˂0.05, 









5.3 Positive association between GLUT1 and O-GlcNAcylation in placental biopsies   
In order to investigate whether protein O-GlcNAcylation, highly sensitive to glucose 
fluctuations, responds to the maternal obesogenic environment via glucose-dependent 
mechanisms, clinical data were correlated with biochemistry data obtained from 
placental biopsies. Protein levels of O-GlcNAcylation, OGT and GLUT1, the most 
abundant glucose transporter constitutively present in the placenta, along with total 
and phosphorylated AMPK, were measured in placenta homogenates by 
immunoblotting using specific antibodies (Figure 5.1, A and B). Interestingly, 
maternal BMI was positively associated with placental OGT levels (p=0.0294, 
R2=0.183) which, in turn, were positively correlated with protein O-GlcNAcylation 
levels (p=0.0023, R2=0.326) (Figure 5.1, C and D respectively). Moreover, protein O-
GlcNAcylation was strongly correlated with placental GLUT1 (p˂0.0001, R2=0.507) 
(Figure 5.1, E). Interestingly, the latter was positively associated with both BWC 
(p=0.0056, R2=0.279) (Figure 5.1, F) and BW (p=0.0105, R2=0.243), but not with any 
of the maternal parameters (data not shown). Previous reports suggested a functional 
interaction between OGT and AMPK in metabolic tissues (Bullen et al., 2014; Gélinas 
et al., 2018). Here, a similar interaction was explored in placental biopsies by 
correlating phosphorylation of AMPK on its activation site (Thr172) with OGT and 
protein O-GlcNAcylation levels. Interestingly, a significant negative correlation was 
found between AMPK activation and OGT protein expression (p=0.0247, R2=0.193) 
(Figure 5.1, G). 
Taken together, these data suggest that placenta responds to maternal BMI by 
upregulating the protein expression of OGT and downstream O-GlcNAcylation levels. 
This is associated with reduced activity of the nutrient sensor AMPK. Placental 
GLUT1 protein expression, which showed a positive association with neonatal weight, 
might be involved in enhancing placental OGT and protein O-GlcNAcylation levels 






Figure 5.1 Association between maternal BMI and biochemical data in placental 
biopsies. Representative immunoblots showing A) global O-GlcNAcylation signal as 
well as OGT, GLUT1 and β actin protein levels and B) phosphorylated and total levels 
of AMPK in placental homogenates from women with increasing BMI. C-G) Linear 
association between protein levels normalized to β actin or total protein amount and 
feto-maternal characteristics. Regression lines and p values are shown. N=26. 








5.4 Role of OGT and GLUT1 in regulating protein O-GlcNAcylation in BeWo cells 
The effects of OGT on trophoblast biological responses were further investigated in 
vitro by using BeWo cells. Interestingly, by comparing immunoblots derived from 
placenta or BeWo cell extracts and stained with the anti-O-GlcNAc antibody, a strong 
correlation in the O-GlcNAc signal profile emerged between placenta and BeWo 
samples (Figure 5.2). The O-GlcNAc signal was detected on proteins with a broad 
range of molecular weights (10-250 kDa). Four areas of high signal intensity (58-62, 
80-95, 110-120 and 140-235 kDa) were evident on immunoblots from both placenta 
and BeWo samples. Well-known OGT targets, such as HCF-1, chromatin remodeling 
factors and components of the nuclear pore complex, are included within the four areas 
of high signal intensity and were identified in BeWo cells as O-GlcNAcylated proteins 
by MS as discussed in Chapter 3. The fact that the areas of O-GlcNAc signal intensity 
overlap between BeWo and placenta extracts suggests that similar clusters of proteins 
are O-GlcNAcylated in human term placenta and BeWo cells further validating the 
use of BeWo cell line for this research study. 
To investigate any direct effects of glucose and a possible role of GLUT1 on OGT 
activity in the trophoblast, BeWo cells depleted of either OGT or GLUT1 using 
specific siRNAs for 48 h, were incubated with normal (5 mM) or high (15 mM) 
glucose concentrations for further 48 h. Significant downregulation of OGT and 
GLUT1 mRNA expression was confirmed by RT-qPCR after 48 h from siRNA 
treatment (Figure 5.3) (p˂0.001 for both siOGT and siGLUT1). Exposure of control 
siRNA cells to 15 mM glucose led to a significant increase in global protein O-
GlcNAcylation compared to 5 mM (p<0.01). OGT depletion significantly reduced the 
amount of O-GlcNAcylated proteins in both 5 and 15 mM glucose treatments 
compared to control siRNA (p˂0.001) (Figure 5.4 A and B). In these cells, O-
GlcNAcylation levels were not affected by increased glucose concentrations. 
Similarly, in GLUT1-depleted cells, the levels of O-GlcNAcylation were significantly 
downregulated in both 5 and 15 mM glucose treatments (p˂0.001), and also in these 
cells, the ability to respond to higher glucose concentrations, by rising protein O-
GlcNAcylation, was abolished (Figure 5.4 A and B).  
These findings suggest that, in the trophoblast cell line BeWo, an excess of glucose 
induces a significant increase in global protein O-GlcNAcylation by mechanisms 





Figure 5.2 Densitometry profiles comparing global O-GlcNAcylation signal in 
protein extracts from placental biopsies and BeWo cells. Modified proteins were 
detected by immunoblotting using the anti-O-GlcNAc antibody RL2 and quantified 
using ImageJ 1.49v. Four areas with greater intensity were identified and protein 
molecular weights are indicated in kDa. The two-dimensional graphs display changes 
in pixel intensity along a line drawn across the immunoblotting lanes. The X-axis of 
the graph represents distance along the drawn line and the Y-axis is the corresponding 
pixel intensity.  
 
Figure 5.3 Gene expression of GLUT1 and OGT after 48 h transfection with 






Figure 5.4 Effect of GLUT1 and OGT downregulation on glucose-induced 
protein O-GlcNAcylation. BeWo cells were treated for 48 h with control siRNA 
(lanes 1-2), siRNA against GLUT1 (lanes 3-4), and against OGT (lanes 5-6) and with 
5 or 15 mM glucose for further 48 h. Representative immunoblots (A) or densitometric 
analysis of total O-GlcNAc signal normalized to β actin levels (B) are shown. N=3; 





5.5 Interactions between AMPK, PKA and OGT in trophoblast BeWo cells. 
A functional interaction between the nutrient sensors OGT and AMPK, that regulates 
nutrient-sensitive intracellular processes, has previously been reported in C2C12 
myotubes (Bullen et al., 2014). Here, a similar interaction was investigated in BeWo 
cells. The two metabolic sensors showed opposite responses to an extracellular 
glucose load. Compared to normal glucose (5 mM) treatment, exposure of BeWo cells 
to hyperglycemia (15 mM) significantly decreased phosphorylation of both AMPK at 
Thr172 (p<0.001) and its downstream target acetyl-CoA carboxylase (ACC) at Ser79 
(p<0.01). The anti-ACC antibody used in this study recognizes both ACC-1 and ACC-
2 isoforms. In contrast, phosphorylation of 4E-BP1 at Ser65 was increased (p<0.01), 
suggesting enhanced mTOR activity. In parallel, a significant increase in global 
protein O-GlcNAcylation signal (p<0.01) was observed although no changes in OGT 
protein expression were found (p=0.08) (Figure 5.5). 
Previous studies in metabolic tissues identified AMPK regulation by the cAMP/PKA 
pathway (Gélinas et al., 2018). This was also evident in BeWo cells, since activation 
of adenylyl cyclase and PKA by forskolin, led to a significant increase in the activation 
of AMPK (p<0.01) and ACC (p<0.01) (Figure 5.6). Conversely, 4E-BP1 activation 
was reduced (p<0.01). Forskolin treatment also reduced OGT protein expression 
(p<0.001) and activity (p<0.01) compared to DMSO-treated cells (Figure 5.6), 
confirming an antagonistic functional response of AMPK and OGT to PKA activation 
in BeWo cells. 
As shown in Chapter 4, OGT and PKA are physically and functionally associated and 
their interplay contributes to regulate target proteins downstream of PKA including 
MAPKs. Here, the role of OGT on PKA-AMPK interactions was explored. Depletion 
of OGT by siRNA in BeWo cells resulted in enhanced phosphorylation of AMPK 
(p˂0.01) and ACC (p˂0.05) in response to forskolin without affecting AMPK 
expression levels (Figure 5.7). This interaction between OGT, PKA and AMPK was 
further investigated, by inhibiting PKA activity using H89. As shown in Materials and 
Methods (Chapter 2, Figure 2.1), preliminary titration experiments identified 5 μM 
H89 as an effective dose to significantly inhibit forskolin-induced phosphorylation of 
two downstream targets of PKA, CREB and ERK1/2. In OGT-depleted cells, 
inhibition of PKA reduced significantly the overall stimulatory effect of forskolin on 
AMPK phosphorylation (p˂0.001) (Figure 5.8). Interestingly, in control siRNA cells, 
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H89 treatment significantly increased expression of OGT (p˂0.01) suggesting that 
PKA might also exert an inhibitory effect on OGT protein expression. This agrees 
with the previously observed downregulation of OGT protein expression and activity 




Figure 5.5 Opposite response of the nutrient sensors OGT and AMPK to a 
glucose load in BeWo cells. Representative immunoblots and densitometry analysis 
showing the effect of glucose (15 mM) treatment on AMPK activation and protein O-
GlcNAcylation. BeWo cells were treated for 48 h with 5 or 15 mM glucose and 
activation of AMPK and downstream targets ACC and 4E-BP1, as well as OGT 
protein levels and global O-GlcNAcylation, were determined using specific 




Figure 5.6 Antagonistic response of AMPK and OGT to PKA activation in BeWo 
cells. Representative immunoblots and densitometry analysis showing the effect of 
forskolin (100 µM) treatment on AMPK activation and protein O-GlcNAcylation. 
BeWo cells were treated for 48 h with forskolin to activate PKA and p-AMPK as well 
as activation of downstream targets ACC and 4E-BP1, and O-GlcNAc signalling were 
determined by immunoblotting using specific antibodies. N=3; ** p˂0.01 vs DMSO. 




Figure 5.7 Role of OGT on PKA-AMPK interactions forskolin-induced in BeWo 
cells. Following treatment with siOGT or control siRNA for 48 h and stimulation with 
100 µM forskolin or DMSO for further 48 h, phosphorylation or total protein 
expression of AMPK and its downstream target ACC was determined by 
immunoblotting. Representative immunoblots and densitometry analysis are shown. 







Figure 5.8 Effect of PKA inhibition by H89 on OGT expression and AMPK 
signalling in forskolin-treated BeWo cells. Representative immunoblots and 
densitometry analysis showing the effects of PKA inhibition using 5 μM H89 on the 
activation of AMPK and OGT protein expression in forskolin-stimulated BeWo cells 
pre-treated for 48 h with siOGT or control siRNA. N=3; *** p˂0.001, ** p˂0.001 vs 







It is well established that maternal BMI is an important determinant of neonate birth 
weight. At the same time, abnormal weight at birth is associated with increased risk to 
develop chronic diseases later in life. The presence of nutrient-sensing systems, 
including AMPK, mTOR and HBP, allows the placenta to detect changes occurring in 
maternal metabolism and adapts its physiology and functions according to the stimuli 
coming from the maternal environment. However, the placental response to changes 
in maternal physiology may become maladaptive during suboptimal maternal 
conditions leading to negative consequences on the growing fetus. In this context, 
many studies have been focusing on evaluating the impact of maternal diabetes on 
placental physiology and fetus health. On the contrary, the effect of maternal BMI on 
placental function in women without diabetes, but with impaired metabolic 
homeostasis, remains largely unexplored although it represents a crucial area of 
research to identify important clues during the ‘pre-diabetes’ stage of disease. This is 
the first study that investigates the impact of maternal BMI on O-GlcNAcylation and 
OGT enzyme in term placentas. Results showed that, maternal BMI exhibited positive 
association with neonatal birth weight which, in turn, was associated with increased 
expression of the placental glucose transporter GLUT1. This is the main GLUT 
isoform expressed by the syncytiotrophoblast plasma membranes, particularly 
abundant on the maternal-facing MVM (Illsley, 2000). Expression of GLUT1 on the 
fetal-facing BM of the syncytiotrophoblast, however, has been shown to constitute the 
rate-limiting step in transplacental glucose transfer (Illsley et al., 1987) and, increased 
abundance of GLUT1 on the BM, may promote increased glucose delivery to the fetus 
and enhanced fetal growth (Acosta et al., 2015; Jansson et al., 1999), in agreement 
with what found in this study.  
It is likely that, in response to enhanced trophoblast glucose uptake and transplacental 
glucose transport in women with higher BMI, adaptive changes lead to increased 
placental expression of OGT and protein O-GlcNAcylation levels. The direct link 
between hyperglycemia and increased protein O-GlcNAcylation has been already 
demonstrated in a variety of biological systems investigating diabetes and diabetes-
associated complications (Ma and Hart, 2013). Although no direct association between 
maternal circulating glucose and placental protein O-GlcNAcylation was detected in 
this study cohort, it is possible that increased glucose uptake through GLUT1, along 
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with enhanced levels of circulating glucose and increased OGT protein expression in 
response to maternal obesity, act synergistically to raise the cellular UDP-GlcNAc 
pool in the HBP and downstream protein O-GlcNAcylation. Certainly, as 
demonstrated with the in vitro data, both OGT and GLUT1, as well as glucose 
availability, directly control the amount of protein O-GlcNAcylation in BeWo cells.  
The interplay between OGT and the placental sensor AMPK was also evaluated in this 
part of the thesis (Figure 5.9). Studies in obese pregnant ewes identified 
downregulation of  AMPK and its downstream target ACC (Zhu et al., 2009). 
Moreover, in obese non-diabetic women giving birth to large babies, placental AMPK 
activity was inversely correlated to maternal BMI and birth weight (Jansson et al., 
2013), suggesting that the activity of AMPK is impaired during maternal obesity with 
negative outcomes on the fetus. The results presented in this thesis Chapter support 
and extend these observations since, for the first time in the human placenta, a negative 
correlation between AMPK activation and OGT expression was found. Studies 
conducted in metabolic tissues have already identified a functional cross-talk between 
OGT and AMPK showing that these two nutrient sensors cooperatively regulate 
nutrient-sensitive intracellular processes that mediate cellular metabolism, growth, 
proliferation, and tissue function (Bullen et al., 2014; Gélinas et al., 2018). As a major 
cellular energy sensor, AMPK is activated in response to increased AMP/ATP ratio in 
conditions associated with energy deprivation (Lin and Hardie, 2018). In various 
cellular settings, AMPK alters OGT substrate selectivity by promoting interaction 
with specific proteins and competes with OGT for the modification of the same or 
proximal site on target proteins (Gélinas et al., 2018). In the placenta, AMPK-OGT 
interactions might mediate the effects of maternal obesity and hyperglycemia on the 
fetus, since activation of placental AMPK in humans is thought to be involved in 
global downregulation of metabolism and mitotoxicity (Landau et al., 2019). The in 
vitro experiments conducted in this part of the thesis, confirmed the presence of a 
direct glucose-activated OGT-driven pathway that diminishes AMPK effects on ACC 
and increases 4E-BP1 activity. This might alter the balance between placental lipid 
synthesis and oxidation pathways, through inhibition of ACC activity, and cell growth 
and protein synthesis, through enhancement of 4E-BP1 activity. Accordingly, 
previous studies in large for gestational age (LGA) infants born to obese women 
identified 4E-BP1 as one of the mTOR intracellular targets that exhibit increased 
levels in response to impaired AMPK (Jansson et al., 2013).  
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An interesting facet of the OGT-AMPK cross-talk is the antagonistic effects exerted 
by PKA on OGT to promote AMPK activation. This study suggests multiple strands 
of interactions: on one hand the cAMP/PKA pathway can attenuate OGT expression 
and activity, whereas OGT promotes impairment of PKA signalling involved in 
AMPK activation and ACC phosphorylation (Figure 5.9). Given that PKA-AMPK 
interaction might be also important for tight junction formation in trophoblast cells 
during forskolin-induced syncytialization (Egawa et al., 2008), OGT might be 
important in regulating AMPK-mediated mechanisms underlying the formation of 
placental barrier as already observed for the PKA-MAPK pathway in Chapter 4.  
Put together, these results expand the understanding around the complex interplay of 
signalling between OGT, AMPK/mTOR and PKA in placental trophoblast cells. This 
mechanism appears to be activated in response to maternal BMI and excessive 
exposure of trophoblast to nutrients in the maternal environment, such as glucose, 
might derange metabolic outcomes and have important consequences for placental 





Figure 5.9 Proposed OGT/PKA interplay controlling AMPK activity in 
trophoblast BeWo cells. Glucose upregulates OGT and downregulates AMPK 
activity, whereas forskolin upregulates AMPK and reduces O-GlcNAcylation 
suggesting that the two nutrient sensors OGT and AMPK are regulated in an opposite 
way by different stimuli in BeWo cells. The activation of AMPK, in forskolin-
differentiated BeWo cells, is increased in siOGT-treated cells while inhibition of PKA 
by H89 prevented activation of AMPK siOGT-induced suggesting that OGT exerts a 
negative control on AMPK activity via PKA-mediated mechanisms (blue). In addition, 
PKA controls OGT protein expression as activation of PKA by forskolin reduces while 
inhibition of PKA by H89 upregulates OGT protein expression (orange). Besides 












The OGT/11β-HSD2 interplay and possible roles 





As discussed in Chapter 1 - Introduction, a major function of the placenta is to prevent 
excessive exposure of the fetus to the maternal stress hormone cortisol. This hormone 
is synthesised by the HPA axis and released in the circulation. One of its functions is 
to restore homeostasis after stress response via activation of nuclear glucocorticoid 
receptors (GRs), which are present in almost every cell in the body (Sapolsky et al., 
2000). The activity of the HPA axis changes considerably during pregnancy and 
lactation as an adaptive response to the modifications occurring in maternal 
physiology (Brunton et al., 2008). Moreover, in the fetus, cortisol controls the 
maturation of many organs contributing to the formation of respiratory, renal, and 
cardiovascular systems (Seckl, 1998). Particularly during early pregnancy, the fetus is 
protected from an excess of maternal cortisol by the activity of placental 11β-HSD2 
which inactivates the hormone by converting it into cortisone. However, the protection 
offered by the 11β-HSD2 barrier can be weakened by maternal diseases and mood 
disorders such as anxiety or depression (Ponder et al., 2011). Because maternal cortisol 
levels are much higher than fetal levels, even moderate variations in placental 11β-
HSD2 expression or activity can significantly alter fetal cortisol exposure (Duthie and 
Reynolds, 2013) impinging on the basic structure of immature organs, particularly 
fetal brain which expresses high levels of GRs, thus affecting organ function and 
predisposing the offspring to an increased risk for neurodevelopmental and 
cardiometabolic disorders in adulthood (Duthie and Reynolds, 2013; Lindsay and 
Nieman, 2005).  
Recently, the OGT enzyme has emerged as a placental biomarker of maternal stress 
as in rodent models of prenatal chronic stress or exposure to glucocorticoids, placental 
O-GlcNAc signalling is perturbed with long-term consequences on the central nervous 
system of the offspring (Howerton et al., 2013; Pantaleon et al., 2017). In this part of 
the thesis the role of maternal depression on placental O-GlcNAc signalling and 11β-
HSD2 expression was evaluated in term placental tissues. Moreover, the interplay 
between OGT and 11β-HSD2 activity was studied in OGT-depleted BeWo cells. The 
trophoblast BeWo cell line has been shown to mimic the biological function of 
placental villous trophoblast including placental 11β-HSD2 barrier properties and 
constitutes a widely employed model to study 11β-HSD2 activity (Mark and Waddell, 
2006; Zhu et al., 2016).  
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6.2 O-GlcNAc signalling is increased in the placenta of depressed mothers 
Maternal depression has been associated with reduced expression of the placental 
barrier 11β-HSD2 and increased exposure of the fetus to maternal cortisol (Seth et al., 
2015). To evaluate whether the placental O-GlcNAc pathway is targeted by maternal 
depression, term placentas from 8 non-depressed and 8 depressed mothers were used 
in this study to measure the 11β-HSD2 and OGT protein levels as well as the global 
O-GlcNAc-modified proteins using immunoblotting. Depression was diagnosed at the 
time of recruitment using the Edinburgh Postnatal Depression Scale (EPDS). The 
neonates body weight was also used as a measure of pregnancy outcomes as it is well-
established that women presenting depressive symptoms are at increased risk of 
having babies with low birth weight (Chang et al., 2014).  
There was a statistical tendency for placental 11β-HSD2 protein levels to be 
downregulated in depressed compared to non-depressed women (p=0.06) (Figure 6.1 
A). However, there was no statistical significance in the birth weight between babies 
born from non-depressed and depressed mothers (Figure 6.1 B). Interestingly, both 
OGT protein levels (p<0.01) and the global O-GlcNAcylation (p<0.05) were 
significantly increased in the placenta from depressed mothers compared to non-
depressed group (Figure 6.1 C). Moreover, OGT protein levels were negatively 
correlated to 11β-HSD2 protein expression (p=0.05, R2=0.242) (Figure 6.1 D).  
To further investigate the possibility of an interplay between OGT and 11β-HSD2, a 
co-IP assay was performed using protein extracts from placental tissues to evaluate 
the physical association between these two enzymes. Results are shown in Figure 6.2 
and confirmed that, in term placental tissues, there is a protein-protein association 




Figure 6.1 O-GlcNAc signalling and 11β-HSD2 protein expression in term 
placentas from non-depressed and depressed women. Representative immunoblots 
and densitometry analysis of A) 11β-HSD2 protein and C) OGT protein and O-
GlcNAcylation levels in homogenates of term placentas and B) birth weight of babies 
born to non-depressed and depressed mothers. D) Linear association between 11β-
HSD2 and OGT protein expression in placentas from non-depressed and depressed 





Figure 6.2 Co-IP assay showing the 11β-HSD2/OGT association in term 
placentas. 11β-HSD2 (lanes 1-2) or OGT (lanes 3-4) protein was immunoprecipitated 
from protein extracts of term placentas from non-depressed mothers using specific 
antibodies and immunoprecipitates as well as 10% input, the protein extract before 
immunoprecipitation (lanes 5-6), were immunoblotted with both anti-11β-HSD2 and 
anti-OGT primary antibodies to be visualized. Two biological replicates are shown on 




6.3 Activity of 11β-HSD2 in OGT-depleted BeWo cells 
To further investigate the functional meaning of the 11β-HSD2/OGT association, the 
BeWo cell line was used in this study to evaluate whether downregulation of OGT 
expression might affect the enzymatic activity of 11β-HSD2, one of the major 
components of the placental barrier. As previously discussed, the role of 11β-HSD2 is 
to prevent that an excess of maternal cortisol reaches the fetus by converting it into 
the inactive metabolite cortisone. In this experiment, OGT expression was transiently 
silenced in BeWo cells using siRNA for 48 h. The culture medium was then changed 
to fresh medium and both control siRNA and siOGT cells were treated with 1 µM of 
cortisol for 3 h. The culture medium was then collected and the levels of remaining 
cortisol were measured using an electrochemiluminescence immunoassay, as a 
measure of the enzymatic activity of 11β-HSD2 (Zhang et al., 2015) (Figure 6.3 A). 
Results indicated that, although the protein levels of 11β-HSD2 showed no statistical 
difference between control siRNA and siOGT-treated cells (p=0.892), the amount of 
cortisol detected in the culture medium of the siOGT-treated cells after 3 h from 
cortisol treatment was significantly lower compared to the levels of cortisol detected 






Figure 6.3 Effect of siOGT on exogenous cortisol levels in BeWo cells. A) BeWo 
cells were treated with siOGT or control siRNA for 48 h followed by treatment with 
1 µM cortisol for 3 h. B) The residual cortisol remaining in the medium was measured 
by electrochemiluminescence while the 11β-HSD2 protein levels were measured by 
immunoblotting. Cortisol concentration is normalized to protein concentration. 11β-
HSD2 levels are normalized to β actin. N=6. Data are expressed as mean ± SEM; 





Previous studies using rodent models demonstrated that placental OGT and its 
biochemical activity can be targeted by maternal stress (Howerton et al., 2013; 
Pantaleon et al., 2017). However, the effect on placental O-GlcNAc signalling seems 
to depend on the nature of the stressor. In particular, Howerton and colleagues found 
that placental O-GlcNAc signalling is downregulated when pregnant mice underwent 
a chronic stress procedure and this was associated with neurodevelopmental 
alterations in the offspring (Howerton et al., 2013). On the other hand, Pantaleon and 
colleagues found that administration of corticosterone, a synthetic glucocorticoid, in 
pregnant mice, significantly increased O-GlcNAc signalling in the placenta impacting 
negatively on key mediators of cell survival such as the AKT pathway (Pantaleon et 
al., 2017). Although with contrasting results, these two studies suggest that the 
placental O-GlcNAc signalling pathway can detect increased maternal stress initiating 
downstream responses and constitutes, for this reason, a placental sensor of stress. 
Mood disorders, including maternal depression, are states of distress associated with 
hyperactivation of the HPA axis, increased maternal cortisol levels and impairment of 
the placental barrier system regulated by 11β-HSD2. All together, these adaptive 
changes to maternal environment may significantly affect fetal development and birth 
weight programming the offspring’s physiology (O’Donnell et al., 2012; O’Donnell 
and Meaney, 2017; Stein et al., 2014).  
In this part of the study, the hypothesis that maternal depression might target the 
placental O-GlcNAc signalling system was tested. The protein levels of OGT and 
global protein O-GlcNAcylation were measured in term placentas from non-depressed 
and depressed mothers and the functional interaction between OGT and 11β-HSD2 
was evaluated in BeWo cells. Results indicated that O-GlcNAc signalling is 
upregulated in the placenta of depressed mothers compared to control group. Although 
the levels of maternal glucocorticoids are not available for this study, the upregulation 
of OGT and O-GlcNAcylation in placentas from depressed mothers is in agreement 
with what observed in the rodent model of corticosterone administration reported by 
Pantaleon and colleagues (Pantaleon et al., 2017). Many studies found that 
upregulation of protein O-GlcNAcylation occurs in different cellular models 
following the application of a diverse array of acute stress stimuli and constitutes a 
protective cellular mechanism in response to stress (Groves et al., 2013; Martinez et 
169 
 
al., 2017; Zachara and Hart, 2004). According to these studies, stress-induced changes 
in O-GlcNAcylation reprogram cellular pathways by promoting survival, for example 
via upregulation of heat shock protein expression, and by inhibiting proteins that 
promote cell death, as for example the pro-apoptotic transcription factors NF-kB and 
CHOP, collectively increasing cellular protection (Martinez et al., 2017). However, 
on the long-term, upregulation of protein O-GlcNAcylation is detrimental to cell 
physiology and has been associated with the development of many clinical conditions 
including hypertension, heart failure, glucose toxicity and type II diabetes (Copeland 
et al., 2008; Ma and Hart, 2013; Marsh et al., 2014), as already extensively discussed 
in Chapter 1 - Introduction. In the context of placenta, a chronic upregulation of 
protein O-GlcNAcylation, as a result of a persistent emotional distress, may have 
devastating consequences on the placental mechanisms which regulate fetal 
programming. For instance, OGT and O-GlcNAcylation are key regulators of 
transcription. Many transcription factors and chromatine-remodelling proteins interact 
directly with OGT and are O-GlcNAc-modified. In Chapter 3, it has been 
demonstrated that O-GlcNAcylation of key proteins involved in transcription 
regulation and epigenetic control occurs also in trophoblast cells. It is well-established 
that changes in the placental epigenetic code is one of the principal mechanisms via 
which maternal stressors mediate a rearrangment in the placental gene expression 
(Bale, 2015; Monk et al., 2016). The consequences of a reorganization at level of gene 
transcription, occurring during in utero life, are amplified by the fact that tissues and 
fetal organs are rapidly developing and are more vulnearble to changes in 
reprogramming trajectories. In this regard, OGT constitutes a crucial link between 
maternal stress and the implications of placental epigenetics in long-term 
programming of diseases (Nugent and Bale, 2015). 
Besides regulation at the transcriptional and epigenetic level, the OGT enzyme may 
act more upstream by regulating directly the activity of the placental barrier 11β-
HSD2. In this study, a physical interaction between OGT and 11β-HSD2 has emerged 
in term placentas. Moreover, a functional study conducted in BeWo cells has 
demonstrated that, when OGT is depleted from the cell, exogenous cortisol is 
metabolized more efficiently than in control siRNA-treated cells. Cortisol is a steroid 
hormone and passively diffuses across the cell membrane due to its lipophilic nature 
(Oren et al., 2004). BeWo cells are not able to synthesize cortisol de novo and studies 
demonstrated that 11β-HSD2 is the only enzyme able to metabolize cortisol in the 
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placenta (Benediktsson et al., 1997; Stirrat et al., 2018). Thus, although the levels of 
the metabolite cortisone were not measured in this study, it is possible to speculate 
that the cortisol levels remaining in the culture medium after 3 h from cortisol 
administration are primarily due to the 11β-HSD2 activity which metabolises cortisol 
inside the cell. OGT depletion might, somehow, upregulate 11β-HSD2 activity in 
BeWo cells resulting in a decrease of cortisol in the culture medium of siOGT cells 
compared to control siRNA treatment. It could be possible that, the presence of OGT 
or O-GlcNAc modification at critical amino acid residues might modify the 
conformation of the enzyme limiting the access to cortisol. The steric impediment 
might be removed when OGT is downregulated allowing enhanced cortisol 
metabolism. The interplay OGT/OGA may also play a critical role in regulating the 
interaction between OGT and 11β-HSD2. For instance, it has been demonstrated that 
in different experimental conditions, OGA works as an adaptor protein recruiting OGT 
to specific substrates (Yang and Qian, 2017). However, further studies are needed to 
better identify the exact mechanism via which O-GlcNAc signalling might regulate 
11β-HSD2 activity in the placenta. Future studies should include measurement of 11β-
HSD2 activity after overexpressing OGT in the cells and co-IP assay involving OGA 
to study the formation of the OGT-OGA-11β-HSD2 complex.  
In summary, this part of the thesis demonstrates that, during maternal depression, the 
protein expression of OGT is promoted leading to increased placental levels of protein 
O-GlcNAcylation. This might have implications at level of the placental gene 
expression profile as well as on the enzymatic activity of the placental glucocorticoid 







Figure 6.4 Potential role of OGT in regulating 11β-HSD2 activity during 
maternal depression. The 11β-HSD2 enzyme constitutes the principal placental 
barrier to maternal cortisol by converting the majority of maternal cortisol into the 
inactive metabolite cortisone. OGT might constitute a negative regulator of 11β-HSD2 
activity as depletion of OGT in BeWo cells reduced the amount of cortisol in the 
medium. Upregulation of OGT protein expression and activity, in term placentas, can 
be induced by maternal depression. This might impair the activity of the 11β-HSD2 




















Over the last decades, O-GlcNAc modification of nucleocytoplasmic proteins has 
emerged as a major regulator of multiple cellular functions and a critical signalling 
pathway linking metabolism with many pathophysiological conditions (Yang and Suh, 
2014). However, its role in human placenta has not been investigated yet. 
The purpose of this thesis was to explore to which extend OGT, and its biochemical 
mark O-GlcNAcylation, are involved in the regulation of different aspects of 
trophoblast physiology with a particular focus on the formation of 
syncytiotrophoblast. In addition, the potential implication of O-GlcNAc modification, 
as a placental sensor of maternal metabolism and stress, was evaluated both in vitro 
and in term placental biopsies. Overall, the results obtained strongly suggest a major 
role played by the O-GlcNAc modification in regulating the formation of 
syncytiotrophoblast and its endocrine function and identified, at the same time, the 
OGT enzyme as a key mediator of the signalling cascades linking maternal 
metabolism to fetal growth. Moreover, this study has identified that, during maternal 
depression, key mechanisms that regulate the placental response to maternal stress can 
be targeted by OGT. Finally, this research work demonstrated, for the first time, that 
in trophoblast BeWo cells, a wide range of proteins, involved in controlling epigenetic 
mechanisms and transcription, are putatively O-GlcNAc-modified, suggesting that 
this still poorly understood post-translational modification has the potential to act as 
the molecular bridge between maternal environmental cues and epigenetic 
mechanisms of in utero programming. Figure 7.1 summarizes the main findings 
emerged in this research project and illustrates the different mechanisms via which 
placental OGT and O-GlcNAcylation can control placenta formation and functions 
and, indirectly, fetal developmental trajectories. 
In this thesis, the role of O-GlcNAcylation in syncytiotrophoblast formation and 
function was investigated in human trophoblast BeWo cells. Throughout pregnancy, 
syncytiotrophoblast fulfils several important placental functions including transport of 
nutrients to the fetus, protection against a variety of insults and production of placental 
hormones (Gude et al., 2004). Given its crucial role in many aspects of pregnancy, 
alterations in syncytiotrophoblast morphology or function are associated with negative 
pregnancy outcomes including preeclampsia and changes in fetal growth trajectories 
with potential short- and long-term impact on the health of both mother and fetus 
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(Backes et al., 2011; Redman and Staff, 2015; Roland et al., 2016; Sferruzzi-Perri and 
Camm, 2016). As demonstrated in this thesis work, depletion of the OGT enzyme 
induced spontaneous differentiation of BeWo cells and enhanced the formation of 
areas of syncytialization and production of the hCG hormone during forskolin-induced 
differentiation, suggesting that certain levels of O-GlcNAcylation are necessary to 
control syncytiotrophoblast formation via mechanisms involving the PKA-ERK1/2-
p38 signalling pathway. Similar results were observed in ESCs by Miura and 
colleagues who showed that the O-GlcNAc modification on the activation site of 
PKCζ was required for the maintenance of the undifferentiated state of ESCs, while 
upregulation of O-GlcNAc levels prevented activation of the PKCζ-MEK-ERK1/2 
pathway and the ability of naïve ESCs to differentiate into primitive endoderm (PrE) 
cells, one of the first cell lineages generated by the embryo (Miura et al., 2018). Taken 
together these findings suggest that, by regulating similar signalling cascades, protein 
O-GlcNAcylation may play a major role in controlling the timing of cell lineage 
differentiation in the embryo and the formation of syncytiotrophoblast from 
cytotrophoblast cells, two crucial steps in embryogenesis and placentation.  
Thus, changes in placental OGT levels may have a significant impact on placenta 
formation constituting a real risk for the developing fetus. In the pioneering study 
conducted by Howerton and colleagues (Howerton et al., 2013; Howerton and Bale, 
2014), which brought to light the first evidence on the importance of placental OGT 
and O-GlcNAc signalling during in utero development, downregulation of placental 
OGT expression, following prenatal maternal stress in mice, was associated with 
adverse consequences on the offspring’s neurodevelopment. Importantly, in this thesis 
work, it was demonstrated that changes in OGT and O-GlcNAc signalling affect both 
morphology and endocrine activity of the syncytiotrophoblast via interplay with PKA-
mediated mechanisms. For instance, the production of the hCG hormone appeared to 
be particularly influenced by changes in the O-GlcNAc signalling pathway in BeWo 
cells showing significant upregulation in OGT-depleted cells and downregulation 
when O-GlcNAcylation was enhanced by PUGNAc. It is known that hCG can 
contribute, both directly and indirectly, to fetal development. Indeed, high hCG 
concentrations during the first trimester of pregnancy are associated with increased 
fetal growth in a sex-specific manner (Barjaktarovic et al., 2017), whereas elevation 
of hCG during the second trimester appears to be associated with fetal growth 
restriction and preterm delivery (Gonen et al., 1992; Lieppman et al., 1993; Onderoğlu 
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and Kabukçu, 1997). Moreover, studies on both humans and rodents showed that, hCG 
can cross the blood–brain barrier and that the hCG receptors are expressed in multiple 
fetal organs, including fetal and neonatal rat brains, strongly suggesting that hCG can 
act directly on regulating fetal neurodevelopment (al-Hader et al., 1997; Lei et al., 
1993). Interestingly, hCG also controls the expression of 11β-HSD2 (Shu et al., 2014), 
a crucial placental enzyme that regulates the transfer of maternal glucocorticoids 
through the placenta protecting, on one hand, the fetus from an excess of maternal 
stress hormones and regulating, on the other hand, fetal development and growth 
(Seckl and Holmes, 2007). Importantly, the novel findings emerged in this research 
work link O-GlcNAc signalling to syncytiotrophoblast formation and hCG production, 
raising the question on whether a functional interconnection of OGT, hCG and 11β-
HSD2 may exist in human placenta.  
Certainly, this thesis has identified an association between OGT and 11β-HSD2 in 
term placental biopsies and BeWo cells. It is known that the 11β-HSD2 enzyme is 
targeted by maternal stressors, such as mood disorders, and that suboptimal expression 
and activity of placental 11β-HSD2 are associated with abnormal fetal development 
and poor health condition in adulthood (Cottrell and Seckl, 2009; Lesage et al., 2006). 
As discussed previously, the abnormalities observed in fetal growth as a result of 11β-
HSD2 defects are due to an increased transplacental passage of glucocorticoids that 
target the growing fetal organs altering their structure and development as well as their 
functionality in adult life. In this thesis, it was shown that placental O-GlcNAc 
signalling is upregulated during maternal depression and that OGT and 11β-HSD2 are 
physically associated in term placentas. More importantly, it has emerged that 
depletion of OGT in BeWo cells appeared to alter the activity of 11β-HSD2 enhancing 
its ability to metabolize cortisol suggesting a novel functional interplay between OGT 
and 11β-HSD2 that opens new exciting opportunities in the study of placental 
glucocorticoids signalling and fetal programming of human diseases.  
As discussed above, certain levels of OGT activity are important for a proper 
syncytiotrophoblast formation. However, similarly to OGT depletion, enhancement of 
placental O-GlcNAc signalling can result in negative outcomes. It has been shown 
that, increased hyperglycemia-induced O-GlcNAcylation prevents embryo 
implantation and development in mice (Pantaleon et al., 2010) and alters placenta 
morphology and placental inflammatory response in rats (Dela Justina et al., 2017, 
2018). However, studies investigating the link between maternal metabolic diseases 
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and O-GlcNAc signalling have not been performed yet in human placenta. According 
to its role as a nutrient sensor, the O-GlcNAc modification is very sensitive to changes 
in the flux of nutrients entering the HBP, particularly glucose. Elevated O-
GlcNAcylation has been associated with glucose toxicity and insulin resistance in 
insulin-sensitive tissues during diabetes and diabetic complications (Ma and Hart, 
2013). However, in this thesis more attention was given to investigate the potential 
link between the placental O-GlcNAc modification and maternal BMI rather than 
maternal diabetes. This mainly because, high maternal body weight is associated with 
a higher risk of GDM (Chu et al., 2007) and constitutes an important area of research 
in terms of pre-diabetes interventions. Moreover, pregnancy outcomes associated with 
maternal obesity and overweight are as poor as those observed in diabetic pregnancies 
(Catalano, 2010), making necessary a better understanding of the molecular 
mechanisms linking suboptimal maternal BMI to fetal development. As demonstrated 
in Chapter 5 and supported by multiple other studies, mothers with higher BMI give 
birth to heavier babies. In addition to that, here it was shown that increased maternal 
BMI was associated with higher circulating glucose levels. Moreover, the placenta of 
heavier babies expressed more GLUT1 transporters, the primary isoform involved in 
the transplacental passage of glucose. These observations are in agreement with the 
literature and suggest that maternal BMI determines neonatal weight, in part, via 
mechanisms involving placental glucose uptake even in absence of diabetes (Acosta 
et al., 2015; Lowe et al., 2019). According to the Pedersen hypothesis, fetal 
overgrowth is the result of increased transplacental transfer of glucose which 
stimulates fetal secretion of insulin and increases adiposity (Pedersen, 1971). In this 
context, one aim of this thesis was to investigate the role played by the placental OGT 
system in mediating maternal metabolic perturbations to the fetus. Interestingly, a 
positive association between maternal BMI and placental OGT protein levels was 
identified. In addition, both OGT and GLUT1 protein levels were positively correlated 
with the levels of global protein O-GlcNAcylation in placental biopsies and silencing 
of OGT or GLUT1 significantly reduced the global O-GlcNAc modification in BeWo 
cells. Taken together, these findings show, for the first time, that maternal BMI targets 
the OGT expression in human placentas determining the increase of protein O-
GlcNAcylation, in part, via mechanisms involving placental glucose transport.  
The consequences of the upregulation of O-GlcNAc signalling can negatively impact 
the placenta function at different levels interfering with a variety of mechanisms 
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involved in controlling fetal growth as discussed here and summarized in Figure 7.1. 
A crucial candidate target of OGT, critically involved in controlling fetal growth, is 
AMPK. As shown in Chapter 5, higher OGT protein levels correlated with lower 
AMPK activation in term placentas, raising the possibility that the two nutrient sensors 
might act in an antagonistic manner in response to environmental stimuli. AMPK is 
the master regulator of cellular energy status switching on and off cell metabolism 
according to ATP availability. For instance, AMPK works as a negative regulator of 
mTOR signalling to limit protein synthesis and cell growth when cell energy is low 
and vice versa. As demonstrated in Chapter 5, in conditions of excessive glucose in 
the culture medium of BeWo cells, AMPK was turned off whereas 4E-BP1, which 
controls protein synthesis downstream of mTOR, was activated along with the O-
GlcNAc signalling. Alterations of the placental AMPK-mTOR axis have been 
associated with suboptimal fetal growth and weight at birth as a consequences of 
caloric restriction or overnutrition in both humans and animal models (Jansson et al., 
2013). As emerged in Chapter 5, in BeWo cells, OGT controls the activation of AMPK 
in a PKA-dependent manner. Indeed, when OGT is silenced and PKA is activated by 
forskolin, AMPK activation is significantly enhanced but not in presence of a PKA 
inhibitor. Taken together, these observations suggest that AMPK and OGT are 
functionally associated via PKA-dependent mechanisms and that by targeting the 
OGT system, maternal metabolic alterations can affect metabolic pathways controlling 
fetal growth such as the AMPK-mTOR signalling pathway. AMPK has been already 
recognised as a therapeutic target and AMPK activators, such as metformin, are 
employed to restore a variety of pregnancy complications including GDM, 
preeclampsia and fetal growth alterations (Kumagai et al., 2018). Thus, this study 
offers new insights regarding a potential OGT-AMPK-mTOR interplay which may 
regulate fetal growth during maternal obesity and provides new promising directions 
for future research investigation.  
One of the most intriguing goals concerning this thesis project was to understand to 
which extent the O-GlcNAc modification might be involved in controlling trophoblast 
physiology and fetal development by acting directly on mechanisms regulating 
placental gene expression. Epigenetic mechanisms have been identified as critical 
mediators of in utero programming due to their ability to dynamically integrate 
environmental signals into gene expression. It is well-established that the maternal 
metabolic status can impact on the placenta “transcriptome” and “epigenome” with 
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consequences on the developing fetus. Importantly, it has been shown that DNA 
methylation can be particularly influenced by changes in maternal nutrition and 
metabolism during early life. For instance, placental DNA methylation is able to 
dynamically adapt to changes in maternal glycemic levels throughout pregnancy 
(Cardenas et al., 2018). More importantly, alterations in the placental methylome 
profile have been associated with maternal obesity, pre-pregnancy BMI and 
gestational weight gain and involve, primarily, genes that control placental and fetal 
growth, including genes that regulate glucose metabolism, such as leptin and 
adiponectin, as well as genes involved in mediating glucocorticoid signalling, such as 
GRs and 11β-HSD2 (Drake et al., 2012; Mitsuya et al., 2017; Nogues et al., 2019; 
Shrestha et al., 2020).  
As discussed previously, OGT activity is strictly related to the amount of nutrients 
entering cells. It is also well-known that OGT is a major regulator of the transcriptional 
and chromatin remodelling machinery which makes O-GlcNAc signalling a good 
candidate to link environmental exposure to nutrients with placental gene 
transcription. In Chapter 3, the “O-GlcNAcome” was explored in the trophoblast 
BeWo cell line. This was the first study that used a proteomic approach to identify O-
GlcNAc-modified proteins in a human trophoblast cell line. Overall, it has emerged 
that O-GlcNAcylation is particularly abundant on factors regulating transcription and 
chromatin remodelling. Many of the identified proteins belong to protein complexes 
involved in methylation of histones. For instance, many components of the 
Set1/COMPASS complex, which controls the tri-methylation of histone H3 Lys4 
(H3K4me3), commonly associated with the activation of transcription of nearby genes 
(Martin and Zhang, 2005), were enriched by the anti-O-GlcNAc antibody in BeWo 
extracts. As suggested by the literature, OGT appears to have a central role in 
regulating the activity of the Set1/COMPASS complex. Briefly, the formation of 
TET2/3–OGT interaction induces O-GlcNAcylation of HCF-1 transcription 
coregulator, allowing the assembling of the complex and the binding of SETD1A 
methyltransferase to chromatin, an event necessary for histone H3K4me3 and 
subsequent transcriptional activation. Reduction of either TET2/3 or OGT activity 
results in a direct decrease in H3K4me3 and concomitant decrease of transcription 
(Deplus et al., 2013). In mammalian cells, H3K4me3 is particularly enriched at 
transcriptionally active promoters where it recruits mostly positive transcription 
regulators (Martin and Zhang, 2005). Surprisingly, the H3K4me3 modification has 
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been found in syncytiotrophoblast cells marking the presence of active transcription 
(Ellery et al., 2009), and it has been shown to ‘prime’ the gene activation of the human 
growth hormone (hPGH), a placental hormone greatly involved in fetal growth, 
placental development and maternal adaptation to pregnancy, in fusing primary 
cytotrophoblast cells isolated from human term placentas (Kimura et al., 2007). 
Misregulation of histone H3K4me3 modification is associated with aberrations in 
neurodevelopment. Interestingly, in mouse placenta, H3K4me3 seems to control OGT 
gene expression itself. In particular, prenatal stress reduced the association of 
H3K4me3 at the OGT promoter, suggesting a transcriptional mechanism via which 
maternal stress can regulate the expression of OGT in the placenta (Howerton et al., 
2013). Besides acting on regulating the epigenetic machinery, O-GlcNAcylation is 
also present on many transcription factors, including Sp1 and Sp3, as emerged in 
Chapter 3. Importantly, Sp1 regulates the transcription of many crucial genes in the 
syncytiotrophoblast including GLUT1 (Okamoto et al., 2001), 11β-HSD2 (Li et al., 
2011) and syncytin-1 (Cheng and Handwerger, 2005). O-GlcNAcylation of Sp1 has 
been shown to increase its stability, nuclear localization and transcriptional activity 
and has been implicated in diabetes and diabetic complications in many tissues (Du et 
al., 2000; Geraldes et al., 2009).  
Taken together, these last observations suggest that protein O-GlcNAcylation might 
control important trophoblast functions, including glucose transport across the 
placental barrier and glucocorticoids metabolism, via direct regulation of placental 
gene expression and that maternal disorders, known to affect placental physiology and 
fetal development, such as obesity or mood disorders, can mediate their deleterious 
effects via changes in placental transcriptome and epigenome involving the O-GlcNAc 





Figure 7.1 Summary of the potential mechanisms by which placental O-GlcNAc 
signalling can participate in fetal programming. Maternal obesity or depression 
enhances the cellular levels of OGT and protein O-GlcNAcylation in the trophoblast 
thus perturbing the activity of signalling pathways involved in the regulation of 
trophoblast formation and function with potential consequences on fetal growth and 
increased risk for developing chronic diseases in adulthood. By interacting with PKA, 
enhanced OGT activity can interfere with the phosphorylation and activation of targets 
downstream of PKA, including CREB, ERK1/2 and p38, reducing the expression of 
specific markers of trophoblast differentiation such as fusogenic proteins, the hCG 
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hormone and the transcription factor GCM1. The hCG hormone itself plays a crucial 
role in regulating syncytiotrophoblast formation via a positive feedback mechanism 
that can be impaired during upregulation of O-GlcNAc signalling. Alterations of the 
cAMP/PKA signalling pathway are associated with aberrant trophoblast 
differentiation which, in turn, can affect fetal growth. Increased OGT activity can also 
interfere with the activation of the nutrient sensor AMPK. Reduced activation of 
AMPK is associated with increased activity of mTOR signalling which promotes 
placental nutrient transport and fetal growth (Jansson et al., 2012). Furthermore, by 
interacting with 11β-HSD2, OGT can also impair cortisol metabolism exposing the 
fetus to increased transplacental levels of maternal glucocorticoids which target the 
developing fetal organs. Finally, inside the nucleus, increased OGT activity can 
stabilize and promote the transcriptional activity of the transcription factor Sp1 
potentially increasing gene expression of GLUT1 which, in turn, can promote 
increased delivery of glucose to the fetus and further potentiate protein O-
GlcNAcylation. Upregulation of O-GlcNAc signalling can also lead to increased O-
GlcNAcylation of the transcription factor HCF-1 promoting the activity of the 
Set1/COMPASS complex which, by increasing the tri-methylation of histone H3 Lys4 
(H3K4me3), can induce further gene transcription of OGT itself and enhance the 
expression of the human placental growth hormone (hPGH), involved in fetal growth 













8.1 Conclusions, limitations and future research 
This thesis work has contributed significantly to identify a critical role for OGT and 
protein O-GlcNAcylation in the regulation of human placental physiology bringing 
novel knowledge to a poorly explored field of research. Overall, the findings that 
emerged from this research work revealed that O-GlcNAcylation is involved at many 
levels in regulating trophoblast physiology and function. Only some aspects have been 
investigated more in-depth due to a limitation of resources and time. Particular 
attention was dedicated to understanding the role of OGT in syncytiotrophoblast 
formation since this is the placental structure that carries out several important 
placental functions. The experiments performed using the human trophoblast cell line 
BeWo identified a clear role for OGT as a negative regulator of syncytiotrophoblast 
differentiation. Although the BeWo cell line is a widely employed model to study 
trophoblast differentiation, showing remarkable similarities with crucial functional 
aspects of human trophoblast, including endocrine activity and transport 
characteristics, there are some limitations associated with the use of cell lines. In 
particular, the gene expression profile of BeWo cells is cancerous and studies showed 
that there is a poor correlation with that of trophoblast cells in primary culture 
(Novakovic et al., 2011). For that reason, primary trophoblast cells, although more 
difficult to obtain and manipulate, are certainly physiologically more similar to an in 
vivo scenario and should be employed in future experiments to overcome the 
limitations associated with the use of cell lines.  
Interesting findings have also emerged from the analysis of term placentas in women 
with BMI ranging from lean to obese, where a positive association between maternal 
BMI and placental OGT signalling was identified along with the reduced activity of 
AMPK, a crucial nutrient sensor involved in the regulation of fetal growth. This is the 
first study conducted on human term placentas which links maternal BMI to changes 
in O-GlcNAcylation levels of placental proteins, suggesting that OGT might constitute 
a key molecular bridge between maternal metabolism and placental regulation of fetal 
growth. However, a major limitation associated with this part of the research can be 
identified in the low number of placenta samples available. Future studies need to be 
carried out on a larger sample size which will allow for multifactorial regression 
analysis of variables. In addition, a more homogeneous enrichment of placentas from 
female and male fetuses is needed in order to address sex differences associated with 
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OGT expression in the placenta. As an X-linked gene, OGT has been shown to escape 
X-inactivation remaining more expressed in the placenta of females compared to 
males. The role of OGT in mediating placental functions according to the sex of the 
placenta is a crucial area for future research since it may explain the sex-specific 
increased risk for developing a number of diseases that are programmed during in 
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